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ABSTRACT
REGULATION OF MAMMALIAN PHOTORECEPTOR PHOSPHODIESTERASE
(PDE) BY ITS NONCATALYTIC GAF DOMAINS AND ITS TWO SMALL
SUBUNITS, GAMMA AND DELTA

By
Hongmei Mou
University ofNew Hampshire, December, 2001

cGMP phosphodiesterase (PDE) is the central effector of visual transduction in
retinal rod photoreceptors. Upon activation by transducin (a G-protein), PDE hydrolyzes
cytoplasmic cGMP to induce the hyperpolarization of the plasma membrane in the outer
segment of the rod cell. The extent and lifetime of activation of PDE must be precisely
regulated in order to control the exquisite sensitivity, speed, and adaptational properties
of the visual transduction pathway. The overall goal of this work was to investigate the
possible regulatory mechanisms of PDE in mammalian rod photoreceptors by its
noncatalytic cGMP binding sites on the PDE catalytic dimer (PaP), and by the
interactions between the inhibitory Py subunit and Pap in their phosphorylated and nonphosphorylated states.
First, the binding of cGMP to the noncatalytic sites on membrane-associated PDE
(PDE-M) and soluble PDE (PDE-S) was characterized. We found that PDE-M
holoenzyme contains 2 non-identical high-affinity cGMP binding sites; one of the cGMP
binding sites is functionally nonexchangeable. In contrast, PDE-S can release and bind

xii
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cGMP at both noncatalytic sites. Activation of PDE reduces more than 100-fold its
cGMP binding affinity at one site, while the second cGMP binding site exhibits a 3-fold
reduction in binding affinity. We postulate that cGMP dissociation from these two non
identical binding sites might contribute differently to controlling the activation and
inactivation kinetics of PDE6 during visual transduction in rod photoreceptors.
We also studied interactions between Py and the mammalian PaP catalytic dimer.
It was found that Py binds to two distinct sites on the catalytic Pap dimer. cGMP
occupancy at the noncatalytic binding sites is responsible for this binding heterogeneity.
Although cGMP binding positively enhances Py binding affinity to Pap, it has no effect
on PDE catalytic activity. Two major domains on Py interact with Pap independently.
The N-terminal half of Py functions to restore and stabilize cGMP binding at the GAF
domain with a binding affinity 50-fold greater than its C-terminal, inhibitory region.
Phosphorylation is an important regulatory mechanism in the visual transduction
pathway. Our results showed that both Py and PaP could be stoichiometrically
phosphorylated in vitro. Py phosphorylation has modest effects on its binding affinity to
PaP and its overall inhibitory potency. However, phosphorylation at Thr22mildly
decreases the ability of the central region of Py to bind to PaP and to stabilize cGMP
binding at the GAF domains. Similar to PDE5, phosphorylation of photoreceptor Pap
regulates cGMP binding at the GAF domains. These results suggest a potential role of
Pap phosphorylation in regulating PDE by regulating cGMP levels in photoreceptor
cells.

xiii
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INTRODUCTION
A. Vision and Photoreceptor Cells
Cells process a diverse range of stimuli, from hormones and neurotransmitters to
sensory signals, such as odorants and light. Light is perceived within the retina of the eye.
The retina consists of five distinct layers: outer nuclear layer (ONL, containing
photoreceptor cells), outer plexiform layer (OPL, consisting of synaptic processes of
photoreceptor, bipolar and horizontal cells), inner nuclear layer (INL, containing bipolar,
horizontal and amacrine cells), inner plexiform layer (IPL, consisting of synaptic contacts
between processes of bipolar, amacrine and ganglion cells), and ganglion cell layer
(containing ganglion cells). Vertebrate photoreceptors consist of two types of cells: rods
and cones. Cone photoreceptor cells, which have higher temporal resolution than rods,
function in bright light and are responsible for color vision. In humans, there are three
different classes of cones, long-wavelength cones (red cones, 560-565 nm maximal
sensitivity), medium-wavelength cones (green cones, 535-540 nm maximal sensitivity)
and short-wavelength cones (blue cones, 440 maximal sensitivity). Rods are the
receptors for dim light conditions and night vision. Compared to cones, rods are
achromatic and have lower temporal resolution. Many more rods than cones (20:1) exist
in mammalian retinas. For example, a human retina has about 1.2xl08 rods but only
3xl06 cones. Both types of photoreceptors function to transduce a photon of light into
atomic motion and then into a discrete nerve impulse. The information provided by the
photoreceptors is further processed by an intricate array of nerve cells within the retina,
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then sent to the brain by the fibers of the optic nerve, and ultimately is processed by the
visual cortex.
As shown in Figure 1.1, photoreceptors are highly compartmentalized and consist
of two major segments, an inner segment (IS) and an outer segment (OS), which are
joined by a slender immotile
connecting cilium. The outer
segment of a rod is specialized for
photoreception, containing a stack of
Outer segm ent

about 1000 discs. The visual receptor
molecules are densely packed in

Connecting
cilium

these membranous structures. The
Inner segm ent

0

composition of the OS is better

■0 e

characterized than any other
Nucleus

membrane involved in signal
transduction: the mass is half protein

Axon

and half lipid (Fliesler and

Synaptic body

Anderson, 1983). Rhodopsin and
Figure 1.1 Rod and Cone photoreceptors
transducin are the two most
abundant proteins in the OS and comprise 70% and 17% of the total protein, respectively.
The remaining proteins are involved in'regulating cyclic nucleotide metabolism (such as
phosphodiesterase and guanylate cyclase) and protein phosphorylations. The inner
segment is rich in mitochondria and ribosomes and functions to generate ATP at a very
rapid rate and to synthesize proteins actively (Hurley, 1992; Fein and Szuts, 1982).

2
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B. Visual Transduction Pathway
1. Visual Excitation
The photoresponse in vertebrate photoreceptors is now understood at a molecular
level. It begins when a photon of light activates an enzymatic cascade involving
rhodopsin (R), transducin (Gt) and phosphodiesterase (PDE) (Figure 1.2).
DISC m em brane
R*

Gt

gdp

n
'/

R*.Gt

Gte-GTP

PDE

PDE*

^

C*
Light

CGMP

Na

Na/K/Ca
exchanger
Plasma m em brane

Figure 1.2. Schematic of the visual excitation cascade

Rhodopsin is a 40-kDa integral membrane protein containing seven trans
membrane helices. The 11-cis-retinal chromophore lies in a hydrophilic pocket of the
protein, near the center of the membrane. Transducin is a member of the heterotrimeric
G-protein family and functions as a signal-coupling protein in visual excitation. This
peripheral membrane protein consists of a (39 kDa), (3 (36 kDa), and y (8 kDa) subunits.
The a subunit (Gta) has a guanyl-nucleotide-binding site, and it interconverts between an
inactive GDP-bound state and an active GTP-bound state. Photoexcited rhodopsin (R*)
activates transducin by forming a complex with it and catalyzing the exchange of GTP

R ep ro d u ced with p erm ission o f th e copyright ow ner. Further reproduction prohibited w ithout perm ission.

for bound GDP. The binding of GTP to transducin leads to the release ofR* for another
round of transducin activation. Indeed, -100 transducin can be activated during the
lifetime of a single R*. The conformational change induced by the binding of GTP also
induces the dissociation of Gta-GTP from Gt0y. Gta-GTP, the active form of transducin,
will in turn activate phosphodiesterase (PDE), the central effector enzyme in the
photoresponse. Rod PDE is a tetramer consisting of a catalytic heterodimer (PaP) to
which two inhibitory y subunits (Py) bind. Transducin activation causes Py to be
displaced from its inhibitory sites on PaP. Hydrolysis of cGMP by activated PDE
decreases the cGMP level in the photoreceptor cells. cGMP is a diffusible intracellular
second messenger used in many signal transduction systems. In rod photoreceptors, R, Gt
and PDE are localized to the disk membrane. cGMP is thus responsible for transmitting
the visual excitation signal from the disk membrane to the plasma membrane (Lagnado,
2000).

The plasma membrane of the rod photoreceptor contains cGMP-gated cationic
channels. In the dark when cGMP levels are high, the cGMP is bound to the channels and
the channels are kept open. Sodium ions flow into the outer segment because the
electrochemical gradient for Na+ is large. This gradient is maintained by Na+-K+ ATPase
pumps located in the inner segment. When cGMP levels decrease following light
activation, cGMP dissociates from the channels, causing the channel to close.
Consequently, the influx of Na+ decreases, and the plasma membrane becomes
hyperpolarized (more negative on the inside). This light-induced hyperpolarization is
then passively transmitted by the plasma membrane from the outer segment to the

4
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synaptic body (for review, see (Pugh, Jr. and Lamb, 2000; Lagnado, 2000; Palczewski
and Saari, 1997).

2. Termination and adaptation of the photoresponse
After the light is extinguished, the rod photoreceptor cell quickly recovers from
light excitation so that it can respond to the next light stimulus. In addition to response
termination, photoreceptor cells are also able to adjust their light sensitivity over a broad
range of background levels of illumination. This process, called light adaptation (or
background adaptation), maintains the working range of the transduction cascade within a
physically useful region of light intensities. The photoreceptor’s sensitivity is also
reduced by previous exposure to light bright enough to bleach a substantial fraction of the
photopigment (greater than 5%). This desensitization and subsequent recovery of
sensitivity occurring in darkness is called bleaching adaptation. The recovery from
bleaching adaptation is also known as dark adaptation. There is a strong similarity
between bleaching adaptation and background adaptation. During bleaching adaptation,
the retina behaves as if it is being illuminated by a steady light of gradually decreasing
intensity.
Although photoreceptor recovery and adaptation is not the simple reverse of the
photo-excitation, response recovery and adaptation mechanisms feed back onto many
steps of the excitation pathway (for reviews, see (Fain et al., 2001; Pugh, Jr. and Lamb,
2000; Pugh, Jr. et al., 1999; Detwiler and Gray-Keller, 1996; Fain et al., 1996)).

5

R ep ro d u ced with p erm ission o f th e copyright ow ner. Further reproduction prohibited w ithout perm ission.

a. Termination and desensitization of R*
First, activated rhodopsin needs to be deactivated so that it does not continue to
catalyze the activation of transducin. Deactivation of rhodopsin is initiated by rhodopsin
phosphorylation at multiple sites in its carboxyl-terminal region by rhodopsin kinase
(RK). The C-terminus of rhodopsin contains seven serines and threonines that are capable
of being phosphorylated in vitro. Nevertheless, it is likely that in vivo only one or a few
amino acids get phosphorylated and contribute to rhodopsin turnoff (Ohguro and
Palczewski, 1995; Kennedy et al., 2001). After phosphorylation, rhodopsin itself has
decreased ability to bind with transducin and to stimulate the GTP/GDP exchange on Gta
(Langlois et al., 1996; Xu et al., 1997). A complete inactivation of R* requires the
binding of arrestin (Gurevich and Benovic, 1993; Wilden, 1995; Krupnick and Benovic,
1998; Krupnick et al., 1997; Krupnick and Benovic, 1998). Arrestin binds specifically the
phosphorylated rhodopsin at its carboxyl-terminal sequence (Krupnick et al., 1994). Once
bound, arrestin completely blocks the interaction of transducin with rhodopsin.
b. Termination of Gta*-PDE*
To return to the dark state, activated PDE also needs to be turned off so that it
stops hydrolyzing cGMP. The turnoff of activated PDE is a key step and also a ratelimiting step of response termination. Gta* is deactivated by the hydrolysis of GTP
bound to Gta* and PDE activity is inhibited upon re-association of the catalytic subunits
of PDE with Py. Gta has an intrinsic GTPase activity (Fung et al., 1981). However,
turnover numbers of intrinsic GTPase are reported to be 1-2 m in1, nearly 100-fold too
slow (Sitaramayya and Liebman, 1983) to account for turnoff of the electrical response.
Therefore, there should exist GTPase-activating proteins (GAPs) in the rod outer segment.

6
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The first GAP identified was Py itself (Arshavsky and Bownds, 1992). Later, it was
reported that Py alone is insufficient for activating transducin GTPase and that one or
more factors in addition to Py must also be present in the outer segment (Angleson and
Wensel, 1993; Angleson and Wensel, 1994; Antonny et al., 1993; Arshavsky et al., 1994).
This supplementary factor was found to be RGS9-l(He et al., 1998). RGS9-1 is a
member of the RGS (the regulators of G protein signaling) family of GTPase accelerating
proteins. In the photoreceptor cell, RGS9-1 forms a tight complex with a G protein 3
subunit 5 type long splice variant (G35L) and functions to stabilize the Gta- GTP in a
conformation most favorable for hydrolyzing bound GTP (Slep et al., 2001) (Bourne,
1997). Actually, Py itself does not activate transducin GTPase but it enhances the
catalytic action of RGS9-1 by recruiting RGS9-1 for hydrolytic transition-state
stabilization (Slep et al., 2001). Deletion of the RGS9-1 gene in mice results in profound
slowing of photoresponse recovery and GTP hydrolysis by transducin in both rods (Chen
et al., 2000) and cones (Lyubarsky et al., 2001). hnmunolocalization of RGS9-1 reveals
that RGS9-1 is present in cones at significantly higher levels than in rods (Cowan et al.,
1998). This might account in part for the faster response kinetics and lower sensitivity of
cones compared to rods (Lyubarsky et al., 2001; Cowan et al., 1998).
c. Restoration of cGMP level by cGMP synthesis
Activation of the PDE hydrolyzes free cGMP, and the free concentration of
cGMP declines rapidly. Therefore, the restoration of the dark state also requires the re
synthesis of cyclic GMP so that the free cGMP concentration can reach a steady-state
concentration to produce a steady-state probability of opening of the cGMP-gated
channels. The synthesis of cGMP is largely produced by specialized photoreceptor

7
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guanylyl cyclases (retGC-1 and retGC2) (Lowe et al., 1995; Shyjan et al., 1992; Yang et
al., 1995). Both retGC-1 and retGC2 are members of a family of membrane-bound
cyclases and present in both rod and cone outer segments. However, retGC-1 is
apparently more abundant in cones.

3. Role of Ca in regulation of visual termination and adaptation
The concentration of Ca2+ is regulated by both the cGMP-gated channel and the
Na+/Ca2+-K+ exchanger. The cGMP-gated channels of both rods and cones are permeable
to a variety of monovalent cations (including Na+, K+, and Li+) as well as divalent cations
(including Ca2+). In darkness, the cGMP-gated channels are partially open and there is a
steady influx of Ca2+ into the photoreceptor. Ca2+ is transported out of the outer segments
by a Na+/Ca2+-K+ exchanger which exchanges four Na+ (inward) for one Ca2+ and one K+
(outward). In the light, the influx of Ca2+ into the outer segment decreases when the
cGMP-gated channels close. However, Na+/Ca2+-K+ exchange is not affected directly by
illumination so that Ca2+ continues to be transported out of the photoreceptor cells. This
results in a decrease in the intracellular Ca2+ concentration. The concentration of Ca2+ is
-500-700 nM in darkness and is -30-50 nM in saturating light (-10-20 fold change in the
free Ca2+ concentration) (Matthews and Fain, 2001; Sampath et al., 1999).
Ca2+-dependent modulation of visual transduction is the most important
mechanism for light adaptation in both rods and cones. Ca2+ regulates most of the turnoff
and restoration processes accompanying the photoresponse, including (a) alteration of the
lifetime of R* by modulation the activity of rhodopsin kinase (b) regulation of GC
activity; (c) regulation of the affinity of the outer segment channels for cGMP. Recently,

8
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Bums and Balyor have suggested that Ca2+ is also involved in the alteration of the gain of
the transduction cascade (Bums and Baylor, 2001).
a. Modulation of R* shutoff
During the response recovery and light adaptation, Ca2+ and recoverin (Rec) alter
the lifetime of R* by modulating the activity of RK. In the dark when the Ca2+
concentration is high, most of the recoverin is in the Ca2+-bound state. Rec-Ca2+ forms a
complex with RK at the membrane, blocking its activity. When Ca2+ drops during the
^I

light response, Rec releases its Ca and dissociates from RK. The elevated concentration
of free RK permits the rapid phosphorylation of R*. Arrestin then binds, substantially
quenching the R* activity. Recoverin has been shown to be important in mediating Ca2+dependent modulation of RK activity in vitro (Chen et al., 1995) and in vivo (Xu et al.,
1997).
b. Regulation of cGMP synthesis
The activity of the photoreceptor specific guanylate cyclase (ret-GC) is Ca2+sensitive (Lolley and Racz, 1982) and its cyclase activity increases as the Ca2+
concentration declines (Dizhoor et al., 1991; Gorczyca et al., 1994; Frins et al., 1996;
Koutalos et al., 1995). At least two small-molecular-weight Ca2+-binding proteins, named
as GC activating proteins (GCAPs), confer such a Ca2+ sensitivity on retGC (Cuenca et
al., 1998; Kachi et al., 1999). GCAP has three Ca2+-binding EF-hand regions (Palczewski
et al., 1994) and has high affinity for Ca2+. In a low Ca2+ situation, unoccupied GCAPs
stimulate the activity of retGC through dimerization of cyclase subunits (Yu et al., 1999).
When the Ca2+concentration is elevated, GCAP in its Ca2+-loaded form inhibits the
catalysis of retGCs. In addition to GCAPs, another GC regulatory protein, called GC

9
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inhibitory protein (GCIP) was recently discovered in amphibian photoreceptors (Li et al.,
1998). GCIP is also a small molecular-weight protein and shares some conserved
sequences with GCAP. GCIP does not stimulate ret-GC in low Ca2+ concentration, but it
inhibits the ret-GC activity when Ca2+ concentration rises. The role of GCIP in cyclase
regulation is presently unclear,
c: Regulation of cGMP-gated channel
The cGMP-gated channel from bovine rods also can be modulated by Ca2+ (Hsu
and Molday, 1993; Gordon et al., 1995; Bauer, 1996; Haynes and Stotz, 1997). In the (3
subunit of the channel, there exists a calmodulin (CaM) binding site which binds CaM at
high Ca2+ concentration (Chen et al., 1994; Weitz et al., 1998). Lowering Ca2+
concentration over the physiological range during illumination releases the CaM from the
channel, increasing the affinity of the channel for cGMP and leading to opening more
channels. Ca2+ also modulates the sensitivity of channel for cGMP by stimulating the
phosphorylation of the channel. One specific tyrosine (Tyr498) in the a-subunits appears
to be site of the phosphorylation by a membrane-associated protein kinase. After
phosphorylation, the sensitivity of cGMP-gated channel increases so that less cGMP is
required to keep it open (Gordon et al., 1992).
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C. Overview of PDE Superfamily
At present, 11 classes of PDE (>20 different genes products) have been reported
(Gopal et al., 2001). Each family is distinguished by its unique combination of enzymatic
characteristics, pharmacological inhibitory profiles and their distinct regulatory
mechanism, as well as their specific tissue, cellular and sometimes also subcellular
distributions (Table 1.1).

1.

Catalytic Domains

All PDEs have an approximately 270 amino acid homology region in the carboxyl
half which forms the catalytic domain (Charbonneau, 1990; Conti, 2000). Different PDEs
have different substrate specificities. PDE1, PDE10 and PDE 11 hydrolyze both cAMP
and cGMP well. PDE2, PDE3, PDE4, PDE7, and PDE8 prefer cAMP as substrate while
PDE5, PDE6 and PDE9 prefer cGMP as substrate. PDE7 and PDE8 have the highest
affinity for cAMP and PDE9 has the highest affinity for cGMP. Of all PDE types, PDE6
has the highest kcat/Km value (Mou et al., 1999a; Norton et al., 2000; Leskov et al., 2000),
which approaches the substrate diffusion limit.
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DPE class (Type)

of the copyright owner. Further reproduction

PDE1

PDE2
PDE3
PDE4

PDE5

to

PDE6

prohibited without perm ission.

PDE7

PDE1A
PDE IB
PDE1C
PDE2A
PDE3A
PDE3B
PDE4A
PDE4B
PDE4C
PDE4D
PDE5A
PDE6A
PDE6B
PDE6C
PDE7A

PDE8

PDE8A
PDE8B

PDE9

PDE9A

PDE10

PDE10A

PDE 11

PDE11A

Common name

Major location

Ca2+ calmodulin
dependent PDE

Brain, heart,
nose

cGMP-stimulated
PDE
cGMP-inhibited
PDE
cAMP-specific
PDE

Brain, heart,
liver
Heart, adipose
tissue
Lung, yeast

cGMP binding
PDE
Photoreceptor PDE

High-affinity
cAMP-specific
PDE, rohpraminsensitive
High-affinity
cAMP-specific
PDE, IBMXinsensitive
High-affinity
cGMP-specific
PDE
cAMP PDE and
cAMP-inhibited
cGMPPDE
cAMP and cGMP
hydrolyzing PDE

Type of regulatory
domain
Ca'VCaM,
phosphorylation.

Preferred
Substrate
cAMP
cGMP

Selective
Inhibitor
SCH 51866

GAF

cAMP

EHNA

Phosphorylation

cAMP

Phosphorylation

cAMP

Rolipram
Ro 201724

Lung, smooth
muscle
Photoreceptor
cells

GAF,
phosphorylation
GAF, y

cGMP

Sildenafil
Zaprinast
Zaprinast
E4021

(Francis et al., 2000; Corbin and
Francis, 1999)
(Francis et al., 2000)

Olfactory cells,
brain, skeletal
muscle

?

cAMP

Not reported

(Loughney and Ferguson, 1996;
Conti et al., 1995)

Thyroid gland

PAS

cAMP

Not reported

(Soderling and Beavo, 2000)

Spleen, small
intestine, brain

?

cGMP

Not reported

(Soderling and Beavo, 2000; Juilfs
etal., 1999)

Brain, skeleton
muscle

GAF

cAMP and
cGMP

Not reported

(Soderling and Beavo, 2000)

Prostate

GAF

cGMP and
cAMP

Not reported

(Yuasa et al., 2001; Yuasa et al.,
2000; Fawcett et al., 2000)

cGMP

Reference
(Kakkar et al., 1999; Zhao et al,
1997)
(Haslam et al., 1999; Juilfs et al.,
1999)
(Shakur et al, 2000)
(Conti, 2000; Torphy, 1998)

2. Regulatory Domains
PDEs have regulatory domains in the N-terminal half of the primary sequence.
For example, PDE1 has a CaM binding site immediately adjacent to the N-terminus,
which can bind Ca2+-CaM with high affinity. PDE4 has a PAS domain (named for their
occurrence in Drosophila Period protein, vertebrate aryl hydrocarbon nuclear translocator,
and Drosophila Single-minded protein) in the N-terminal region but its function is
presently unclear. PDE2, PDE5, PDE6 , PDE 10 and PDE11 have two cGMP binding
repeats, called GAF domains (named for their occurrence in cyclic GMP -regulated
PDEs, some adenylyl cyclase and the bacterial transcription factor FhlA) (Aravind and
Ponting, 1997) (Fig. 1.3). The GAF domains of all PDEs are set apart from most others
GAF domain-containing proteins by the presence of a (R/K)XmNKnD motif (Turko et al.,
1996; Granovsky et al., 1998b; Ho et al., 2000). PDE6 -GAF has the highest affinity for
cGMP (Gillespie and Beavo, 1989; Mou et al., 1999a; Norton et al., 2000). Homologous
GAF domains in PDE10A and PDE11A seem to lack a high-affinity allosteric cGMP
binding ability (Soderling et al., 1999; Fawcett et al., 2000). cGMP occupancy of the
GAF domains regulates, directly or indirectly, the catalytic rate of these PDE enzymes.
cGMP binding to the GAF domains of PDE2 allosterically increases the affinity of the
catalytic site for substrate by direct allosteric interactions. cGMP binding to the GAF
domains of PDE5 makes it a very good substrate for PKG (cGMP-dependent protein
kinase) orPKA (cAMP-dependent protein kinase). Once phosphorylated, catalysis is
stimulated at the active sites.
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Figure 1.3. The domain structure of GAF-containing phosphodiesterases.

3. Regulation of PDE by phosphorylation
PDE1, PDES, PDE4, and PDE5 are reported to be regulated and activated by
serine/threonine phosphorylation mechanisms. The kinases responsible for
phosphorylation and the possible functions of phosphorylation are listed in Table 1.2.
Phosphorylation of PDE 1 by PKA or CaM kinase II has not been shown to alter the
catalytic properties of this enzyme directly, but it does decrease the affinity of the
enzyme for Ca2+/CaM (Hashimoto et al., 1989; Sharma and Wang, 1985; Sharma and
Wang, 1986; Florio et al., 1994). In the cell, this is equivalent to decreasing the affinity
for Ca2+. The phosphorylation of PDE3 by PKA or insulin-dependent kinase stimulates
its activity directly and is used as a mechanism for attenuating the amplitude of the
cAMP signal in the cell (Macphee et al., 1988; Rascon et al., 1994; Smith et al., 1991;
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859

Ahmad et al., 2000). Phosphorylation also is an important mechanism of regulation of
the activity of PDE4 to rapidly decrease cAMP levels (Sette et al., 1994a). As mentioned
above, the major effect of phosphorylation of PDE5 is to cause a modest decrease in the
Kmfor cGMP and to allosterically enhance the cGMP-binding abilities (Corbin et al.,
2000).

Table 1.2. Phosphorylation of PDE superfamily
PDE
PDE1

Type
PDE1A
PDE IB
PDE1C

Protein kinase*
PKA
CaMII
?

PDE3

PDE3A
PDE3B

PKA
insulin-dependent
kinase

PDE4

PDE4A
PDE4B
PDE4C
PDE4D
PDE5A

?
?
?
PKA
PKA
PKG

PDE5

Function
References
decrease the affinity (Hashimoto et al.,
of enzyme for CaM 1989; Sharma and
Wang, 1985;
Sharma and Wang,
1986; Florio et al.,
1994)
Increase the enzyme (Macphee et al.,
activity for cAMP
1988; Rascon et al.,
1994; Smith et al.,
1991)
Increase the enzyme (Sette et al., 1994b)
activity for cAMP

Increase the affinity
of enzyme for
cGMP at the active
sites and the
noncatalytic cGMP
binding sites

(Corbin et al., 2000;
Turko et al., 1998)

*: PKA: cAMP-dependent icinase; PKG: cGMP-dependent kinase; PKC: protein kinase cdk5: cyclindependent kinase type 5; MAP kinase: myosin-dependent kinase; CaMII: CaM-dependent kinase II
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D. Structure and Regulation of PDE6
1. PDE Structure and Function
Photoreceptor PDE (PDE6 ) is the key effector enzyme in the vertebrate visual
transduction cascade. There are several isoforms of PDEs in photoreceptors: a
membrane-associated rod PDE (PDE-M), a soluble rod PDE (PDE-S) and a cone PDE
(PDE-C).
a. PDE-M
PDE-M is the most abundant photoreceptor PDE and is a tetramer containing two
similar but nonidentical catalytic subunits, a (99.2 kDa) and p (98.3 kDa), as well as two
identical y subunits (9.7 kDa) (Baehr et al., 1979; Ovchinnikov et al., 1986; Ovchinnikov
et al., 1987; Lipkin et al., 1988; Deterre et al., 1988). On each Pa and Pp, there is a
catalytic site and a noncatalytic cGMP binding site. Py functions to inhibit the cGMP
hydrolysis at the active sites (Hurley and Stryer, 1982) as well as to stimulate and
stabilize cGMP binding at noncatalytic cGMP binding sites (Yamazaki et al., 1982; Cote
et al., 1994; Mou et al., 1999b; Cote et al., 1994). Py also has recognition sites for binding
transducin (Yamazaki et al., 1990; Granovsky et al., 1998a; Ford et al., 1998; Skiba et al.,
1995; Skiba et al., 1995; Morrison et al., 1989; Cunnick et al., 1990).
b. PDE-S
PDE-S has the same Pa, Pp and Py subunits to those of PDE-M, except that PDES has a unique subunit, P8 . P8 was first identified as a 17 kDa protein that
immunoprecipitated with bovine retinal PDE (Hurwitz et al., 1985), and is supposed to
keep PDE-S soluble by interacting with the methylated, prenylated C-terminus of the
PDE catalytic subunits (Cook et al., 2000).
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c. PDE-C
The subunit stoichiometry of cone PDE is not as well defined as other isoforms of
PDE6 but is thought to consist of two identical a ’-subunits (Pa’), one or two 9.3 kDa
inhibitory y subunits (Py’), and one or two 17 kDa 8 subunits (P5). However, the
immunocytochemistry experiment on bovine retinal sections indicates that P8 exists only
rod outer segments (Florio et al., 1996), suggesting that PS bound to PDE-C may be a
artifact.

2. Regulation of PDE6 function by interaction of Py with PDE
Interactions between Py and the PaP are essential for the regulation of PDE
function in vertebrate rod photoreceptors during visual transduction (Fig. 1.4). Although
extensive studies have shown the significance of the interaction between PaP and Py,
actual binding affinity ofPy for PaP has never been conclusively determined. By
measuring the effects of dilution on the catalytic activities of membrane-bound native
PDE and purified PDE in solution, the dissociation constant of the bovine rod PDE has
been estimated indirectly to be less than 10 pM (Wensel and Stryer, 1986) and of the frog
rod PDE to be about 28 pM (D'Amours and Cote, 1999). High affinity binding of Py with
PaP results in very low basal activity in the dark-adapted state.
Previous peptide studies have indicated that two major regions on Py provide the
major interactions with PaP: (a) the carboxyl terminus amino acids (Lipkin et al., 1988;
Artemyev and Hamm, 1992; Takemoto et al., 1992; Brown, 1992; Skiba et al., 1995;
Granovsky et al., 1997)and (b) the central polycationic region (Granovsky et al., 1998a;
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Artemyev et al., 1996). The C-terminal region of Py, especially the last 7-10 amino acids,
interacts directly with the active sites (Artemyev and Hamm, 1992; Granovsky et al.,
1997). The binding of the C-terminal region to the active sites is regulated in a reciprocal
manner by noncatalytic cGMP occupancy at the GAF domain of frog PDE (D'Amours et
al., 1999). The central lysine-rich region of Py also interacts with Pap with high affinity,
but the function of this region ofPy is not quite clear. Cross-linking experiments
indicated that the site on P oeB that interacts with Py is between the second GAF domains
and catalytic sites (Natochin and Artemyev, 1996), raising the possibility that the central
region ofPy might be responsible for the regulation of noncatalytic cGMP binding.
Actually, it has been reported that a Py central peptide (Py24-45) was able to restore high
affinity cGMP binding to bovine cone PDE (Granovsky et al., 1998b).

3. Regulation of PDE function by interaction of Py with transducin
a. Models for transducin activation of PDE
When photoreceptor cells are exposed to light, Gta* -GTP binds to Py and
displaces it from its inhibitory site on PaP, causing activation of PDE. The activation of
PDE by transducin is the key step in the visual transduction and has been investigated
extensively. A number of models have been proposed for the mechanism of PDE
activation and for the subunit composition of the activated complexes. In addition, the
activation process has been reconstituted on membranes with purified PDE and purified
transducin (Fung and Nash, 1983; Tyminski and O'Brien, 1984; Wensel and Stryer, 1986;
Bennett and Clerc, 1989; Malinski and Wensel, 1992; Otto-Bruc et al., 1993; Melia et al.,
2000).
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The first model is that two transducins bind a single PDE with equal affinity and
each transducin contributes equally to PDE activation (Wensel and Stryer, 1990). To
support this, co-immunoprecipitation experiments have revealed a GTP-specific
interaction between Gta and Py in a one-to-one stoichiometry (Fung and GriswoldPrenner, 1989). A direct measurement also suggested that Gta bound per PDE ratio at
saturation is close to 2 (Clerc and Bennett, 1992).
However, there is evidence that the binding of the first high affinity Gta* to PDE
elicit 80-100% of the maximal activity of PDE, whereas the binding of the second low
affinity Gto* to PDE elicits little or no additional activation of PDE (Bruckert et al.,
1994). In this case, PDE would be nearly maximally activated through its interaction with
only one Gta* in the physiological situation. The interaction of the second transducin to
PDE might function to ensure a rapid deactivation of Gta* through the enhancement of
the rate of GTP hydrolysis (Bruckert et al., 1994). A recent reconstitution experiment
with purified PDE and transducin on cationic membranes was consistent with this model
that PDE is maximally activated when one Gta-GTPyS bound to the vesicles per PDE
(Melia et al., 2000). If this is true, then either there is only one catalytic site on PDE that
can be relieved of its inhibitory constraint by Py (Berger et al., 1999), or the two catalytic
sites on PDE are simultaneously activated by a single Gta-GTPyS.
The third model is that a higher affinity transducin contributing 30% or less of the
catalytic activity, with occupation of a second lower affinity transducin needed for full
activation (Bennett and Clerc, 1989; Clerc et al., 1992). This model has suggested that
transducin activation could stimulate the maximum catalytic potential of the PaP
catalytic dimer. However, Norton et al. showed that the rate of cGMP hydrolysis for
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taPDE is only half of the rate of trypsinized PDE (Norton et al., 2000). Therefore,
transducin activation fails to relieve completely Py inhibition at both active sites.
Activation of PDE catalysis by one, not two, activated transducin molecules in frog ROS
homogenates further confirms that the third model is unlikely,
b. Sites of interaction of Gta with Py
There are multiple distinct sites of interaction between activated Gta and Py (Fig.
1.4). The interaction between Gta-293-314 and Py46-87 is important for PDE activation,
especially the residue lie87, which is involved in relieving the inhibitory constraint ofPy
to allow the entry of substrate into the active pocket (Slep et al., 2001; Sondek et al.,
1994). Trp70 is important for Py GAP activity (Slepak et al., 1995) A second site of
interaction involves the polycationic region Py24-45 and residues 250-275 on the Gta
subunit (Cunnick et al., 1994; Artemyev et al., 1993). This interaction is supposed to
function as an anchor for transducin to form a complex with PDE6 during activation. A
Gta-induced conformational change in the Py24-46 region may result in a decreased
affinity ofPy for PaP and an increased affinity for Gta (Artemyev et al., 1993).
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Figure 1.4. Model of multiple sites of interaction of Py with PaP, Gta, RGS9 and
other proteins.

4. Regulation of PDE6 function by its GAF domains
The physiological function of the noncatalytic sites on PDE6 differs from what is
known about the regulatory properties of the PDE2 or PDE5 GAF domains. Two possible
regulatory mechanisms have been proposed for noncatalytic cGMP binding sites: (1)
regulating the free cGMP concentration by binding and buffering the cytoplasmic cGMP
concentration (Yamazaki et al., 1996) and (2) regulating the duration of PDE6 activation
by altering Py ability to act as a GAP for transducin inactivation (Cote et al., 1994).
a. Regulating the free cGMP concentration
In dark-adapted rod outer segments, the cytoplasmic cGMP concentration is about
3.5 pM, consistent with predictions of the cytoplasmic cGMP concentration based on
activation of the cGMP-gated ion channel of rod photoreceptors. However, the total
cGMP concentration is 60 pM (Cote and Bownds, 1984). About 95% of the total cellular
cGMP is bound to two classes of cGMP binding sites on PDE (Cote and Brunnock, 1993).
During visual excitation when cytoplasmic cGMP concentration is decreased, the bound
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cGMP is dissociated from the lower affinity cGMP binding sites. However, whether this
mechanism can help to restore the cGMP concentration in the cytoplasmic is questionable.
First, kinetics of cGMP dissociation from the high affinity binding sites is too slow to
participate in restoring cGMP concentration during the time of visual excitation and
recovery (Cote and Brunnock, 1993; Cote et al., 1994; Yamazaki et al., 1996; Norton et
al., 2000; Mou et al., 1999a). Second, only 50% or less of bound cGMP can be released
to buffer the cytosolic cGMP concentration during the visual excitation (Cote et al 1984;
Cote et al., 1986; Cote et al., 1989). Finally, the dissociated cGMP would be hydrolyzed
in milliseconds, if PDE remained activated (Calvert et al., 1998; Arshavsky et al., 1992).
b. Regulating the lifetime of Gta* by altering Py affinity for acting as a GAP
It has been reported that cGMP binding to the PDE noncatalytic sites modulates,
in a reciprocal way, the binding affinity of Py to both amphibian Pa(3 (D'Amours and
Cote, 1999) and mammalian PaP (Mou et al., 1999a; Mou and Cote, 2001a). In
amphibian PDE, cGMP binding to the non-catalytic sites lowers basal activity of PDE
holoenzyme. By gradually diluting frog ROS homogenates to the picomolar
concentration of PDE, D'Amours and Cote have estimated that the apparent binding
affinity of Py for PDE was 28 pM when cGMP occupied the non-catalytic sites, whereas
the binding affinity ofPy was 16-fold weaker when the sites were empty (D'Amours and
Cote, 1999). In mammalian PDE, cGMP binding to the non-catalytic sites increase the
binding affinity ofPy at least 10-fold at one of the binding site (Mou and Cote, 2001b).
Py, in combination with RGS9 and G05L, serves as a GTPase-activating protein
for transducin, accelerating transducin inactivation (Arshavsky et al., 1992; Arshavsky
and Bownds, 1992; Makino et al., 1999; Skiba et al., 2001; Skiba et al., 2000; Kovoor et
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al., 2000; Chen et al., 2000; Cowan et al., 1998; He et al., 1998). Py in its dissociated
form has a higher GAP activity than Py bound to the PDE-transducin complex (Tsang et
al., 1998; Cowan et al., 2000). Therefore, noncatalytic cGMP binding to the GAF
domains of PDE regulates some aspects of photoreceptor light adaptation by altering the
ability Py to act as a GAP.
Fig 1.5 describes a model of how the GAF domain regulates the lifetime of PDE
during visual excitation. When the sites are occupied by cGMP, Py has a higher affinity
for PDE and PDE forms a complex with activated transducin. In this state, the rate of
GTP hydrolysis is relatively slower, and PDE stays active for a relatively longer time. If
photoreceptors are exposed to continuous light, the cytoplasmic cGMP will be lowered,
inducing cGMP dissociation from the GAF domains. Emptying cGMP binding sites
induces a conformational change on PaJ3 so that Py has relatively lower affinity for PDE.
Activated transducin then removes Py from the PDE catalytic subunits. As a consequence,
the rate of GTP hydrolysis is accelerated by the Py-RGS9-1-G(35L complex and the
duration of PDE activation is reduced.
Whether or not the two PDE noncatalytic cGMP binding sites play an equal role
in the regulation of GTPase activity is not clear. In the nonactivated state, cGMP
dissociation from each of the PDE noncatalytic sites is independent of the occupation
state of the other site and there is a lack of cooperativity in cGMP binding to the
noncatalytic sites (Cote and Brunnock, 1993; Mou et al., 1999a; Norton et al., 2000).
However, once activated by transducin, cGMP dissociation from two noncatalytic
binding sites becomes heterogeneous. Removing the Py subunit results in rapid release of
cGMP from only one of the noncatalytic sites on frog PDE, and cGMP dissociation from
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the second binding site remains similar to that of the nonactivated PDE (Norton et al.,
2000). It is possible that cGMP dissociation from two different noncatalytic sites act to
regulate transducin GTPase based on the duration and/or intensity of light stimulation.
The former one is important to regulate the lifetime of PDE* in a short light response,
and the latter one is essential to regulate the lifetime of PDE* during adaptation to
continuous illumination.

G ta*

GM P

cGMP

Figure 1.5. Model for how cGMP binding to the GAF domains on PDE determines
the rate at which PDE is inactivated by transducin GTPase.
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5. Regulation of PDE function by GARP
GARPs are a class of glutamic acid-rich proteins. In rod photoreceptor cells, three
GARPs have been found: GARP1 (130 kDa) and GARP2 (62 kDa) are both soluble,
while the third one is the p-subunit of the cyclic nucleotide-gated channel (240 kDa)
(Sugimoto et al., 1991; Korschen et al., 1995; Ardell et al., 1995; Finn et al., 1996).
In mammalian rod outer segments, GARPs are restricted to the rim region and
incisures of discs and function as multivalent proteins that interact with the some key
players of cGMP signaling, such as PDE and guanylate cyclase, and retina-specific ATPbinding cassette transporter (ABCR) (Korschen et al., 1999). The assembly of these
signaling molecules into macromolecular complexes may provide intracellular signaling
pathway with higher specificity, sensitivity and speed in rod photoreceptors. Recently,
work done in our lab suggested that GARP2 also exists in frog photoreceptor cells
(Maftei et al., 2000). Immunoaffinity chromatography and co-immunoprecipitation
analyses suggested that frog GARP2 forms a tight complexes with PDE, transducin, and
RGS9 (Maftei et al., 2000). No similar GARPs have been found in cones (Korschen et al.,
1999). GARP2 potently inhibits PDE activity and associates more strongly with lightactivated than nonactivated PDE (Korschen et al., 1999). This sequestration of PDE
independent of inactivation of transducin might be a an important inactivation
mechanism at high light intensities, when a significant fraction of active PDE is reaching
the disc margin. In this way, GARPs may function to down-regulate cGMP turnover in
the daylight when rod function is saturated.
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6.

Regulation of PDE6 function by post-translational modifications

a: Isoprenylation/methylation of PDE6
Many proteins in the visual excitation pathway (such as rhodopsin, transducin and
PDE) as well as other regulators of transduction [rhodopsin kinase (RK), arrestin and its
homologues, RGS9-GJ35L, etc.] are either membrane-associated or integral membrane
protein. About 70-80% of the phosphodiesterase activity found in bovine rod outer
segments is membrane-bound (Cook et al., 2001). In frog rod outer segments, > 90% rod
PDE is membrane-associated (Norton et al., 2000). The association of multiple cascade
components to the membrane facilitates the interaction of these proteins during signaling
so that vertebrate photoreceptors can respond to light as a 2 -dimentional collision
process, ensuring both a high degree of signal amplification and fast signal termination
on the physiological subsecond time scale.
Rod PDE is anchored to the disc membrane through its C-terminal isoprenylated
and carboxymethylated modifications (Cook et al., 2001; Qin et al., 1992). Limited
proteolysis of the C-terminus of the PDE catalytic subunits correlates with loss of
membrane binding (Catty and Deterre, 1991; Wensel and Stryer, 1986; Ong et al., 1989),
suggesting that C-terminal modifications are the major contributor to PDE interaction
with disc membranes. The P a subunit is modified by a farnesyl (C-15) group on the
cysteine of the C-terminal motif CCVQ, whereas the Pj3 subunit is modified by a
geranylgeranyl (C-20) group on the cysteine of CRIL (Qin et al., 1992; Anant et al.,
1992). In addition, both C-termini are methylated (Ong et al., 1989).
The 17 kDa P 8 subunit has previously been shown to co-purify with the soluble
form of PDE6 , and it functions to solubilize the membrane-bound form by interaction
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with the methylated, isoprenylated C-terminus of the PDE catalytic subunits (Cook et al.,
2000). After released from the disc membrane, PDE cannot be activated by transducin.
Therefore, solubilization of PDE by PS might be a possible desensitization mechanism
during light adaptation. The binding of PS to membrane-associated PDE is regulated by
the C-terminal prenylation and methylation of the catalytic subunits. Prenylation and
methylation are both potentially reversible and regulated by prenyl (methyl) transferase
and prenylester (methylester) hydrolase (Rando, 1996).
b: ADP-ribosylation of Py
ADP-ribosylation of Py has also been demonstrated as a potential mechanism for
the regulation of the interaction between Py and Gta. Rod outer segments contain two
endogenous glycosylphosphatidylinositol-anchored ADP-ribosyltransferase isozymes,
and these two isozymes have similar properties in ADP-ribosylating Py. Two arginines
(Arg33 and Arg36) in the central region of Py are ADP-ribosylated when Py is free or
complexed with the catalytic subunits of PDE (Bondarenko et al., 1999; Bondarenko et
al., 1997). After ADP-ribosylation, Py loses its interaction with Gtcc-GTP (Bondarenko et
al., 1999). ADP-ribosylation ofPy is reversible. Bondarenko et al. have shown that a
soluble fraction ofROS contains an enzyme(s) to release the radioactivity of [32P]ADPribosylated Py in a concentration- and time-dependent manners (Bondarenko et al., 1999).
This suggests that reversible Py ADP-ribosylation may function as a negative regulator of
transducin-dependent activation of PDE in phototransduction,
c. Phosphorylation of Py and PaP
There are 8 potential phosphorylation sites in the Py sequence. The central region
ofPy contains most of the predicted phosphorylation sites. To date, several protein
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kinases have been found to exist in ROS and some of them have predicted
phosphorylation sites on Py (Table 1.3).
Py phosphorylation has been studied both in vivo (Hayashi, 1994; Matsuura et al.,
2000) and in vitro by several protein kinases, including phosphatidylinositol (PI)stimulated kinase (Hayashi et al., 1991), protein kinase C (PKC) (Udovichenko et al.,
1994), PKA (Xu et al., 1998), and cdk5 (originally termed “Py kinase”) (Tsuboi et al.,
1994b; Tsuboi et al., 1994a; Hayashi et al., 2000; Matsuura et al., 2000).

Table 1.3: Protein kinases found in the rod outer segment of photoreceptors
Protein kinase
found in ROS*
RK
PKA
PKC
PKG
MAP kinase
Cdk5 (Py
kinase)
CaMII
CKII
Protein-tyrosine
kinase (such as
Src)

Reference

Consensus
Sequence

(Lee et al., 1981)
(Walter, 1984)
(Kelleher and Johnson, 1985;
Udovichenko et al., 1997)
(Taylor and Uhler, 2000)
(Ko et al., 2001)
(Hayashi et al., 2000)
(Liu et al., 2000)
(Hollander et al., 1999)
(Bell et al., 2000)

RX 1.2S/TX
XS/TXR/K

Potential
sites on Py
Thr62
Thr15
Thrj5

(R/K)2.3XS/TX
PXS/TP
KS/TPXK

ThrJi
Thr22...... ~
Thr22

RXXS/TX
XS/TXXD/E

Thr14
Not Found
Tyr*4

-

*: RK: Rhodopsin kinase; PKA: cAMP-dependent kinase; PKG: cGMP-dependent kinase; PKC: protein
kinase cdk5: cyclin-dependent kinase type 5; MAP kinase: mitogen-activated protein kinase; CaMII: CaMdependent kinase II

The physiological function of Py phosphorylation is not clear in the current
scheme of phototransduction. However, Py phosphorylation by the PKA, PKC or cdk5
has been reported to enhance the inhibitory effect of Py on Pap catalysis (Xu et al., 1998;
Udovichenko et al., 1994). In addition, phosphorylation of Py by PKC is reported to
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eliminate the binding heterogeneity of Py to PaP, resulting in a single class of Py binding
sites (Udovichenko et al., 1994). These earlier studies suffered from several deficiencies
that limited their usefulness. For example, the concentration of PDE used in their assays
was in the nanomolar range, whereas the Py affinity occurs in the pM range; thus, Py
should inhibit the catalysis of PDE in a concentration-dependent manner and the effect of
Py phosphorylation would be obscured. In addition, PDE preparations used in the earlier
studies also contained transducin which can also bind Py, further complicating analysis of
Py phosphorylation.
Yamazaki and his colleagues have also suggested that phosphorylated Py loses or
decreases its ability to interact with Gta*. Phosphorylated Py has less ability to inhibit
GTPyS binding to Gta or to inhibit GTPase activity of Gta, but it gains a 10-15 times
higher ability to inhibit Gta-activated PDE than that of non-phosphorylated Py (Xu et al.,
1998; Tsuboi et al., 1994b; Hayashi et al., 2000). They proposed that the Py
phosphorylation is probably involved in the PDE inactivation and light recovery phase of
phototransduction and that it operates without shutoff of Gta*. They also reported that Py
in frog ROS homogenates can be phosphorylated in vivo in a light-stimulated manner
(Tsuboi et al., 1994b; Hayashi et al., 2000). However, the total phosphorylation level of
Py is rather low (< 10 %) so that the real physiological function of Py phosphorylation is
remained uncertain.
To date, there is only one report demonstrating phosphorylation of PDE catalytic
subunits in vitro by recombinant PKA or PKC (Udovichenko et al., 1993). PKC
phosphorylates only P a subunit of PDE holoenzyme or trypsinized PDE. In contrast,
PKA phosphorylates both P a and PP subunits. In addition, PKA does not phosphoiylate
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trypsin-activated PDE. Since trypsinization removes the part of C-terminal regions from
Pap, it is possible that PKA phosphorylates PDE catalytic subunits at its C-terminal
region while PKC phosphorylates PDE catalytic subunits at other region. Udovichenko et
al. reported that a synthetic peptide AKVISNLLGPREAAV (Pa30-44) inhibited
phosphorylation of PDE catalytic subunits by PKC from ROS, suggesting that Ser34 of
P a subunit is a likely phosphorylation sites for PKC. Currently, the function of PDE
catalytic subunit phosphorylation on PDE regulation is not clear.

E: Goal and Hypotheses to be Tested
The overall goal of my dissertation research to define the regulatory mechanisms
that determine how long, and to what extent, this central enzyme in vision remains
activated following exposure of mammalian rod photoreceptors to light. My whole work
is divided into three sections:
(1) Study how cGMP catalysis and binding to noncatalytic sites on mammalian rod
PDE is regulated by its small molecular weight subunits (y and 8 )
Photoreceptor PDE (PDE6 ) associated with membranes in rods is an oligomer
consisting of similar a and p catalytic subunits and two identical inhibitory y subunits
(aPyy) (Deterre et al., 1988). On each a and P subunit there is one catalytic site
preferring cGMP to cAMP as a substrate, and one noncatalytic site which binds cGMP
with high affinity. cGMP is the primary intracellular messenger for controlling the
physiological response of both rod and cone photoreceptor cells to light (Pugh, Jr. and
Lamb, 1993; Yau, 1994; Pugh, Jr. et al., 1999). Characterization of the binding of cGMP
to the noncatalytic sites in PDE will help to evaluate their role in regulating PDE during
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phototransduction. For the photoreceptor PDE, most of our knowledge about the role of
the noncatalytic sites in PDE regulation has been obtained with amphibian rod PDE. It
has been found that cGMP occupancy at the noncatalytic binding sites of frog
photoreceptor PDE enhances the association of Py with PaP in a reciprocal manner, and
it has been postulated that cGMP binding at the noncatalytic binding sites may determine
whether the Py subunit can participate as an accessory GTPase-activating protein for
accelerating transducin inactivation (Arshavsky et al., 1992; Cote et al., 1994). In
addition, the noncatalytic sites on frog rod PDE have been postulated to serve as a
cytoplasmic buffer for cGMP, possibly serving to help restore cGMP levels during
recovery from the light stimulation (Cote and Brunnock, 1993; Yamazaki et al., 1996).
Compared to amphibian PDE, much less is known about the cGMP binding properties to
noncatalytic cGMP-binding sites on photoreceptor PDE from mammalian rod
photoreceptors. In this part of my work, my goal is to characterize the properties of
cGMP binding to noncatalytic sites on mammalian rod photoreceptor PDE, and also
investigate how they are regulated by Py and P5.
(2) Functionally map the domains on Py that interact with and regulate PDE
function
Interactions between Py and the PaP catalytic dimer are essential for the
regulation of cGMP levels in vertebrate rod photoreceptors during visual transduction. Py
has multiple functions: it functions to inhibit the cGMP hydrolysis at the active sites
(Hurley and Stryer, 1982) as well as to stimulate and stabilize cGMP binding at
noncatalytic cGMP binding sites (Yamazaki et al., 1982; Cote et al., 1994); Py also has
recognition sites for binding transducin (Skiba et al., 1995; Morrison et al., 1989;
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Cunnick et al., 1990); In addition, Py serves as a GTPase-activating protein (GAP)
together with RGS9 (Arshavsky & Bownds, 1992; He et al, 1997). By using synthetic
peptides of Py or site-directed mutants of recombinant Py, it has been found that Py
contains at least two regions that interact with PaP: a central cationic region and a
hydrophobic C-terminal region (Artemyev & Hamm, 1992; Takemoto et al., 1992).
Cross-linking studies have shown that the carboxyl-terminus ofPy interacts with the
catalytic sites of PaP both physically and functionally (Artemyev et al., 1996). The
central region is also important in the interaction ofPy with PaP but does not directly
contribute to PDE inhibition (Artemyev et al., 1996). Cross-linking experiments have
also localized a region just past the end of the second noncatalytic cGMP-binding domain
that binds to the central polycationic domain of Py (Artemyev et al., 1996). This suggests
that the central region ofPy might be responsible for the regulation of noncatalytic cGMP
binding. It has been reported that a Py central peptide (Py24-45) was able to restore high
affinity cGMP binding to bovine cone PDE (Granovsky et al., 1998), but a similar
peptide has no major effect on frog rod PDE (D'Amours & Cote, 1999). Thus, how Py
stimulates and stabilizes high affinity cGMP binding is still elusive. In this part, I will
first measure carefully the binding affinity of the full-length Py to PDE catalytic PaP
subunits. Then I will functionally map the distinct domains on the inhibitory Py subunit
which regulate cGMP binding at the noncatalytic binding sites as well as cGMP catalysis
at the active sites of mammalian rod PDE6 .1 will also identify the region that contributes
most to the high binding affinity ofPy to Pap. This work will help us to understand how
cGMP binding at noncatalytic binding sites and cGMP catalysis at the active sites of
mammalian rod PDE 6 are regulated by distinct domains of the inhibitory Py subunit.
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(3) Investigate the role of Py and PaP phosphorylation in regulating PDE during
phototransduction.
A role for Py phosphorylation in modulating the interaction between Py and PaP
as well as with the transducin a subunit has been suggested in several studies (Xu et al.,
1998; Tsuboi et al., 1994a and 1994b). In addition, several protein kinases known to exist
in rod photoreceptors have potential phosphorylation sites on Py. However, the
mechanism for PDE to be regulated by Py phosphorylation during the photoresponse is
still not known. Furthermore, we do not know if Pap phosphorylation also participates in
regulating photoreceptor PDE. In this work, I will examine how Py or PaP
phosphorylation regulates PDE by modifying the interaction between Py and Pap, as well
as the catalytic properties of PDE at its active site and the noncatalytic cGMP binding
affinity to its GAF domains. I hypothesize that Py or Pap phosphorylation does not
regulate directly Py binding affinity or PDE catalysis, but rather serves to regulate its
allosteric cGMP binding properties.
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Chapter I
cGMP binding to noncatalytic sites on mammalian rod photoreceptor
phosphodiesterase is regulated by binding of its y and 8 subunits*
Abstract
The binding of cGMP to the noncatalytic sites on two isoforms of the
phosphodiesterase (PDE) from mammalian rod outer segments has been characterized to
evaluate their role in regulating PDE during phototransduction. Nonactivated, membraneassociated PDE (PDE-M; 01PY2) has one exchangeable site for cGMP binding;
endogenous cGMP remains nonexchangeable at the second site. Non-activated, soluble
PDE (PDE-S; 0^ 728) can release and bind cGMP at both noncatalytic sites; the 8 subunit
is likely responsible for this difference in cGMP exchange rates. Removal of the 8 and/or
y subunits yields a catalytic a|3 dimer with identical catalytic and binding properties for
both PDE-M and PDE-S: high affinity cGMP binding is abolished at one site ( K d > 1
pM); cGMP binding affinity at the second site (Kd ~ 60 nM) is reduced 3-4 fold
compared to he nonactivated enzyme; the kinetics of cGMP exchange to activated PDEM and PDE-S are accelerated to similar extents. The properties of nonactivated PDE can
be restored upon addition of y subunit. Occupancy of the noncatalytic sites by cGMP may
modulate the interaction of the y subunit with the a(3 dimer and thereby regulate

*. This chapter was published in its entirety in J. Biol Chem. (274, 18813-18820, 1999)
and was Scientific Contribution no. 1994 from the New Hampshire Agricultural
Experiment Station. This work was supported by NIH grants EY-05798 (R.H.C.) and
EY-08197 (J.A.B.).
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cytoplasmic cGMP concentration and the lifetime of activated PDE during visual
transduction in photoreceptor cells.
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Introduction
The cGMP phosphodiesterase (PDE) 1 present in rod and cone retinal
photoreceptors is the central effector enzyme for vertebrate visual excitation. Photo
activation of the visual pigment rhodopsin leads to G-protein (transducin) activation,
which then proceeds to the activation of PDE. The activated a-subunit of transducin (atGTP) is believed to activate the membrane-associated rod PDE holoenzyme (subunit
stoichiometry: 0 ,372) by displacing the inhibitory y subunits (Py) from the active sites of
the catalytic heterodimer (Pa{3). The enhanced hydrolytic activity of the activated PDE
rapidly reduces cytoplasmic cGMP levels, and then leads to dissociation of bound cGMP
from the cGMP-gated ion channel, closure of the ion channel, and finally a
hyperpolarization of the membrane. These steps constitute the excitation pathway for
vertebrate visual transduction (for reviews, see (Pugh, Jr. and Lamb, 1993; Helmreich
and Hofmann, 1996; Palczewski and Saari, 1997; Helmreich and Hofmann, 1996;
Palczewski and Saari, 1997)).
The photoreceptor PDE is a member of a family of phosphodiesterases that all
share the ability to hydrolyze cyclic nucleotides. The PDE in rods and cones (classified as
PDE6 ; (Beavo, 1995)) is most closely related to the cGMP-specific PDE (PDE5) based
on several criteria, including overall amino acid sequence similarity, substrate preference
for cGMP over cAMP, inhibition of catalysis by isozyme-selective drugs, and the
presence of a consensus sequence in the N-terminal half of the protein that represents
noncatalytic cGMP binding domains. In the case of PDE5, binding of cGMP to the
noncatalytic cGMP binding sites may regulate activity indirectly via protein
phosphorylation of the enzyme (reviewed in ref. (Bums et al, 1996)). The cGMP-
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stimulated PDE (PDE2) also contains noncatalytic cGMP binding sites that allosterically
regulate catalysis at the active site (Martins et al., 1982).
For the photoreceptor PDE, most of our current knowledge about the role of the
noncatalytic sites in PDE regulation has been obtained with amphibian rod PDE. It has
been found that cGMP occupancy at the noncatalytic binding sites of frog photoreceptor
PDE enhances the association of Py with Pap in a reciprocal manner, and it has been
postulated that cGMP binding at the noncatalytic binding sites may determine whether
the Py subunit can participate as an accessory GTPase-activating protein for accelerating
transducin inactivation (Yamazaki et al., 1980; Yamazaki et al., 1982; Arshavsky et al.,
1992; Cote et al., 1994; Yamazaki et al., 1982; Arshavsky et al., 1992; Cote et al., 1994).
In addition, the noncatalytic sites on frog rod PDE have been postulated to serve as a
cytoplasmic buffer for cGMP, possibly serving to help restore cGMP levels during
recovery from the light stimulation (Cote and Brunnock, 1993; Yamazaki et al., 1996;
Yamazaki et al., 1996).
Much less is known about the function of noncatalytic cGMP binding sites on
photoreceptor PDE during visual transduction in mammalian rod photoreceptors. Two
distinct isoforms o f rod PDE have been described in bovine rod photoreceptors, a
membrane-associated PDE (PDE-M) and a soluble PDE (PDE-S) (Baehr et al., 1979;
Gillespie et al., 1989; Gillespie et al., 1989). The only known difference between the two
isoforms is the presence of a 17 kDa 8 subunit (P8) associated with PDE-S but not PDE-

1. The abbreviations used are: PDE, photoreceptor phosphodiesterase; PDE-M,
membrane-associated bovine rod PDE; PDE-S, soluble bovine rod PDE; nPDE, non
activated PDE; tPDE, trypsinized PDE; Pa(3, catalytic dimer of PDE; Py, inhibitory 10
kDa y subunit of PDE; P8 , 17 kDa 8 subunit associated with PDE-S; KD, dissociation
constant.
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M (Gillespie et al., 1989). The PS subunit can solubilize membrane-associated PDE in
vitro (Florio et al., 1996), but its role in visual transduction has not been determined. The
noncatalytic cGMP binding sites on bovine PDE-M have been shown to bind and release
cGMP very slowly (Gillespie and Beavo, 1989a), and little is known about the cGMP
binding properties of PDE-S. Thus, it remains unclear whether the noncatalytic sites on
mammalian rod PDE play a similar physiological role to what has been proposed for the
amphibian system.
In this chapter, we first show that PDE-M and PDE-S in their nonactivated states
have different cGMP binding properties. Both high affinity cGMP sites on PDE-S are
slowly exchangeable, whereas PDE-M contains one exchangeable and one
nonexchangeable noncatalytic site. The presence of the 8 subunit in PDE-S suggests a
role for this subunit in enhancing cGMP exchange at one noncatalytic site that is
nonexchangeable in PDE-M. Second, activation of the two isoforms leads to similar
behavior of PDE-S and PDE-M in terms of: (1) a large decrease in cGMP binding affinity
at one noncatalytic site; (2) a ~ 10-fold acceleration of cGMP exchange at the remaining
high affinity site; and (3) similar hydrolytic rates at the active site. While it is unlikely
that cGMP binding and release at the noncatalytic sites regulate PDE activity during the
early events of visual excitation, changes in cGMP occupancy at the noncatalytic sites
may help regulate the lifetime of activated PDE during later stages of the visual
transduction pathway.
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E x p e r im e n t a l P r o c e d u r e s
Materials—Bovine retinas were purchased from W.L. Lawson, Inc. Radiochemicals were
obtained from NEN Life Sciences Products, and scintillation fluid (Ultima Gold) was
from Packard Instrument Co. Zaprinast was a gift of Rhone-Poulenc Rorer (Dagenham,
U.K.). Sulfolink coupling gel was obtained from Pierce. Pefabloc was obtained from
Boehringer-Mannheim. cGMP antisera for radioimmunoassays were purchased from
Chemicon. Filtration and ultrafiltration products were from Millipore. Superdex 200 and
Mono Q columns, as well as pGEX-2T vector and glutathione-Sepharose 4B were from
Pharmacia. The thrombin cleavage capture kit was from Novagen. The reverse-phase
columns for Py purification were from Vydac. Electrophoretic reagents and
immunochemicals were from Bio-Rad. All other chemicals were obtained from Sigma.
Preparation o f nonactivated PDE-S (nPDE-S) and PDE-M (nPDE-M) —Both PDE-S and
PDE-M were first partially purified from frozen bovine retinas by modifications of the
ion exchange and immunoaffinity chromatography procedures described previously
(Gillespie et al., 1989; Gillespie and Beavo, 1989a; Gillespie and Beavo, 1988; Gillespie
and Beavo, 1989a; Gillespie et al., 1989). Under infrared illumination, thawed retinas
were stirred in a beaker containing 1.5 ml per retina ofROS Buffer (60 mM KC1, 30 mM
NaCl, 2 mM MgCl2, 20 mM MOPS, 1 mM dithiothreitol, 0.2 mM phenylmethylsulfonyl
fluoride, pH 7.2) containing 47.5% (w:v) sucrose. The retinal homogenate was
centrifuged for 1 h a t 8,000 x g (4°C), and the supernatant (containing both membraneassociated and soluble PDE isozymes) was removed from the pellet. The pellet was
homogenized in 0.4 ml ROS Buffer per retina to extract additional soluble PDE
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isozymes, and then centrifuged at 96,000 x g for 45 min at 4°C. The supernatant resulting
from this spin was pooled with the soluble PDE isozymes obtained below.
The sucrose-containing supernatant from the first centrifugation was diluted 2fold with ROS Buffer, and then centrifuged (23,000 x g for 45 min at 4°C). The pellet
contained crude ROS which were used to extract PDE-M. The supernatant of this spin
(containing soluble PDE isozymes) was combined with the other soluble PDE-containing
supernatant. DE-52 anion exchange chromatography was employed to separate cone PDE
from PDE-S, essentially as described by Gillespie and Beavo (Gillespie and Beavo,
1988). PDE-S was further purified by immunoaffmity chromatography using the
monoclonal antibody ROS 1 (Hurwitz et al., 1984) immobilized on a Sulfolink agarose
gel.
The crude ROS pellet (containing PDE-M) was restispended in ROS buffer,
homogenized, and centrifuged at 27,000 x g for 45 min at 4°C to remove soluble proteins.
After repeating this isotonic washing and centrifugation of the ROS membranes twice,
the ROS membranes were exposed to light at 4°C. PDE-M was extracted four times from
the ROS membranes by the following sequence: (1) resuspension and homogenization of
the ROS membrane pellet in 0.5 ml/retina of 10 mM Tris, 1 mM MgCfe, 1 mM
dithiothreitol, 0.2 mM phenylmethylsulfonyl fluoride (pH 7.5); (2) centrifugation at
96,000 x g for 45 min at 4°C; (3) collection of the PDE-M-containing supernatant.
Immunoaffmity purification of the hypotonically extracted PDE-M was then performed.
Immunopurified PDE (PDE purity, ~80%) was concentrated in a Centricon
concentrator, and placed in storage buffer (100 mMNaCl, 2 mM MgCfj, 10 mM Tris, 2
mM dithiothreitol, 0.4 mM Pefabloc, pH 7.5) containing 50% glycerol at -20°C. Both
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PDE-S and PDE-M were further purified by gel filtration chromatography on a Superdex
200 HR 10/30 column equilibrated with Buffer A (120 mM NaCl, 5 mM MgCfe, 25 mM
HEPES, pH 7.5, 2 mM dithiothreitol, 0.2 mM Pefabloc). After elution, the purified PDE
was concentrated and stored as described above. SDS polyacrylamide gel electrophoresis
of the purified, non-activated PDE-S (nPDE-S) and non-activated PDE-M (nPDE-M; Fig.
1A, lanes 5 and 6, respectively) shows that >90% of the Coomassie-stained bands
represent the catalytic and low molecular weight subunits of PDE. For five different
purified PDE preparations, we recovered 2.6 ± 1.1 nmol of purified nPDE-M and 1.0 ±
0.4 nmol nPDE-S per 100 bovine retinas using these procedures.
Preparation o f trypsinized PDE-M (tPDE-M) and PDE-S (tPDE-S)—To prepare
Pap dimers from nPDE-S and from nPDE-M, limited proteolysis with L-1-tosylamido-2phenylethyl chloromethyl ketone-treated trypsin was performed (Baehr et al., 1979; Miki
et al., 1975; Hurley and Stryer, 1982; Baehr et al., 1979; Hurley and Stryer, 1982).
Purified nPDE (0.8 - 1.0 mg/ml) was prepared in 25 mM MOPS (pH 7.5) containing
25% glycerol, and incubated at 4°C with 50 pg/ml of trypsin for 35-40 min. These
conditions were optimized to obtain complete enzyme activation (using a PDE activity
assay) without causing the appearance of a 70 kDa proteolytic fragment of the catalytic
subunits (as judged by Coomassie-stained SDS polyacrylamide gels of the trypsinized
enzymes [Fig. 1.1A, lanes 3 and 4; see also (Catty and Deterre, 1991; Artemyev et al.,
1996; Artemyev et al., 1996)]. Proteolysis was halted with a 10-fold weight excess of
soybean trypsin inhibitor. Analysis of the trypsinized PDE-S (tPDE-S) preparation at this
stage showed that the P8 subunit was not degraded to a significant extent (Fig. 1.1B, lane
4).
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The trypsinized PDE (tPDE) was then diluted >500-fold into Buffer A to enhance
dissociation of the low molecular weight subunits and their proteolytic fragments.
Ultrafiltration (BioMax, 30,000 molecular weight cut-off) of the tPDE was performed to
concentrate the enzyme. Substantial amounts of a -4,500 kDa band that immunoreacted
with the C-terminal Py polyclonal antibody (UNH9710-4P) remained in the tPDE
samples at this stage (Fig. 1.1B, lanes 3 and 4).
To prepare pure Pa|3 preparations from the trypsinized enzyme preparations, the
tPDE was further purified by Superdex-200 chromatography using Buffer A as the
mobile phase. This was followed by anion exchange chromatography on a Mono Q HR
5/5 column equilibrated in 250 mM NaCl, 1 mM MgCk, 25 mM Tris (pH 7.5), 1 mM
DTT, and 0.2 mM phenylmethylsulfonyl fluoride, using a linear gradient from 250 to 500
mM NaCl to elute Pa(3 dimers. The purity of the Pa(3-S or Pa(3-M prepared from tPDE-S
ortPDE-M, respectively, was found to be >90% by Coomassie stained gels (Fig. 1.1 A,
lanes 3 and 4), with undetectable levels of Py or P5 immunoreactivity (Fig. 1.1B, lanes 5
and 6).
Determination o f the catalytic constant (kcat) fo r trypsin-activated PD E~W e routinely
determined the concentration of native PDE by measuring the maximum hydrolytic
activity (Vmax) of a PDE-containing sample following limited proteolysis to fully activate
the enzyme (described above); using activity measurements instead of total protein
determinations to estimate the PDE concentration distinguishes native (i.e., non
denatured) PDE from denatured enzyme and minor impurities present in our PDE
preparations.
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To calculate the concentration of enzyme from the equation, [Pa3] = ^W/kcat, we
needed to accurately determine the catalytic constant (kcat) for our PDE-M and PDE-S
preparations. The determination of the kcat required independent knowledge of the PDE
concentration, which was obtained by total protein determinations (Bradford method) and
by measuring the maximum cGMP binding site density (Bmax). The latter approach relies
on observations that bovine nPDE-M can bind 2.0 mol of cGMP per mol catalytic dimer
(Gillespie and Beavo, 1989a) and that tPDE is capable of binding only 1 mol of
[3H]cGMP per mol of catalytic dimer under our conditions (see Results). For the case of
PDE-M, the trypsin-activated enzyme has a kcat - 5550 ± 100 mol cGMP
hydrolyzed/s/mol [3H]cGMP bound (n = 24) at 22°C. Trypsin-activated PDE-S is able to
hydrolyze 5620 ±110 mol cGMP/s/mol [3H]cGMP bound (n = 16). We have used the
average value, kcat = 5600 cGMP hydrolyzed/Pafl/s, in our calculations of PDE
concentration. This value is 22 ± 3% (n = 4) higher than that obtained in identical PDE-S
and PDE-M samples in which the Bradford assay was used to quantitate PDE
concentration (kcat = 4930 cGMP hydrolyzed/PDE/s).
Purification ofP yand PS—The recombinant bovine rod Py subunit was expressed
in bacteria as described in (Artemyev et al., 1998) with the following modifications.
Following cation exchange chromatography, Py was chromatographed on a preparative
€18 reverse-phase column (300 A, 22 x 250 mm) using a linear gradient of 30-50%
acetonitrile in 0.1% trifluoroacetic acid. The purity of the Py peak was verified on an
analytical Vydac C4 reverse-phase column (300 A, 4.6 x 25 mm) and by SDS
polyacrylamide gel electrophoresis (Fig. 1.1 A, lane 1). The concentration ofPy was
routinely measured spectrophotometrically after having empirically determined the
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extinction coefficient (S277 - 7550 cm-M'1 in 45% acetonitrile, 0.1% trifluoroacetic acid)
in conjunction with amino acid analysis. The inhibitory activity of Py preparations was
assessed as described previously (Hamilton et al., 1993), and was typically >95% active.
The recombinant P8 subunit was expressed and purified by two different methods
(this work was done by Terry A. Cook, University of Washington, Seattle, WA). In the
first method, the PS subunit was overexpressed in Sf9 cells using a baculovirus
expression system; the protein was then purified by anion exchange chromatography and
ultrafiltration, as described in detail in Florio et al. (Florio et al., 1996). The second
method was to subclone the 17K-11 PS coding sequence (Florio et al., 1996) into the
pGEX2T expression vector and to express the P8-GST fusion protein following standard
procedures. Following purification on a glutathione-Sepharose affinity column, the fusion
partner was cleaved and the protease removed with the use of a thrombin cleavage
capture kit according the manufacturer’s instructions. The PS was concentrated by
ultrafiltration and stored in 50% glycerol at -20°C. [Upon sequencing the P8-GST
construct, a PCR artifact was discovered that caused an amino acid substitution at
position 85 from glutamine to arginine. No functional differences could be detected when
the cleaved fusion protein containing the substitution was compared with the PS
expressed from Sf9 cells.]
The concentration of PS was determined using the Bradford assay. The purity of
different PS preparations was found to exceed 80% for both methods (e.g., Fig. 1.1A
lane 2); immunoblot analysis with the 17K-II PS antibody revealed a single
immunoreactive band at -17 kDa.
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Measurements o f cGMP binding to noncatalytic sites on PDE—Two different
methods were used to quantitate cGMP binding to the noncatalytic sites on PDE, cGMP
radioimmunoassay and a membrane filtration assay. Purified, concentrated PDE was first
diluted in Buffer B (77 mM KC1, 35 mMNaCl, 2,0 mMMgCl2, 1.0mMCaCl2, 1.18mM
EGTA ([C a2+free] - 240 nM), 10 mM HEPES, pH 7.5) supplemented with final
concentrations of: 1.0 mM dithiothreitol, 0.5 jig/ml leupeptin, 0.2 mM Pefabloc, and 0.7
pg/ml pepstatin. In experiments where depletion of endogenous nucleotides was
attempted by incubating the PDE at 37°C (24 h for nPDE, 2 h for tPDE), Buffer B was
supplemented with 5-fold greater concentrations of protease inhibitors and dithiothreitol,
as well as 0.1 mg/ml bovine serum albumin and 30% glycerol [to minimize loss of PDE
activity (<20% over the 24 h period)]; before use, the nucleotide-depleted PDE was
diluted > 10-fold in Buffer B lacking the supplements.
To measure the amount of endogenous cGMP remaining bound to PDE following
purification, a cGMP radioimmunoassay was used. Briefly, PDE-containing samples
were quenched with 50% HC1 in ethanol, then centrifuged to remove precipitated
material. The acidic supernatant was dried down under vacuum, and the neutralized
sample was resuspended in 0.1 M citrate, pH 6.2. The radioimmunoassay was performed
as described in Cote et al. (Cote, 2000), with an operating range of 0.15 to 3 pmol of
cGMP per sample, as judged by comparison with a standard curve using known amounts
of cGMP treated identically to the unknown samples.
To determine the equilibrium and kinetic properties of [3H]cGMP binding to the
various PDE preparations, a membrane filtration assay was used (Cote, 2000). PDEcontaining samples in Buffer B were incubated with the indicated concentrations of
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[3H]cGMP in the presence of 0.1 or 0.8 mM zaprinast, a photoreceptor PDE catalytic site
inhibitor (Gillespie and Beavo, 1989b). The higher zaprinast concentration was used with
activated PDE samples to insure that the extent of [3H]cGMP hydrolysis during the
incubation period was <10% under all conditions tested. In separate experiments, we
verified that 2 - 1000 pM zaprinast was unable to compete with [3H]cGMP bound to the
noncatalytic sites of nPDE-M to which excess Py had been added to prevent ligand
hydrolysis.
Following incubation of PDE with the radiolabeled cGMP, portions were directly
filtered on prewet nitrocellulose membranes (Millipore HA membrane, 0.45 pm), and
quickly (< 4 s) rinsed with three 1-ml portions of ice-cold Buffer B Nonspecific binding
was determined as described previously (Cote and Brunnock, 1993). The membrane
filtration technique is useful for measuring relatively high affinity ligand binding (Kd < 1
pM); lower affinity cGMP binding sites are likely to release bound cGMP during the
washing procedure and may go undetected.
Analytical procedures—A colorimetric, coupled-enzyme assay was employed for
measurements of cGMP hydrolytic rates, as described in detail in (Cote, 2000). SDS
polyacrylamide gel electrophoresis followed the procedure ofLaemmli (Laemmli, 1970).
Immunoblot analyses of the Py and P5 subunits were performed with polyclonal
antiserum UNH9710-4P to the C-terminal region (a. a. 63-87) ofPy or antiserum 17K-II
to residues 23-41 of the P8 protein (Florio et al., 1996) along with a goat anti-rabbit
secondary antibody coupled to horse-radish peroxidase, using standard protocols
(Gallagher, 1998). Protein concentrations were estimated with the Bradford assay
(Bradford, 1976) using bovine serum albumin as a standard; a correction factor of 1.2
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was applied for estimates of purified PDE catalytic subunit concentrations (Gillespie and
Beavo, 1989a). Data analysis was performed using Sigmaplot (SPSS, Inc.) and KELL
(Biosoft). All experiments were repeated at least three times, and error estimates
represent the S.E.M.
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Figure 1.1. Purity and subunit composition of nonactivated and trypsin-activated
PDE-M and PDE-S enzymes used in this study. A. 15% SDS polyacrylamide gels
stained with Coomassie Blue. Purity of proteins analyzed was >90% except where noted.
Lane 1, recombinant bovine Py (0.42 nmol); Lane 2, recombinant bovine PS (2.5 jig;
~80% purity). Lane 3, purified Pa(3-S (80 pmol); Lane 4, purified Pa{3~M (80 pmol);
Lane 5, nPDE-S (120 pmol); Lane 6, nPDE-M (80 pmol; Lane 7, molecular weight
markers (in kDa). B. Immunoblot analysis using PS antibody 17K-II (upper panel) or Py
antibody UNH9710-4P (lower panel). In lanes 1 - 6 ,1 pmol of the indicated enzyme was
loaded. Lane 1, nPDE-M; Lane 2, nPDE-S; Lane 3, tPDE-M after concentration but prior
to gel filtration, showing an inununoreactive 4.5 kDa Py proteolytic product; Lane 4,
tPDE-S before concentration or purification, showing undegraded PS immunoreactivity
and a 4.5 kDa Py peptide; Lane 5, purified Pa(3-M; Lane 6, purified Pcc(3-S; Lane 7, Py (6
pmol); Lane 8, PS (20 ng); Bars, molecular weight markers.
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R esu lts
The soluble and membrane-associated isoforms o f bovine rod PDE have different
cGMP binding properties in their nonactivated states—As reported previously, the
nonactivated, membrane-associated PDE (nPDE-M; affyz) of bovine rod photoreceptors
binds 2 mol of cGMP per mol PDE very tightly and exchanges its bound cGMP very
slowly (Gillespie and Beavo, 1989a). To directly compare the cGMP binding properties
of the soluble PDE (nPDE-S; a j^ S ) with nPDE-M, we measured both the amount of
endogenous cGMP remaining bound to purified, nonactivated PDE (nPDE) by cGMP
radioimmunoassay, and the amount of exchangeable [3H]cGMP binding sites by a
membrane filtration assay (see “Experimental Procedures”). For the case of the
membrane-associated isoform, we found that purified nPDE-M retained 1.9 ± 0.04 mol
cGMP per PDE holoenzyme (a(3y2) as judged by a cGMP radioimmunoassay (Fig. 1.2).
Approximately 0.1 ± 0.04 mol [3H]cGMP was able to bind to nPDE-M in this condition.
These results are identical to previous measurements where tightly bound, endogenous
cGMP (1.8 ± 0.3 mol cGMP/PDE) as well as [3H]cGMP binding (0.1 mol cGMP/PDE)
were analyzed by HPLC (Gillespie and Beavo, 1989a). Incubation of nPDE-M for 24 h at
37°C resulted in the loss of 1 mol of endogenous cGMP per PDE with the concomitant
ability to bind 1 mol of [3H]cGMP per PDE (Fig. 1.2). We conclude that nPDE-M
consists of 2 high affinity, noncatalytic cGMP binding sites, of which only one is able to
release its bound cGMP under these conditions.
The nonactivated, soluble isoform of rod PDE (nPDE-S) also retains bound
endogenous cGMP following its extensive purification (1.7 ± 0.04 mol cGMP/mol PDE;
Fig. 2). Upon addition of exogenous [3H]cGMP, the total binding stoichiometry is 2.0 ±
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Figure 1.2. Effects of temperature and added Py and PS subunits on the noncatalytic
cGMP binding sites of nPDE-M and nPDE-S. Purified nPDE-M and nPDE-S were
diluted to 50 nM concentration in Buffer B (containing the higher levels of supplements,
including 30% glycerol and 0.1 mg/ml bovine serum albumin as stabilizers), as described
in the Experimental Procedures. The PDE samples were then incubated under the
following conditions, as indicated in the heading: -37°C, 24 h at 4°C; +37°C, 24 h at
37°C; +Py, addition of 10 mol Py/mol Pa{3 to PDE at onset of 37°C incubation; +P5,
addition of 5 mol PS/mol Paf3 at onset of 37°C incubation. After the incubation period,
portions were removed for analysis of endogenous cGMP remaining bound by cGMP
radioimmunoassay (hatched bars). Other portions were incubated with 1 pM [3H]cGMP
for 30 min at 4°C, and then membrane filtration performed (open bars). The y-axis is
expressed as mol cGMP bound per mol PDE holoenzyme for each assay, as well as the
sum of the endogenous and [3H]cGMP binding (filled bars).
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0.1 mol cGMP/mol PDE, identical to nPDE-M. One major difference between nPDE-M
and nPDE-S is the ability of the soluble isoform to release -90% of its endogenous
cGMP upon 24 h incubation at 37°C, as well as being able to bind 1.9 ± 0.08 mol
[3H]cGMP/PDE. We conclude that both high affinity noncatalytic binding sites on nPDES are able to undergo nucleotide exchange, whereas only one site is exchangeable in
nPDE-M.
One obvious difference between nPDE-M and nPDE-S is the presence of the PS
subunit associated with nPDE-S. To test whether the PS subunit could account for the
different cGMP binding properties noted above, we incubated nPDE-M with an excess of
recombinant PS subunit. As shown in Fig. 1.2, incubation with PS can cause the release
of endogenous cGMP from the formerly “nonexchangeable” binding site on nPDE-M;
only 0.3 ±0.03 mol cGMP/mol PDE remain bound after a 24 h incubation at 37°C, while
addition of [3H]cGMP to the nucleotide-depleted enzyme permits 1.9 ± 0.05 mol
cGMP/mol PDE to bind. This result indicates that PS can bind to nPDE-M (in accord
with a previous reconstitution study (Florio et al., 1996)) and enhance the rate of cGMP
exchange at one of the noncatalytic cGMP binding sites that is essentially
nonexchangeable when PS is absent.
We also examined the effects of adding a 10-fold molar excess of Py on the
cGMP binding properties of nPDE-M and nPDE-S. In all cases where Py was added, the
amount of endogenous cGMP that was retained following the 24 h incubation was
increased to - 1.4 mol cGMP/mol PDE, regardless of whether the PS subunit was also
added in molar excess (Fig. 1.2). The ability of [3H]cGMP to bind was reduced in a
corresponding manner (-0.5 - 0.6 mol [3H]cGMP/mol PDE) for both nPDE-M and
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nPDE-S. We conclude that the Py subunit acts to reduce the rate of cGMP dissociation
from exchangeable noncatalytic sites on both nPDE-M and nPDE-S.
Activation o f PDE by limited proteolysis o f the P y subunit alters the cGMP
binding properties o f PDE— Since addition of Py reduces the amount of endogenous
cGMP released as well as the amount of [3H]cGMP that could associate with the
noncatalytic sites of nPDE-M or nPDE-S (Fig. 1.2), we reasoned that removal of the Py
subunits from the holoenzyme would enhance the ability of cGMP to exchange between
the bound and free state. To test this, we exposed a preparation of purified nPDE-S to
mild trypsin proteolysis (Hurley and Stryer, 1982) for various times at 4°C. As described
in the “Experimental Procedures,” this treatment degrades the Py subunit and relieves
inhibition of catalysis at the active site, with no detectable effect on the apparent
molecular weights of P5 or Pap on SDS polyacrylamide gels (Fig. 1.1). We then
measured the ability of 1 pM [3H]cGMP to occupy the noncatalytic sites, as well as the
maximum hydrolytic rate of tPDE-S. Fig. 1.3 shows that the time course of activation by
trypsin correlated well with the ability to bind up to 1 mol [3H]cGMP per catalytic dimer.
[Identical trypsin time course experiments performed on nPDE-M gave essentially
identical results to those shown for nPDE-S in Fig. 1.3 (data not shown).] Separate
measurements by radioimmunoassay of the endogenous cGMP remaining bound to fully
activated tPDE-S at the time when the [3H]cGMP was added (< 0.3 cGMP/PDE)
indicated that >85% of the total bound cGMP had dissociated and been degraded by the
activated enzyme. Therefore, the inability to bind more than 1 mol cGMP per mol PDE
could not be due to endogenous bound cGMP preventing [3H]cGMP association. One
possible conclusion from this result is that the proteolytic destruction ofPy had lowered
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(below the level of detection by membrane filtration) the binding affinity for cGMP at
only one of the two noncatalytic sites. Another possibility we considered was that trypsin
had damaged the catalytic subunits so that high affinity cGMP binding at one of the
noncatalytic sites was permanently lost.
To distinguish these possibilities, we prepared purified catalytic dimers of PDE-S
(PaP-S) from which all traces of the low molecular weight subunits had been removed
(see “Experimental Procedures” and Fig. 1.1); this Pap-S preparation also lacked
detectable amounts of endogenous cGMP at the noncatalytic sites. Purified Pap-S was
able to bind 1 mol cGMP per mol PDE in the absence of Py, in agreement with the results
with tPDE-S in Fig. 1.3. Following addition of increasing amounts of Py to PaP-S, we
observed a progressive increase in [3H]cGMP binding that correlated with the inhibition
of hydrolysis at the active site (Fig. 1.4). Addition of 2 mol Py per mol PaP-S permitted
an additional 0.9 mol [3H]cGMP per mol Pap-S to bind, and inhibited 90% of the
hydrolytic activity of the enzyme. [Identical results were obtained upon titration ofPaPM with Py (data not shown).] In none of our experiments did we detect an effect of
adding P8 on cGMP binding to high affinity sites on PaP-S or PaP-M.
Several interesting conclusions can be drawn from the above results. First,
purified PaP dimers derived from PDE-S and PDE-M are able to bind 1 mol cGMP per
PaP in the complete absence ofPy, P8 or their proteolytic fragments. Second, it follows
that removal ofPy from PDE reduces the binding affinity of cGMP for one of the two
noncatalytic sites below the level of detection of binding assay ( K d >

1

pM). Third, the

proteolytic treatment of PaP is reversible upon addition of stoichiometric amounts ofPy.
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Figure 1.3. Activation of nPDE-S by limited proteolysis follows the same time course
as ability to bind [3H]cGMP to one noncatalytic site on PDE. Purified nPDE-S was
incubated with trypsin (45 pg/ml) at 4°C as described in “Experimental Procedures.” At
the indicated times, portions were treated with soybean trypsin inhibitor to stop
proteolysis, and the tPDE-S (590 nM) was then incubated at 37°C for 30 min to permit
release and degradation of any rapidly exchangeable cGMP. The enzymatic activity
(using 2 mM cGMP as substrate; circles) or ability to bind 1 pM [3H]cGMP (5 min at
37°C, to minimize binding to non-activated sites; squares] were determined as described
in the “Experimental Procedures ” These data points are from one of three representative
experiments, and the curves represent a fit to a single exponential model.
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Figure 1.4. Addition of stoichiometric amounts of Py is sufficient to restore cGMP
binding to the second high affinity noncatalytic binding site of PaP-S. Purified PapS was first depleted of endogenous cGMP by incubation at 37°C (<0.1 mol cGMP
bound/mol Pap-S), as described in “Experimental Procedures.” The indicated amounts of
purified Py were incubated with PaP-S for 30 min at 4°C prior to commencing activity
(1.4 nM PDE) and binding assays (5 nM PDE). The hydrolytic activity was measured
with 10 mM cGMP as substrate and normalized to the rate in the absence of added Py
(5240 mol cGMP hydrolyzed/mol PDE/s). 1 pM [3H]cGMP was incubated for 30 min at
37°C prior to filter binding. The symbols represent individual data points from one of
three similar experiments.
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Rate of cGMP hydrolysis (% of maximum)

•

This shows that the Py subunit is the major target of action of trypsin, and that the limited
proteolysis does not destroy the ability of PaP to bind cGMP at the “low affinity” site if
Py is added back. Finally, in contrast to the two non-identical cGMP binding sites on
Pap, no difference in binding affinity of Py to the two Py binding sites on PaP could be
discerned for either PDE-S or PDE-M. We infer this from the observation that addition of
1 Py per PaP restores approximately one-half of the total cGMP binding that requires Py
binding to Pap.
Kinetic and equilibrium analysis ofcGMP binding to noncatalytic sites on PDE-S
and PDE-M—To better understand the regulation of cGMP binding at the two non
identical binding sites on the soluble and membrane-associated rod PDE isoforms, we
analyzed the kinetics and equilibrium binding of cGMP to both nPDE and PaP
preparations for both PDE-S and PDE-M. Equilibrium binding measurements were
performed at 37°C over the range of 2 to 400 nM cGMP for each PDE preparation, and
the Kd and Bmav determined (Fig. 1.5; see Table 1.1 for average values from several
experiments). In all cases, the equilibrium binding data fit a model for a single class of
non-interacting binding sites, even in the case of nPDE-S where the stoichiometry of
binding indicated 2 binding sites per holoenzyme (Table 1.1). For the case of PDE-S,
limited trypsin proteolysis of the enzyme resulted in the loss of detectable cGMP binding
at one of the noncatalytic sites, and a 4-fold reduction in cGMP binding affinity at the
remaining site. For the case of nPDE-M where only one site is available to exchange
cGMP (the other retaining bound endogenous cGMP; Fig. 1.2), trypsinization reduces the
binding affinity 3-fold; note, however, that we cannot distinguish whether the
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exchangeable or nonexchangeable site is responsible for the cGMP binding we detect in
activated Pap-M.
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Figure 1.5. Equilibrium binding of cGMP to nonactivated and activated rod PDE
isozymes. Purified PDE preparations were first incubated at 37°C to remove
exchangeable, bound cGMP, as described in “Experimental Procedures.” Except for
nPDE-M (~1 mol endogenous cGMP bound/mol PDE), each PDE preparation retained <
0.1 mol endogenous cGMP/mol PDE following nucleotide depletion. Each preparation
was diluted to 5 nM (final concentration) in Buffer B, and incubated with the indicated
concentrations of [3H]cGMP at 37°C for 30 min prior to membrane filtration. Curves
represent the fit to a single-site binding model. A. Binding of nPDE-M (squares), Kd =
20 nM and BmaX= 0.95 mol cGMP/mol PDE; binding to Paf3-M (circles), Kd = 58 nM
and Bmax = 1.04 mol cGMP/mol PDE. B. Binding of nPDE-S (squares), Kd - 19 nM,
BmaX= 2.12 mol cGMP/mol PDE; binding to Potj3-S (circles), Kd = 54 nM and Bmav =
1.08 mol cGMP/mol PDE. The symbols represent individual data points from a single
experiment; see Table I for average values for n determinations.
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It is evident from comparing the Kd values of the two isoforms that the single
exchangeable noncatalytic binding site we detect in nPDE-M has the same binding
affinity for cGMP as the 2 sites that bind [3H]cGMP in nPDE-S. Likewise, trypsin
activation of each isoform results in a loss of detectable binding to one of the two cGMP
binding sites per PaP, and a uniform decrease in binding affinity ( K d ~ 60 nM) of cGMP
at the other site. These results strongly suggest that PDE-M and PDE-S have very similar
or identical cGMP binding sites on the PaP dimer. Further, association of Py and P5 with
PaP each have distinct effects in modulating cGMP binding to the two noncatalytic sites
ofPDE.
Kinetic analysis of the association and dissociation kinetics of cGMP binding to
PDE provides an additional approach for understanding how cGMP binding to the
noncatalytic sites is regulated. Fig. 6 shows that when the Py and P8 subunits are
removed from the catalytic dimer to form PaP-S, both the association and dissociation
rates of cGMP with the one remaining high affinity noncatalytic site are accelerated . The
association rate constant (k+i) is increased 6-fold upon removal ofPy and P5 from PaP-S,
while the dissociation rate constant (k_i) increases 16-fold (Table 1.1). Kinetic analysis of
the noncatalytic sites on PDE-M (Table 1.1) is in general agreement with the results
obtained with PDE-S. Upon removal of Py, the k+i ofPaP-M for the one high affinity
binding site is increased 4-fold compared to nPDE-M, while the k.i is increased 17-fold
by Py removal. The similar kinetic behavior of PDE-M and PDE-S indicates that the
binding of Py—rather than P8—is the major factor affecting the ability of cGMP to bind to
and dissociate from the noncatalytic sites on both PDE-S and PDE-M. Furthermore, the
interaction ofPy with PaP has its greatest effect on the cGMP dissociation rate constant,
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rather than the k+i or the Kd. This is intriguing since it is the rate of cGMP dissociation
from noncatalytic sites on PDE that is most relevant to proposed physiological roles of
these sites in regulating PDE during recovery or light adaptation (see Discussion).
While we cannot measure detectable [3H]cGMP binding to the second
noncatalytic site on PaP with our filter binding assay, some minimum values of the
binding parameters can be inferred. The time required for filtration (~4 sec) sets a limit to
highest dissociation rate constant that can be measured (Cote, 2000). Since the half-time
for cGMP dissociation from the higher affinity site on PaP-S or PaP-M is -100 sec
(Table 1.1), the lower affinity site must have a dissociation rate at least 25-fold larger in
order for any bound cGMP to be released (and therefore not detected) during the filtration
process. This implies that the Kd for the lower affinity site is likely to be >25-fold larger
(>1.5 pM) than the value measured for PaP-S and PaP-M. We conclude that activation
of PDE reduces the binding affinity at one site only 3-4-fold, while the other binding site
undergoes a >25-fold reduction in affinity with a concomitant acceleration of the cGMP
dissociation rate.
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Figure. 1.6. The kinetics of cGMP association and dissociation to PDE-S are
accelerated upon enzyme activation. Purified nPDE-S and PaP-S were depleted of
their endogenous nucleotides by incubation at 37°C for 16 and 2 h, respectively. A.
Association kinetics were obtained at 37°C by adding -500 nM [3H]cGMP to 8 nM
nPDE-S (circles) or Pap-S (squares) at time zero, and filtering samples at the indicated
times. The data were analyzed as a pseudo-first order reaction with the association rate
constant k+J = (kobs - k-i)/[cGMP]tot., where kobs is the first-order rate constant for the
single exponential, k_i is the dissociation rate constant (determined in part B.), and
[cGMPJtot. is the total [3H]cGMP concentration. The data fit a single exponential junction
for both nPDE-S (kobs = 9.8 ± 1.0 x 10'3 see1; Bmax = 1.7 ± 0.1 [3H]cGMP bound/PDE)
and Pap-S (kobs = 0.068 ± 0.011 sec'1; Bmax = 0.9 ±0.1 [3H] cGMP/PDE). B. Dissociation
kinetics were determined at 37°C by first adding 500 nM [3H]cGMP to -6 nM nPDE-S
(circles) or PaP-S (squares) and incubating for 30 or 2 min, respectively. Dissociation
was initiated by addition of 1 mM (final concentration) unlabeled cGMP, and samples
were filtered at the indicated times thereafter. The curves represent the fit of the data to a
single exponential decay function for both nPDE-S (Li = 5.8 ± 0.6 x 10'4 s'1; Bm« = 1.9 ±
0.1 cGMP/PDE) and Pap-S (k.x = 7.3 ± 0.7 x 10'3 s'1; Bmax .= 0.9 ± 0.1 cGMP/PDE). The
symbols represent individual determinations from one experiment; see Table I for
average values for n separate determinations of the rate constants.
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T a ble 1.1

Comparison o f the fHJcGM P binding properties o f bovine rod PDE isoforms
The experimental conditions for the equilibrium binding measurements and the kinetics
measurements are provided in the legends to Figs. 1.5 and 1.6, respectively. The data
represents the mean (± S.E.M.); the value in parentheses is the number of independent
determinations.
PDE'*

Max
[’KjcGMP
binding
(cGMP/PDE»
nPDE-ff 1.00 + 0.04
(3)
Pap-M
1.02 ± 0.04
(4)
nPDE-S
1.85 + 0.09
(4)
0.93 + 0.03
PaP-S
(3)

Measured
Kd
(nM)

Dissociation
Association
kinetics, k.j illliiiiiliililliil

18 ± 2 (3)

3.9 ±0.1 x
10*4 (3)
6.8 ± 1.0 x
10’3 (5)
4.5 ±0.9 x
10‘4 (5)
7.2 ± 0.4 x
10° (5)

56 ± 4 (4)
14 + 2 (4)
57 ± 13
(3)

■M
HM
(fyr'see'1)
2.2 ± 0.6 x 104
(4)
9.8 + 1.9 x 104
(8)
2.3 ± 0.4 x 104
(4)
1.3 ± 0 .2 x l0 5
(4)

Kinetic
Kd - ki/k-i
(nM)"'
18
71
20
55

anPDE refers to PDE holoenzyme containing the low molecular subunits; Pa(3 refers to
activated PDE catalytic dimer lacking Py and/or P8. The -M and -S suffix refer to
membrane-associated and soluble forms of PDE, respectively.
bnPDE- M has one nonexchangeable site (Fig. 1.2) which cannot be detected in these
experiments.
cThe kinetic Kd is in general agreement with the measured K d, indicating the internal
consistency of the equilibrium binding and kinetic data.
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D is c u s s io n
We have shown that mammalian rod photoreceptor PDE isoforms can undergo
substantial changes in cGMP binding to two non-identical, high affinity noncatalytic sites
upon activation of the enzyme by removal of the Py subunits. We also report that the
soluble and membrane-associated isoforms of bovine rod PDE have different binding
properties in their nonactivated states. Finally, our results demonstrate that the Py subunit
is primarily responsible for altering cGMP exchange upon activation, and that the P8
subunit may interact with Py binding to the enzyme to permit cGMP exchange at a site on
non-activated PDE that is nonexchangeable in PDE-M but exchangeable in PDE-S.
The two high affinity noncatalytic binding sites on bovine rod PDE are not
identical—Previous work established that the PDE-M holoenzyme contains 2 high
affinity cGMP binding sites that retain bound cGMP even following extensive
purification (Gillespie and Beavo, 1989a). We have extended that work to demonstrate
that the soluble isoform of rod PDE also contains 2 high affinity cGMP binding sites. Of
greater significance is the demonstration that the two noncatalytic sites are not identical
in their cGMP binding properties. The presence of one functionally nonexchangeable
cGMP binding site on nonactivated PDE-M is in marked contrast to the two
exchangeable sites found in bovine rod PDE-S (Fig. 1.2), cone PDE (Gillespie and
Beavo, 1988), or the amphibian membrane-associated rod PDE (Cote et al., 1994).
Activation of bovine rod PDE reveals a fundamental difference between the two
non-identical noncatalytic sites on both bovine rod isoforms. Removal of the Py subunits
from PDE-M or PDE-S eliminates detectable binding (KD> 1 pM) of cGMP to one of
the two classes of noncatalytic sites on the Pa(3 dimer. This effect represents a shift of >
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100-fold in overall cGMP binding affinity at this site, and a rate of dissociation that is too
fast to detect by filter binding (ti/2 < 4 s). The remaining cGMP binding sites exhibit a 3fold reduction in overall binding affinity upon removal of Py compared to the [3H]cGMP
binding sites on nPDE-M or nPDE-S. We conclude that the Py subunit not only acts in its
well-known role as an inhibitor of cyclic nucleotide catalysis at the active sites on PaJ3,
but also serves to regulate the affinity of interaction of cGMP with the two distinct
noncatalytic sites on the PaP dimer. The amphibian PDE, in contrast, shows no
detectable cGMP binding to P«P when the Py subunits are removed by limited
proteolysis (Yamazaki et al., 1980; Yamazaki et al., 1982; Yamazaki et al., 1982) or by
extraction with activated transducin (Cote et al., 1994).
No intrinsic differences in the catalytic Pa/3 dimers derivedfrom PDE-S and
PDE-M—Based on the results of this study and previous work (Gillespie et al., 1989;
Florio et al., 1996; Florio et al., 1996), it appears very likely that the catalytic subunits are
identical in PDE-S and PDE-M. The molecular weights of a and (3 are indistinguishable
on SDS polyacrylamide gels (Gillespie et al., 1989), the catalytic constant of tPDE-S is
identical to that of tPDE-M [see “Experimental Procedures” and ref. (Gillespie et al.,
1989)], and the noncatalytic cGMP binding sites show very similar kinetic and
equilibrium binding behavior for the purified PaP dimers derived from PDE-S and PDEM ( Figs. 5 - 6 and Table I).While a definitive statement awaits direct amino acid
sequence comparisons of the a and P subunits ofPDE-S and PDE-M, all available
evidence indicates that binding of the P8 subunit to the PDE holoenzyme confers the
differences in behavior seen with nPDE-S and nPDE-M.
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Two distinct actions o f PS on PDE—We report a new function that can be
ascribed to the binding of the PS subunit to rod PDE: the ability of PS to permit cGMP
release from a second noncatalytic binding site on nPDE-S that remains functionally
nonexchangeable in PDE-M. How this effect of PS on PDE-S relates to the other known
function of PS—namely to solubilize PDE that would otherwise remain attached to rod
outer segment disk membranes (Florio et al., 1996)—is not clear at present. However,
membrane association of PDE is not required for PS binding, since purified nPDE-M to
which recombinant PS has been added is able to exchange endogenous cGMP at both
noncatalytic sites in the absence of membrane attachment.
Physiological significance o f noncatalytic cGMP binding sites on mammalian rod
PDE isoforms—In the dark-adapted photoreceptor, cytoplasmic cGMP levels are in the
low micromolar range, and both noncatalytic sites on nPDE-S and nPDE-M will be frilly
occupied. The mechanism by which transducin activates PDE to rapidly lower
cytoplasmic cGMP levels during visual excitation is well understood, and quantitatively
accounts for the rising phase of the photoresponse (for review, see (Olson and Pugh, Jr.,
1993)). Thus, there is no need to invoke the noncatalytic cGMP binding sites on bovine
rod PDE to describe the regulation of PDE during the initial events of photo-excitation.
We consider instead possible ways the noncatalytic cGMP binding sites may be involved
in later stages of the visual transduction pathway, namely recovery from light stimulation
and/or light adaptation.
A role for the noncatalytic sites to buffer free cGMP levels during the recovery
phase of the flash photoresponse has been proposed for amphibian rod photoreceptors
(Yamazaki et al., 1996). In this model, the noncatalytic sites serve to buffer cytoplasmic
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cGMP levels in the dark, and upon PDE activation release bound cGMP to accelerate the
return to the resting state. Our data show that activation of mammalian rod PDE by
removing the Py subunit results in the immediate loss of detectable binding to one of the
noncatalytic sites on both PDE-M and PDE-S. This rapidly dissociating class of sites has
the potential to release its bound cGMP on the same time scale as recovery phase of the
photoresponse (<1 sec in mammalian photoreceptors (Baylor et al., 1984; Lyubarsky and
Pugh, Jr., 1996; Lyubarsky and Pugh, Jr., 1996)). However, upon cGMP release from the
bound state, it is likely that the free cGMP would be destroyed by the still-active catalytic
sites, and therefore not contributes to elevating the cytoplasmic cGMP levels during
photoresponse recovery. This conclusion is supported by recent measurements of cGMP
dissociation and hydrolysis in amphibian rod outer segment suspensions (Calvert et al.,
1998).
An alternative hypothesis is that the noncatalytic sites on PDE may indirectly
regulate the lifetime of transducin-activated PDE via modulation of Py binding affinity to
PaP (Cote et al., 1994). This idea is based on the following observations in amphibian
and mammalian photoreceptors: removal of bound cGMP from the noncatalytic sites in
frog ROS reduces Py binding affinity to PaP (Arshavsky et al., 1992) and correlates with
an accelerated transducin GTPase activity (Arshavsky and Bownds, 1992); in bovine
ROS, Py serves as a GTPase accelerating factor (Angleson and Wensel, 1994; Arshavsky
et al., 1994; Arshavsky et al., 1994) acting in concert with the RGS9 protein (He et al.,
1998; Tsang et al., 1998; Tsang et al., 1998). Accordingly, cGMP dissociation from the
rapidly dissociating class of sites on activated PDE might signal Py to interact with RGS9
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to stimulate GTPase activity of transducin to inactivate PDE during the recovery phase of
the photoresponse.
cGMP dissociation from the second, high affinity class of binding sites on bovine
rod PDE is too slow (ti/2 - 1 .6 min; Table 1) to be implicated in the recovery process of
the dark-adapted photoresponse. It is possible that cGMP dissociation from these
noncatalytic sites may act to gradually reduce the lifetime of activated PDE during
adaptation to continuous illumination, and thereby lead to the smaller, faster responses
characteristic of the light-adapted state. Coles and Yamane (Coles and Yamane, 1975)
and Cervetto et al. (Cervetto et al., 1984) have shown a gradual acceleration of recovery
of the flash photoresponse when amphibian rod photoreceptors are exposed to continuous
illumination; this response acceleration slowly develops over the same general time
frame as cGMP dissociation from the higher affinity noncatalytic sites on PDE. Future
work is needed to establish whether a strict temporal correlation exists between
occupancy of cGMP at the noncatalytic sites and the kinetics of the recovery phase of the
light-adapted photoresponse, and whether these studies performed with lower vertebrates
are relevant to the regulation of mammalian rod phototransduction.
In conclusion, cGMP binding and dissociation at the noncatalytic sites on the
photoreceptor PDE may indirectly regulate the enzyme by affecting the strength of the
interaction of the Py subunit with the catalytic subunits. This in turn may direct whether
Py interacts with the Pap dimer to regulate catalytic activity, or with transducin and its
GTPase accelerating protein, RGS9, to regulate the kinetics of transducin inactivation. In
addition, there is conflicting evidence at present (Arshavsky et al., 1992; Granovsky et
al., 1998; Granovsky et al., 1998) as to whether the noncatalytic sites can allosterically
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regulate hydrolytic activity at the active sites, as has been demonstrated for PDE2
(Martins et al., 1982). The results in this paper provide a strong foundation for unraveling
the complex interplay between the noncatalytic and catalytic sites on photoreceptor PDE
and the low molecular weight Py and PS subunits that interact with and regulate the
action of this central effector enzyme in visual transduction.
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Chapter II
The catalytic and GAF domains of the rod cGMP phosphodiesterase
(PDE6) heterodimer are regulated by distinct regions of its inhibitory y
subunit*
ABSTRACT
The central effector of visual transduction in retinal rod photoreceptors, cGMP
phosphodiesterase (PDE6), is a catalytic heterodimer (aP) to which low molecular
weight inhibitory y subunits bind to form the nonactivated PDE holoenzyme (aPy2).
While it is known that y binds tightly to aP, the binding affinity for each y subunit to aP,
the domains on y that interact with aP, and the allosteric interactions between y and the
regulatory and catalytic regions on ap, are not well understood. We show here that the y
subunit binds to two distinct sites on the catalytic aP dimer ( K d i < 1 pM, Kru = 3 pM)
when the regulatory GAF domains of bovine rod PDE6 are occupied by cGMP. Binding
heterogeneity of y to aP is absent when cAMP occupies the noncatalytic sites. Two major
domains on y can interact independently with o.p, with the N-terminal half of y binding
with 50-fold greater affinity than its C-terminal, inhibitory region. The N-terminal half of
y is responsible for the positive cooperativity between y and cGMP binding sites on «P,
but has no effect on catalytic activity. Using synthetic peptides, we identified regions of
the amino acid sequence of y that bind to aP, restore high-affinity cGMP binding to low-

*. This chapter was published in its entirety in J. Biol. Chem. (276, 27527-27534, 2001)
and was Scientific Contribution #2088 from the New Hampshire Agricultural Experiment
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affinity noncatalytic sites, and retard cGMP exchange with both noncatalytic sites.
Subunit heterogeneity, multiple sites of y interaction with ap, and positive cooperativity
of y with the GAF domains are all likely to contribute to precisely controlling the
activation and inactivation kinetics of PDE6 during visual transduction in rod
photoreceptors.

Station. This work was supported by National Institutes of Health Grant EY-05798 (to
R.H.C.).
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I n t r o d u c t io n
The extent and lifetime of activation of the photoreceptor cGMP
phosphodiesterase (PDE61; E.C. 3.1.4.35) must be precisely regulated in rod and cone
cells in order to control the exquisite sensitivity, speed, and adaptational properties of the
visual transduction pathway in vertebrate photoreceptors. The membrane-associated rod
photoreceptor PDE6 consists of a dimer of two homologous catalytic subunits (Pap) to
which two low molecular weight inhibitory subunits (Py) bind (holoenzyme
stoichiometry: aPy2). The catalytic subunits contain GAF domains which are responsible
for high-affinity, noncatalytic binding of two cGMP molecules per holoenzyme. It is well
established that relief of the inhibitory constraint on PDE6 arises from the binding of
activated heterotrimeric G-protein (transducin) to Py following photoactivation of the
visual pigment, rhodopsin (reviewed in refs. (Pfister et al., 1993; Pugh, Jr. and Lamb,
1993; Bownds and Arshavsky, 1995; Artemyev et al., 1998; Pugh, Jr. and Lamb, 1993;
Bownds and Arshavsky, 1995; Artemyev et al., 1998)). However, the strength of the
interaction between Py and Pap has been difficult to quantitate and Kd values vary
widely [from picomolar (Wensel and Stryer, 1986; Hamilton et al., 1993; Skiba et al.,
1995; Hamilton et al., 1993; Skiba et al., 1995) up to nanomolar values (Otto-Bruc et al.,
1993; Yamazaki et al., 1996b; Yamazaki et al., 1996b)]. In addition, it has not been
conclusively demonstrated whether both Py molecules bind with equal affinity to PaP to

1 The abbreviations used are: PDE, cyclic nucleotide phosphodiesterase; PDE6, PDE
from photoreceptor cells; Pap, catalytic heterodimer of rod PDE6; Py, inhibitory 10-kDa
y subunit of rod PDE6; a t, a-subunit of rod photoreceptor G-protein, transducin; K d ,
dissociation constant; kcat, turnover number for activated PDE6, based on the PaP
concentration; Ki, inhibition constant; RGS-9, regulator of G-protein signaling-9; LY,
Lucifer Yellow.
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form the nonactivated holoenzyme [although two different binding sites on Pap have
been inferred using mutant Py; ref. (Berger et al., 1999)]. Finally, recent evidence
suggests that binding of activated transducin to PDE6 relieves inhibition at only one of
the two active sites, further supporting the idea of catalytic subunit heterogeneity with
respect to Py binding (Melia et al., 2000; Norton et al., 2000; Norton et al., 2000).
Use of synthetic peptides to defined regions ofPy, as well as mutagenesis of the
Py subunit, have revealed that Py has multiple sites of interaction with rod PaP, with the
a-subunit of activated transducin (at*), and with the Regulator of G-protein Signaling-9
(RGS-9). The C-terminal residues ofPy (amino acids 77 - 87) have been shown to
interact directly with the catalytic sites of PaP to inhibit catalysis (Skiba et al., 1995;
Lipkin et al., 1988; Brown, 1992; Granovsky et al., 1997; Brown, 1992; Skiba et al.,
1995; Granovsky et al., 1997). A second major site of interaction between Py and PaP
has been identified in the lysine-rich central portion (amino acids 24-45) of the Py
sequence (Lipkin et al., 1988; Artemyev and Hamm, 1992; Takemoto et al., 1992; Lipkin
et al., 1993; Natochin and Artemyev, 1996; Artemyev and Hamm, 1992; Takemoto et al.,
1992; Lipkin et al., 1993; Natochin and Artemyev, 1996), but the function of this
interaction is unclear. a t* has been shown to interact with Py at two distinct regions: one
in its C-terminal domain (amino acid residues 65 - 87), and the second in the central,
lysine-rich region ofPy (Lipkin et al., 1988; Brown, 1992; Artemyev and Hamm, 1992;
Artemyev et al., 1992; Slepak et al., 1995; Slep et al., 2001; Artemyev et al., 1992;
Artemyev and Hamm, 1992; Brown, 1992; Slepak et al., 1995; Slep et al., 2001). Finally,
Py also serves to potentiate the GTPase-activating protein function of RGS-9 by
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interacting with the protein in the neighborhood of W70 (Slepak et al., 1995; Slep et al.,
2001; Tsang et al., 1998; Tsang et al., 1998; Slep et al., 2001).
In this paper, we show that the Kd of Py binding to rod PDE6 is in the picomolar
to sub-picomolar range. Furthermore, Py does not bind with equal affinity to the two sites
on PaP when cGMP occupies the noncatalytic regulatory sites located on the Pap dimer.
We also demonstrate that the central region ofPy stabilizes high-affinity cGMP binding
to the noncatalytic sites, and the affinity of the central region ofPy exceeds by 50-fold the
affinity of its C-terminal region. Finally, using a series of synthetic peptides, we identify
important residues in the central region that contribute to the stabilization ofPy binding
to Pap.

74

R ep ro d u ced with p erm ission of th e copyright ow ner. Further reproduction prohibited w ithout p erm ission .

E x p e r im e n t a l P r o c e d u r e s
Materials—Bovine retinas were purchased from W.L. Lawson, Inc. The Py mutant, Pyl45C [consisting of the first 45 amino acids of bovine rod Py plus a C-terminal cysteine
residue; ref. (Skiba et al., 1996)] was a kind gift of Dr. N.P. Skiba, while zaprinast was
generously supplied by Rhone-Poulenc Rorer (Dagenham, UK). Crude synthetic peptides
were prepared at New England Peptide or at the protein facility at the University of New
Hampshire. Radiochemicals were from PerkinElmer Life Sciences. Gel electrophoresis
and immunoblotting supplies were from Bio-Rad Laboratories. Ultima Gold scintillation
fluid was from Packard Instrument Co., filtration and ultrafiltration products were from
Millipore, protein assay reagents were from Pierce Chemical Co., and all other chemicals
were from Sigma.
Preparation ofPDE6—Membrane-associated bovine rod PDE6 was purified to >90%
homogeneity from frozen bovine retinas as described previously (Mou et al., 1999). The
resulting nonactivated PDE holoenzyme (subunit stoichiometry: a{3y2) was stored in 50%
glycerol at -20°. The PDE6 catalytic heterodimer (PaP) was prepared by limited
proteolysis of the Py subunits, followed by Mono Q ion-exchange chromatography to
remove proteolytic fragments of Py (Mou et al., 1999). The PaP preparation was >95%
pure as judged from Coomassie-stained SDS-PAGE. No shift in the apparent molecular
weight of the a or P subunit was observed following this treatment. [Attempts to prepare
PaP without resorting to proteolytic digestion of Py were unsuccessful.] Immunoblot
analysis with an anti-peptide Py antibody (UNH9710) directed to the C-terminal region
(amino acids 63-87) of Py revealed no detectable full-length Py; a 5 kDa band
representing the major proteolytic product ofPy exhibited <5% of the original Py
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immunoreactivity (Mou et al., 1999; Cote, 2000; Mou et al., 1999). To remove
endogenous cGMP bound to the noncatalytic regulatory sites on PaP, the PaP was
incubated at 37° for 30 min prior to use.
Preparation and purification o f P yand Pyl-45C—Full-length bovine rod Py or the Nterminal fragment, Pyl-45C, was expressed in E. coli using the pETl la expression vector
(Slepak et al., 1995) and purified as described previously (Artemyev et al., 1998; Mou et
al., 1999; Mou et al., 1999). The total Py concentration was initially determined
spectrophotometrically (S277 = 7550 cm M '1), and verified by assaying its inhibitory
activity (Cote, 2000); these two estimates varied by <10%. The concentration of Py 1-45
was measured with a colorimetric protein assay (Smith et al., 1985). To fluorescently
label Pyl-45C with Lucifer Yellow (Pyl-45C-LY), the procedure of Artemyev et al.
(Artemyev et al., 1992) was used, followed by purification of Pyl-45C-LY by reversedphase high-pressure liquid chromatography.
Peptide purification—Following automated peptide synthesis, peptides were cleaved
from the resin with anhydrous HF and lyophilized. Crude, acidic peptides (Py55-75 and
Py63-87) were first purified by anion-exchange chromatography using DEAE Sephadex
A-25 and a linear NaCl gradient at pH 7.5. Other peptides were initially purified by
cation exchange chromatography on CM Sephadex C25 using a linear NH4HCO3
gradient at pH 8.0. All peptides were further purified by reversed-phase high-pressure
liquid chromatography on a 22 x 250 mm, 300 angstrom Ci8 column (Vydac), using a
linear gradient of 30 - 70% acetonitrile in 0.1% trifluoroacetic acid. After lyophilization,
each peptide was resuspended in 10 mM Tris, pH 7.5, and its concentration determined
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with the bicinchoninic acid protein assay (Smith et al., 1985) using bovine serum albumin
as a standard.
Analytical procedures and data analysis—The concentration of PDE and its catalytic
activity were determined as described in detail elsewhere (Mou et al., 1999; Cote, 2000;
Cote, 2000). Bovine serum albumin (250 fig/ml) was added when assaying enzyme
concentrations in the sub-nanomolar range to prevent loss of activity. A membrane
filtration assay was used to determine the equilibrium and kinetic properties of cGMP
binding to high-affinity noncatalytic sites on PDE (Mou et al., 1999; Cote, 2000; Cote,
2000). The PDE inhibitor, zaprinast (0.1 - 1.0 mM), was included in the assay solution to
insure that <10% hydrolysis of [3H]cGMP occurred. Nonspecific binding was determined
as described previously (Cote and Brunnock, 1993). The fluorescence assay of Pyl-45CLY binding to Pap was conducted in an Aminco-Bowman Series 2 spectrofluorimeter
using an excitation wavelength of 430 nm and an emission wavelength of 520 nm
(Artemyev et al., 1992).
Except where noted, experiments were performed three times, and the results
presented as the mean ± standard error of the mean (SEM). Nonlinear regression analysis
of the data was performed using Sigmaplot 2000 (SPSS, Inc.).
For the results in Figs. 1 and 2, two different curve-fitting equations were used to
fit the Py binding data. The first equation represents the standard equilibrium binding
equation for a single class of noninteracting sites:

B =^

m

(Eq.l)

KD+[Pr]
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where B is the amount of Py bound, Bmav is the maximum extent of binding, Kd is the
dissociation constant, and the free Py concentration, [Py], is assumed to be approximated
by the total added Py concentration (i.e., [Py] = [Py]x).
Because the free Py concentration was not experimentally measured, Eq. 1 can
only be used to estimate the Kd when ligand depletion from solution is not significant.
For high-affinity binding reactions, this condition is met when the total number of
binding sites (Px) is near the Kd. However, if we substitute the conservation of mass
equation ([Py]x - B + [Py]) into Eq. 1, we can estimate the Kd for any Px without having
to assume that [Py] s [Py]T:

max

J

V

where, x = -Kd - Px - [Py]x. This analytical approach was previously used to study highaffinity binding of GTPyS to transducin (Malinski et al., 1996).
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R esu lts
Quantitative analysis o f P y binding toP afi—Given the > 100-fold range of reported Kd
values for Py binding to PDE6 in the literature (see Introduction), we suspected that
stoichiometric binding of Py to PaP was occurring in those instances where the PaP
concentration exceeded the intrinsic Kd value for the binding reaction. To directly test
this, we examined the ability of Py to inhibit catalysis as a function of the PaP
concentration (Fig. 2.1 A). At PaP concentrations > 50 pM, there was a linear increase in
the extent of inhibition up to the plateau as the Py concentration was increased; the
concentration ofPy needed to attain >90% inhibition was approximately twice the
concentration of PaP. This behavior represents a titration phenomenon in which added Py
stoichiometrically binds to PaP with very high affinity until essentially all of the binding
sites are occupied (2 mol Py per mol PaP). At PaP concentrations < 10 pM, the inhibition
curve departed from stoichiometric behavior, and an excess ofPy was needed to fully
inhibit the enzyme (Fig. 2.1 A).
The Py binding data in Fig. 2.1A was analyzed using two equations for
equilibrium binding ofPy to Pap. The first approach (Eq. 1) assumed that the
concentration of free Py, [Py], was approximately equal to the total added Py
concentration, [Py]x (i.e., no ligand depletion). When Eq. 1 was used to estimate the
binding affinity of Py at each concentration of PaP tested, we found that the value of the
apparent Kd increased in direct proportion to the concentration of Pap. (Fig. 2. IB,
circles). For example, at 1 pM PaP, the calculated Kd for Py binding was 1.6 pM, while
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at a concentration of 500 pM Pap, the curve-fitting to Eq. 1 gave an apparent Kd = 300
pM.
We re-examined the Py binding data with Eq. 2 (which is not constrained by the
assumption that [Py] = [Py]x) to estimate the apparent Kd for Py binding. Over the
concentration range of 1 to 500 pM PaP, the calculated Kd showed little dependence on
the PaP concentration. The convergence of the two estimates for the apparent Kd as the
PaP concentration was lowered to 1 pM indicated that both Eq. 1 and Eq. 2 returned
similar estimates when Pt < Kd and when the free Py concentration could be
approximated as the total Py concentration. We conclude that the most reliable condition
for determining the binding affinity ofPy is when the PaP concentration is in the low pM
range.
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Figure 2.1. Inhibition of catalytic activity by Pyat various concentrations of Paj$.
PaP and Py were prepared as described in Experimental Procedures. A. The ability of
increasing amounts ofPy to bind to and inhibit hydrolysis of cGMP was determined at
the following PaP concentrations (in pM): 1.0 (•), 5.0 (A), 10 (♦), 50 (▼), 200 (■), and
500 (o). The substrate concentration was 100 pM cGMP at < 50 pM PaP or 2.0 mM at
200 and 500 pM Pap. The curves represent the fit of the data to Eq. 2. B. The affinity of
Py binding to Pap (apparent K d) was estimated using either Eq. 1 (o ) or Eq. 2 (□) at each
indicated Pap concentration. The points represent individual determinations except for 1
pM (mean ± SEM, n = 6).
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Heterogeneity in P y binding to P afi—Closer examination of the results at the lowest PaP
concentration we could easily test (1 pM) indicated that the two Py binding sites on Pap
were not identical when we assayed Py inhibition of cGMP hydrolysis (Fig. 2.2, circles).
When 1 pM PaP was incubated with up to 1 mol Py per mol PaP, stoichiometric binding
ofPy to PaP was observed. This is evident from the fact that the data fit a straight line for
the first 50% of the binding curve (Fig. 2.2, dotted line). After binding 1.0 Py per PaP,
the remaining Py binding sites required an excess of free Py in order fully inhibit PaP.
Attempts to fit the entire binding curve to Eq. 1 {upper dashed line, Fig. 2.2) or Eq. 2
failed to generate statistically valid regression coefficients, so we fit the data to a
modified form of Eq. 1 that included two independent classes of binding sites. This
approach gave the best fit to the experimental data (Fig. 2.2, solid line), and resolved two
classes ofPy binding sites with Kd values of 0.3 and 7 pM. [The 0.3 pM value is an upper
limit for the higher affinity Kd. Because this site exhibits titration behavior, the true,
binding affinity may be greater than the curve-fitting estimate.] Note that the data cannot
distinguish between two independent classes ofPy binding sites and a model in which the
first Py to bind reduces the binding affinity of Pap for the second Py (negative
cooperativity).
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Fig. 2.2. Py binding affinity at 1 pM P a p reveals two classes of binding sites in the
presence o f cGMP. Pap (1.0 pM) was incubated with various concentrations of Py at 4°
for 10 min, and then the extent of inhibition of cGMP (•, 100 pM concentration; n = 7)
or cAMP (▲, 500 pM concentration; n = 6) hydrolysis was determined at 22°. The
cAMP data was well fit as a single class ofPy binding sites using either Eq. 1 {dashed
line: K d = 3.7 ± 0.3 pM, Bmax = 1.80 ± 0.03 mol Py bound per mol PaP) or Eq. 2 (K d =
2.6 ± 0.3 pM, Bmax = 176 ± 0.04 Py per Pap; not shown). The cGMP data did not fit a
single site model using either Eq. 1 {dashed line) or Eq. 2 (not shown), as judged by
statistical analysis of the regression. For values of total added Py < 1.0, the binding curve
fit a linear model {dotted line), consistent with stoichiometric binding (K d < 1 pM) of 1
mol Py per mol PaP in the presence of cGMP. A two-site model was also used (by
extension of Eq. 1) to fit the entire data set {solid line), and resolved the binding curve
into two classes of sites with Kdi = 0.3 ±0.1 pM and Kd2 = 6.6 ± 2.3 pM.
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cGMP binding to noncatalytic sites on P afi is responsible fo r P y binding heterogeneity—
We have previously demonstrated that bovine rod PaP (in the absence of Py) contains
high- ( K d = 60 nM) and low-affinity ( K d > 1 pM) cGMP binding sites, and that the lowaffmity site is restored to its high-affinity state upon Py addition (Mou et al., 1999). We
hypothesized that the Py binding heterogeneity in Fig. 2.2 might result from
heterogeneity in cGMP binding to the noncatalytic sites. To test this, we needed to
measure Py binding when the noncatalytic sites are not occupied with cGMP. cAMP is an
alternate substrate for PDE6 catalysis and binds with negligible affinity to amphibian
PDE6 ( K d > 40 mM) (Hebert et al., 1998). Fig. 2.3 {triangles) demonstrates that cAMP is
able to weakly bind to bovine PaP, as judged by its ability to compete with cGMP
binding to the one high-affinity site present on PaP (Mou et al., 1999). Assuming simple
competition between cGMP and cAMP binding, cAMP binds to the high-affinity
noncatalytic site with a Kd ~ 200 pM.
When we re-examined the binding affinity ofPy to PaP in the presence of 500
pM cAMP, we found that Py binds to PaP with a single Kd value of 3 pM (Fig. 2.2,
triangles). No evidence of binding site heterogeneity or cooperativity was evident when
Py interaction with PaP was assayed based on its inhibition of cAMP hydrolysis. This
implies that cAMP binding to noncatalytic sites does not affect Py binding to Pap. In
contrast, binding of cGMP to noncatalytic sites induces an allosteric transition that
increases Py binding affinity > 10-fold to one site on Pap. The other Py binding site
maintains an affinity for Pap similar to the Kd observed when cAMP is present.
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Lack o f direct allosteric communication between the catalytic and noncatalytic sites on
bovine P aft—Because cGMP binding induces a conformational change in Paf3 that
enhances Py affinity, we hypothesized that the GAF domain might also allosterically
regulate hydrolytic activity in the catalytic domain [in analogy to the cGMP-stimulated
PDE, PDE2; ref. (Martins et al., 1982; Yamamoto et al., 1983; Yamamoto et al., 1983)].
To test this, we compared the kinetic parameters of Potj3 using cGMP or cAMP as the
substrate. Table 2.1 shows that when cGMP is the substrate, PaJ3 achieves a catalytic
efficiency ( k oat/K M = 4x108 IVfY1) approaching the diffusion-controlled limit for a
bimolecular collision. PDE6 has a 100-fold greater specificity for cGMP compared to
cAMP, as judged by the decrease in the kcat/KM value when cAMP is the substrate. Most
of the reduction in substrate specificity for cAMP can be ascribed to the 65-fold increase
in its Km value (Table 2.1). For both cGMP and cAMP, no cooperativity could be
detected (Table 2.1), but this is not unexpected since the high-affinity noncatalytic site on
PaP is occupied over most of the concentration range we were able to test.
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Table 2.1
Kinetic parameters fo r cyclic nucleotide hydrolysis by bovine rod P a f
Pap was depleted of endogenous, bound cGMP by incubation at 37° for 30 min. 5 pM
Pap (for cGMP as substrate) or 50 pM PaP (for cAMP measurements) was added to 0.1
- 2000 pM cGMP or 15 pM to 60 mM cAMP and the initial rate of hydrolysis
determined.

Condition
cGMP substrate
cAMP substrate
cAMP substrate + cGMP
occupying noncatalytic
sitesa

Km

kcat

(pM)
14 ± 1.0
910+100
830 ± 60

(s-1)
5440± 80
3060± 100
3160 ±70

kcat^KM

(MfV1)
3.9x10*
3.4xl06
3.8xl06

Hill
coefficient
0.9 ±0.1
0.9 ±0.1
1.0±0.1

aTo load cGMP on the noncatalytic sites of Pap, 200 nM PaP was first incubated with 5
pM cGMP, 100 pM zaprinast, and 10 pM Py 1-45. To remove unbound low molecular
weight compounds, the PaP was concentrated by ultrafiltration. The PaP was washed
three times by resuspending in buffer (containing Pyl-45) and re-concentrating. The final
PaP preparation contained 1.1 - 1.6 mol cGMP bound per mol PaP
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To directly test whether cGMP occupancy of the noncatalytic sites affected
catalysis, we first pre-incubated Pap with cGMP and the N-terminal half of Py (Pyl-45)
to load cGMP onto both noncatalytic sites. [Pyl-45 has no effect on catalysis of PaP
(data not shown), but stabilizes high-affinity cGMP binding at both noncatalytic sites on
PaP; see below.] The complex of PaP with bound Pyl-45 and cGMP was then incubated
with increasing concentrations of cAMP to determine its kinetic parameters. No
significant change in Km, kcat or Hill coefficient could be discerned when compared with
PaP incubated with cAMP alone (Table 2.1). These results confirm and extend previous
observations with amphibian PDE6 (Arshavsky et al., 1992; D'Amours and Cote, 1999;
D'Amours and Cote, 1999) that no direct allosteric mechanism regulates catalysis via the
state of occupancy of the GAF domains on PDE6, as is the case for PDE2 (Martins et al.,
1982; Yamamoto et al., 1983; Yamamoto et al., 1983). Thus, the differences in the Km
and kcat values for cAMP and cGMP are due to differences in substrate specificity at the
active site, not on the state of occupancy of the GAF domain.
The N-terminal half o f P y binds to P afi with much greater affinity than the C-terminal
region—Previous work has documented that two major domains of interaction with Pap
exist on Py: the C-terminal residues and the polycationic central region (see Introduction).
To understand how distinct binding domains on Py contribute to the very high-affinity
binding ofPy to PaP, we assayed the ability of these individual domains ofPy to bind to
Pap. We first assayed the ability of the C-terminal peptide, Py63-87, to bind to, and
inhibit, cyclic nucleotide hydrolysis at the active site. Based on previous work
(Granovsky et al., 1997), we expected that Py63-87 would act as a simple competitive
inhibitor with respect to cyclic nucleotides. When cAMP is used as substrate, Py63-87
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acts as a simple competitive inhibitor of catalysis with an inhibition constant, Ki, equal to
3.5 pM (Fig. 2.4). The affinity of this inhibitory domain is 6 orders of magnitude weaker
than the entire Py molecule (Kd = 3 pM), indicating that the N-terminal 62 amino acids
most likely contain the major site(s) of high-affmity interaction.
To directly measure the binding affinity of the N-terminal half of Py to Pap, we
assayed the interaction of Pyl-45 covalently labeled with Lucifer Yellow (Pyl-45-LY)
with Pap. Fig. 2.5A demonstrates that either in the absence of cyclic nucleotides or in the
presence of cAMP, PaP binds to Pyl-45-LY as a single class of binding sites with a Kd =
68 ± 15 or 62 ± 14 nM, respectively. In both cases, the maximum extent of binding was
the same.
To test how the fluorescent probe altered the binding affinity of Pyl-45, we also
tested the effectiveness of Pyl-45 in restoring high-affinity cGMP binding to the lowaffinity site on PaP (Mou et al., 1999). In the absence ofPy or Pyl-45, PaP is able to
bind 1 mol cGMP per mol PaP at micromolar levels of [3H]cGMP (see Fig. 2.3,
triangles). Addition of increasing amounts of Pyl-45 in the presence of 600 nM
[3H]cGMP stimulates cGMP binding to a second site on PaP (Fig. 2.5B) with a Kd - 80
nM, a value in good agreement with the Kd for binding ofPyl-45-LY to Pap.
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Figure 2.3. cAMP binding affinity for the noncatalytic sites of bovine rod P a p in the
absence of Py or upon addition of Py or Pyl-45. 1 pM [3H]cGMP and the indicated
concentrations of cAMP were added to 10 nM PaP in the absence of Py (A), or
following pre-incubation with 20 nM Py (•) or 10 pM Pyl-45 (□, mean ± range for n =
2). The ability of cAMP to compete with [3H]cGMP binding to noncatalytic sites was
determined by filter binding, and the data was fit to a single class of non-interacting sites
to obtain the following K 1/2 and B^ax values, respectively: PaP, 4.0 mM, 0.9 cGMP/Pap;
PaP+Py, 0.4 mM, 2.0 cGMP/PaP; Pap+Pyl-45,0.3 mM, 2.0 cGMP/Pap. The Kd for
cAMP binding was calculated from the K 1/2 value (Cheng and Prusoff, 1973) using Kd =
60 nM for cGMP binding.
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Figure 2.4. Competitive inhibition of Py63-87 with cAMP at the active site of Pap.
PaP (2 nM) was incubated with 1.0 (open circles), 2.0 (upside-down triangles), 5.0
(triangles), 10 (squares) or 20 (filled circles) pM Py63-87 for 10 min at room temperature
before adding the indicated amounts of cAMP and determining the initial rate. The data
were plotted as the reciprocal of fraction of the maximum rate (v* = v/Vmax) versus the
reciprocal of the substrate concentration. The inhibition constant, Ki, for Py63-87 was
calculated to be 2.9 ± 0.3 pM from a replot of the slopes versus the corresponding
inhibitor concentrations. The data is representative of three experiments with an average
Ki = 3.5 ±0.5 pM.
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We conclude that the N-terminal half of Py (Pyl-45) binds to PaP about 50-fold
more tightly than the C-terminal region (Py63-87). Furthermore, if each binding domain
were to interact with PaP independently, the sum of the interaction energies of Pyl-45
and Py63-87 (Kd ~ 10'13 M) would account reasonably well with the measured Kd for
full-length Py.
Relationship between occupancy o f the GAF domain and P y binding affinity—In Fig. 2.2,
we showed that heterogeneity in Py binding to PaP (assayed by inhibition of cyclic
nucleotide hydrolysis) was dependent on the state of occupancy of the noncatalytic sites.
The cGMP-dependent enhancement of full-length Py binding affinity is also observed
with the fluorescently labeled N-terminal half of Py. Fig. 2.5A shows that Pyl-45-LY
undergoes a 2.3-fold increase in binding affinity, with no significant change in maximum
binding, when the GAF domains are occupied by cGMP compared to empty or cAMPfilled sites. Thus, occupancy of the noncatalytic site by cGMP is required to induce the
conformational change in PaP that enhances Py binding affinity.
These results and our previous study with bovine rod PaP (Mou et al., 1999) are
in accord with a simple reciprocal relationship: cGMP occupancy of the noncatalytic sites
enhances Py affinity to one of its binding sites and, conversely, Py binding to PaP
enhances cGMP binding affinity to its low-affinity noncatalytic site. Unexpectedly, this
correlation does not apply when cAMP occupies the noncatalytic sites. Fig. 2.3 shows
that addition ofPy or Pyl-45 to PaP enhances 10-fold the ability of cAMP to compete
with cGMP for binding to both noncatalytic sites. This suggests that Py binding induces a
conformational change in PaP that enhances the affinity of both cGMP and cAMP for
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PaJ3. However, Fig. 2.5A reveals that cAMP occupancy of the noncatalytic sites is not
sufficient to induce an increase in Pyl-45-LY binding to Pa|3. It appears that cGMP, but
not cAMP, is needed to induce a conformational change in PaP that enhances Py binding
affinity. This conclusion is supported by experiments with cGMP analogs that show
intermediate effects on the relationship between cyclic nucleotide occupancy and
enhanced Py binding affinity (H.M. and R.H.C., unpublished observations).
Defining the amino acid residues responsible fo r high-affinity interactions of Py
with P afi—We prepared a set of synthetic peptides corresponding to various regions of
the Py primary sequence to identify regions ofPy that stabilized high-affinity binding of
Py. We first measured the ability of these peptides to compete with full-length,
endogenous Py bound to nonactivated PDE6, as judged by the increase in catalytic
activity at the active site. Fig. 2.6A shows that two peptides, Pyl-45 and Py 18-41, were
able to compete with full-length Py to activate PDE6 to 70-80% of its maximal rate and
with K 1/2 values of 1 and 11 pM, respectively. The Py21-46 peptide showed a significant
drop in its ability to compete with Py when compared with Pyl8-41, suggesting that
amino acid residues 18-20 may stabilize a peptide conformation of Pyl8-41 that enhances
its interaction with Pap. Several other peptides were able to stimulate cGMP hydrolysis
to a limited extent (20-40% activation) and with low affinity (K 1/2 ~ 400 - 500 pM),
including Pyl-18, Py 10-30, and Py35-56. The peptide Py55-75 was completely ineffective
in competing with Py. These results indicate that the interaction ofPy with PaP may
consist of multiple low-affinity sites of interaction along the N-terminal half of the Py
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molecule, with high-affinity interactions occurring in the region of amino acid residues
18 through 41.
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Figure 2.5. High-affinity binding of P y l - 4 5 to P a P . A. The relative increase in
fluorescence (F/F0) of Pyl-45 labeled with Lucifer Yellow (Pyl-45-LY) was measured
after addition of the indicated amounts of Pap. The buffer used for these assays
contained 10 mM HEPES, pH 7.8,100 mM NaCi, 1 mM MgCk, 200 pM zaprinast, and
either no nucleotide (•), 10 mM cAMP ( A ) or 10 pM cGMP (■). The curves represent
the fit of each data set to a hyperbolic function: no nucleotide, Kd ~ 68 ± 15 nM,
(F/F0)max = 3.3; cAMP, KD - 62 ± 14 nM, (F/FoW = 3.4; cGMP, KD= 28 ± 5 nM,
(F/Fo)max = 3.5. No evidence for cooperativity was detected using the Hill equation to fit
the data. B. The ability of Pyl-45 to restore high-affinity cGMP binding to a low affinity
class of noncatalytic sites on Pap (10 nM) was measured following incubation of PaP
with the indicated concentration of Pyl-45 and 600 nM [3H]cGMP. The data represents
the average of 4 different experiments, and the curve is the fit of the data to a hyperbolic
function (Kd = 83 nM; 6 ^ = 1.9 mol cGMP bound per mol Pafi).
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Figure 2.6. Ability of Py peptides to interact with Pap. A. The catalytic activity of
nonactivated PDE6 holoenzyme (5 nM) was tested following incubation of PDE6 with
increasing concentrations of Py peptides. The maximum extent of activation and the K 1/2
for the Py peptides were determined by fitting the concentration dependence to a
hyperbolic function. The ordinate represents the log(Ki/2) for each peptide and the
abscissa visually depicts each Py peptide tested. The maximum percent activation of
cGMP hydrolysis induced by each peptide was: Pyl-45, 81%; Pyl8-41, 69%; Py 10-30,
42%; Py35-56, 32%; Py21-46, 25%; Pyl-18, 18% ; Pyl5-26, 14%; Py35-46, 11%; Py3541, 9%; Py55-75, <5%. B. The ability of Py peptides to restore high-affinity cGMP
binding to low affinity sites on PaP was determined as described in the legend to Fig. 5B,
and the Kd values plotted on the ordinate on a log scale. The Bmay for restoring highaffinity binding (% of restoration observed with Py = 100%) was: 100% (Py, Pyl-45,
Pyl0-30, Py 18-41), 90% (Py21-46), 70% (P/35-56, Py35-46), 40% (Py35-41), and 0%
(Pyl-18, Py 15-26, Py55-75, Py63-87). C. The [3H]cGMP dissociation kinetics were
determined at 22° by pre-incubating 5 nM PaP with 0.6 pM [3H]cGMP and 200 pM of
the indicated Py peptide until binding equilibrium was attained. Dissociation of bound
[3H]cGMP was initiated by addition of 2 mM unlabeled cGMP, and the data fit to a
single exponential decay function to determine the tin from the equation: ti /2 = 0.693/k.i,
where k_i is the dissociation rate constant.
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We showed above that the N-terminal half of Py, Pyl-45, could restore highaffinity cGMP binding to a low affinity class of noncatalytic sites on PaP (Figs. 2.3 &
2.5B). To better define this region on Py, we tested the ability of peptides to bind to PaP
and restore high-affinity cGMP binding to this class of sites. Fig. 2.6B shows that Pyl841 and Py21-46 both fully restored cGMP binding to PaP with a binding affinity reduced
approximately 10-fold compared to Pyl-45. Pyl0-30 was also able to fully restore cGMP
binding, but its interaction with Pap was 10-fold further reduced. Even though Py 15-26
failed to interact with PaP to restore cGMP binding, the overall results with several other
peptides suggest that residues 18 to 30 ofPy are important in stabilizing Py binding to
Pap.
We also tested peptides covering amino acids 35 - 56 of the Py sequence (Fig.
2.6B). While full restoration of cGMP binding could not be observed with Py35-56 or
smaller peptides, all three peptides showed Kd values in the 20 - 30 pM range. The
effectiveness of the shortest peptide, Py35-41, to stimulate cGMP binding to Pap
indicates that these residues are important in direct binding to PaP and in stabilizing a
high-affinity conformation of the second noncatalytic site on PDE6.
Although Pyl-45 has 10-fold higher affinity for PaP than Py 18-41, we could not
detect any interaction of the peptide Pyl-18 with PaP in terms of restoring high-affinity
cGMP binding (Fig. 2.6B). It is possible that some of the N-terminal residues may
stabilize a conformation of Pyl-45 that favors its binding to PaP compared to Py 18-41.
Two other peptides, Py55-75 and Py63-87, completely lacked the ability to restore cGMP
binding even at 300 pM peptide concentrations.
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The binding affinity of cGMP for the noncatalytic sites was determined in the
presence of 200 pM of each peptide to examine whether the low- and high-affinity
noncatalytic sites could be distinguished (data not shown). All Py peptides that were
competent to restore cGMP binding to the low-affinity sites failed to alter the Kd for
cGMP binding ( K d range:

51-63

nM). No evidence for binding site heterogeneity could

be detected. We conclude that binding of Py or central region Py peptides induces a
conformational change in the low-affinity noncatalytic site that enhances its affinity for
cGMP to a value indistinguishable from the high-affinity noncatalytic site.
The restoration of cGMP binding shown in Fig. 2.6B describes the ability ofPy
peptides to act on the low-affinity noncatalytic sites on Paj3. To examine both high- and
low-affinity noncatalytic sites, we examined whether Py peptides could alter the rate of
[3H]cGMP dissociation from the noncatalytic sites of PaP. Fig. 2.6C shows that most of
the peptides were able to retard the rate of [3H]cGMP dissociation from the noncatalytic
sites. In all instances, the dissociation kinetics was fit to a single exponential loss of
[3H]cGMP binding; no evidence for two distinct classes of sites was evident (not shown).
As expected, Pyl-45 retarded most effectively cGMP exchange at both noncatalytic sites
on PaP, causing a 16-fold increase in the half-time for [3H]cGMP release from
noncatalytic sites. The Py peptides Py 18-41 and Py 10-30 also retarded cGMP exchange
by greater than 10-fold. Comparison of Pyl8-41 (ti/2 = 84 min) with Py21-46 (ti/2 = 41
min) supports the importance of amino acid residues 18-20 in stabilizing binding ofPy
peptides to PaP. The Py peptide, Py35-46, is nearly as effective as the larger Py21-46 in
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slowing the rate of cGMP dissociation from Pap, while the seven amino-acid Py35-41
also acted to increase the half-time for cGMP dissociation 3-fold.
Two peptides, Py55-75 and Py63-83, were unable to affect cGMP dissociation
compared to PaP lacking Py peptides (ti/2 = 6 min), in agreement with their inability to
restore cGMP binding to low affinity sites (Fig. 2.6B). The fact that the Pyl-18 and Pyl5
26 peptides slowed cGMP dissociation ~ 3-fold from the high-affinity noncatalytic sites
of PaP (Fig. 2.6C) without being able to restore cGMP binding to the low-affinity site
(Fig. 2.6B) suggests that this region ofPy may affect only the high-affinity GAF domain
ofPDE6.
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D is c u s s io n
This paper shows that Py binds to two distinct high-affinity binding sites on Pa(3
when cGMP occupies the noncatalytic sites. Our work also describes the reciprocal
allosteric regulation of PDE6 resulting from Py binding to PaP and cGMP binding to
high-affinity sites in the GAF domains of PaP . Since no direct allosteric communication
between the GAF domains and the active sites is detected, we conclude that the Py
subunit is required to facilitate allosteric communication between the regulatory and
catalytic domains of PDE6. Finally, we have mapped regions within the N-terminal half
of the molecule that interact with Pap, some of which induce conformational changes at
the GAF domain.
Implications o f high-affinity, two-site P y binding to P afffor PDEfunction. Our
quantitative analysis ofPy binding to PaP helps to make sense of the wide range of
apparent binding affinities reported in the literature. The majority of studies of the Py
affinity for PaP have been carried out with concentrations of enzyme much greater than
the Kd value for Py binding. Under these conditions, Py will bind in a stoichiometric
manner (Fig. 2.1). Even when the appropriate model is applied to the binding data (i.e.,
Eq. 2), it is difficult to extract meaningful values for the Kd values. For example, we
were unable to satisfactorily fit data obtained at > 800 pM PaP concentrations to Eq. 2,
primarily because the estimate of the free Py concentration is very uncertain (H.M and
R.H.C., unpublished). In previous reports where the PDE concentration was lowered into
the picomolar range [e.g., refs. (Wensel and Stryer, 1986; Hamilton et al., 1993;
D'Amours and Cote, 1999; Hamilton et al., 1993; D'Amours and Cote, 1999)], the
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binding affinities of Py for PaP were much closer to the values we report. Previous
evidence supporting two distinct Py binding sites on PaP has mostly been obtained
indirectly, based on heterogeneity in transducin activation of PDE6 (Melia et al., 2000;
Norton et al., 2000; Bennett and Clerc, 1989; Bruckert et al., 1994; Bruckert et al., 1994;
Melia et al., 2000; Norton et al., 2000). However, Berger et al. (Berger et al., 1999) have
reported two classes ofPy binding sites on PaP when probed with a fluorescently labeled
mutant ofPy.
The functional heterogeneity in Py binding to PaP is a consequence of the state of
occupancy of the noncatalytic sites with cGMP (Fig. 2.2)—but not cAMP. Since the
membrane-associated bovine rod PDE6 holoenzyme has one exchangeable and one
nonexchangeable cGMP binding site (Mou et al., 1999), we hypothesize that the very
high affinity ( K d < 1 pM) Py binding site may correlate with this nonexchangeable cGMP
site. This Py binding site associated with the nonexchangeable cGMP site is unlikely to
function during visual transduction. Instead, it may serve a structural role in stabilizing
the native conformation of the PDE6 holoenzyme. This idea is supported by studies
showing that mutations in the GAF domains of PDE6 [(Gal et al., 1994); reviewed in ref.
(Dryja et al., 1999)] or a disrupted or mutated Py gene (Tsang et al., 1996) can affect the
levels of expression and/or activation of PDE6. It might also explain the difficulty in
expressing functional PDE6 in various expression systems (Piriev et al., 1993; Qin and
Baehr, 1994; Granovsky et al., 1998; Qin and Baehr, 1994; Granovsky et al., 1998) if co
expression of catalytic and Py subunits must occur to properly fold the nascent
polypeptide chains of PDE6.
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Allosteric regulation o f PDE6 requires P yto communicate between the GAF domain and
the catalytic domain. In addition to a catalytic domain near the C-terminus that is
conserved in all members of the vertebrate PDE superfamily, most PDE families contain
N-terminal domains that serve regulatory functions. It has been proposed (Conti, 2000)
that a common regulatory feature of the N-terminal domain is to alter the inhibitory
constraint on catalysis via conformational changes in the catalytic dimer. Almost half of
the known PDE families (PDE2, PDE5, PDE6, PDE 10, and PDE11) contain two tandem
GAF domains (Aravind and Ponting, 1997) which in most cases code for functional,
noncatalytic cGMP binding sites. For PDE2 and PDE5, binding of cGMP to the GAF
domain induces a conformational change in the catalytic dimer that either directly or
indirectly stimulates catalysis (Martins et al., 1982; Yamamoto et al., 1983; Bums et al.,
1992; Corbin et al., 2000; Yamamoto et al., 1983; Bums et al., 1992; Corbin et al., 2000).
For PDE6, we show that loading the GAF domain with cGMP has no direct influence on
PDE6 kinetic parameters (Table 2.1).
Nonetheless, cGMP binding to the GAF domain of PDE6 does induce a
conformational change in the catalytic dimer. Occupancy o f the noncatalytic sites
enhances the interaction of Py (Fig 2.2) or Pyl-45 (Fig. 2.5 A) to the catalytic dimer. This
effect is specific for cGMP (Fig. 2.5A). Conversely, addition ofPy to bovine rod PaP
enhances cyclic nucleotide binding affinity to the noncatalytic sites (Fig. 2.3) in a
reciprocal manner. For cGMP, Py acts to restore high-affinity binding to a low affinity
class of sites on bovine Pap; the other, high-affinity class of cGMP sites undergoes no
change in affinity (Mou et al., 1999). For cAMP, addition ofPy or Pyl-45 to PaP
increases the binding affinity 10-fold to both noncatalytic sites on PaP (Fig. 2.3).
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We conclude that unlike PDE2 or PDE5, the GAF domain in the PDE6 catalytic
subunit is allosterically uncoupled from its catalytic domain unless Py is bound to bridge
the two domains. Furthermore, the heterogeneity in Py binding to PaP suggests that only
one Py binding site on PaP is sensitive to cGMP occupancy of the noncatalytic sites.
Future efforts will identify which catalytic subunit contains the cGMP-sensitive Py
binding site and the high-affinity noncatalytic site on Pap.
P yis a multi-functional subunit with several sites o f interaction with the PDE6
transduction complex. The Py subunit of PDE6 contains within its 87 amino acid
sequence numerous sites of interactions with PaP, transducin, RGS-9 and perhaps other
proteins (see Introduction). In this study, we have focused on Py-Pap interactions, and
find that the N-terminal half ofPy binds 50-fold more tightly to the catalytic dimer than
the C-terminal region (Py63-87). This high-affinity binding domain in the region of
residues 18 - 41 of Py explains why a t* activation of the PDE6 holoenzyme sometimes
displaces the inhibitory constraint of Py without causing complete dissociation ofPy from
Pap (Wensel and Stryer, 1986; Clerc and Bennett, 1992; Clerc and Bennett, 1992). The
correlation ofPy dissociation from transducin-activated PDE with loss of cGMP from the
GAF domain (Norton et al., 2000) also makes sense based on the reduced binding affinity
ofPy or Pyl-45 in the absence of cGMP (Figs. 2.2 & 2.5).
Within the central region of the Py subunit, amino acids 18 - 20 and 35 -4 1 both
contribute to stabilizing Py binding to PaP (Fig. 2.6). Other Py interaction sites probably
exist within this polycationic region that went undetected with our selected peptides,
including potential sites of regulation via phosphorylation at T22 and/or T35 (Tsuboi et
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al., 1994; Xu et al., 1998; Matsuura et al., 2000; Xu et al., 1998; Matsuura et al., 2000) or
via ADP-ribosylation at R33 or R36 (Bondarenko et al., 1997).
Our results demonstrate that the N-terminal 18 amino acids of Py play no direct
role in inhibiting catalysis or stimulating high-affinity cGMP binding to PaP (Fig. 2.6),
contrary to a previous study (Yamazaki et al., 1996a). However, the N-terminus of Py
probably contains weak sites of interaction with PaP and may help stabilize a highaffinity conformation of the 18-41 region ofPy.
Significantly, the one peptide that shows no detectible interaction with PaP,
namely Py55-75, contains a major site of interaction with activated transducin, a t* (see
Introduction). A recent structural determination of the interaction of the C-terminal half
ofPy with a t* has shown that a t*binds to several residues in the vicinity of W70 ofPy to
cause the displacement of the C-terminal residues ofPy known to block the active site
(Slep et al., 2001).
Summary. Our results extend previous models postulating two major sites of
interaction between PDE6 and activated transducin—both of which are mediated through
the inhibitory Py subunit. The extreme C-terminus ofPy functions to block catalysis at
the active site, but has relatively low affinity for Pap. It is the high-affinity interactions
of the central, polycationic region ofPy (particularly residues 18-41) that stabilize
binding to PaP, thereby insuring that a very small fraction of PDE6 holoenzyme is
catalytically active prior to light activation. High levels of cGMP in dark-adapted
photoreceptor cells result in saturation of the noncatalytic sites on PDE6, further
enhancing Py affinity to one binding site on the PDE6 holoenzyme. Upon activation of
the phototransduction cascade, binding of activated transducin to the PDE6
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holoenzyme—specifically in the vicinity of W70 of Py—is sufficient to displace the Py
C-terminus and cause activation at one active site on Pa(T [The very high-affinity Py
binding site ( K d < pM) when cGMP is present likely prevents at* displacement ofPy at
the second active site (Melia et al., 2000; Norton et al., 2000; Norton et al., 2000)]. At
early times following light stimulation, a t* remains associated with the PDE6
holoenzyme, and does not physically dissociate as a a t*-Py complex. Following PDE6
activation, cGMP levels in the outer segment drop and remain low until the inactivation
process re-inhibits PDE6. The positive cooperativity between the GAF domains and the
central region ofPy suggests that a sustained lowering of cGMP levels (e.g., during light
adaptation) will lead to cGMP dissociation and a lowered Py affinity for Paf3. This
cGMP-dependent allosteric transition could cause the multi-functional Py subunit to
become available to interact with RGS-9 to facilitate an enhanced GTPase rate on a t*,
consistent with biochemical and structural studies (Slep et al., 2001; Arshavsky and
Bownds, 1992; Calvert et al., 1998; He et al., 1998; Calvert et al., 1998; He et al., 1998;
Slep et al., 2001).
While homology modeling of the GAF domain (Ho et al., 2000) and the catalytic
domain (Xu et al., 2000; Granovsky and Artemyev, 2000; Granovsky and Artemyev,
2000) of PDE complement recent structural information on Py binding to at* (Slep et al.,
2001), we still lack crystal structures revealing the interactions of each Py molecule with
the a and J3 subunits of the rod PDE6 heterodimer. The present study provides the
biochemical basis for understanding how the central and C-terminal domains of Py bridge
the regulatory and catalytic domains of the rod PDE6 heterodimer to control the
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magnitude and duration of PDE activation during visual excitation, recovery, and light
adaptation.
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Chapter III
Regulation of PDE6 by phosphorylation of the inhibitory y subunits and
the catalytic ap subunits
Abstract
Many proteins in the visual transduction pathway become phosphorylated upon
light activation. Since PDE6 is the key effector enzyme in phototransduction, it is quite
possible that PDE function is regulated by reversible phosphorylation of its subunits. In
this study, we first examined the effect of phosphorylation of the inhibitory rod PDE y
subunit (Py) on its interaction with the PDE6 catalytic subunits (PaP) after
phosphorylation at Thr22 by mitogen-stimulated protein kinase (MAPK) and at Thr35 by
cAMP-dependent protein kinase A (PKA). Our results showed that phosphorylation of
Py neither abolishes the heterogeneity in Py binding to Pap nor greatly affects the
potency ofPy to inhibit both trypsinized PDE and transducin-activated PDE. However,
phosphorylation at Thr22 mildly decreases the ability of the central region ofPy to bind to
PaP and to stabilize the cGMP binding at the GAF domains. Py bound to PaP is a poor
substrate for phosphorylation, but transducin activation enhances its ability to be
phosphorylated in bovine rod outer segments (ROS). PaP can also be phosphorylated by
PKA and MAPK under in vitro conditions. PKA prefers PP as a substrate while MAPK
can phosphorylate both P a and Pp. An unknown protein kinase from ROS membrane
associates with PDE with a moderate affinity and phosphorylates PDE at its a subunit.
No alteration in kcat and Km has been detected after the phosphorylation of PaP. However,
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cGMP occupancy at the noncatalytic sites reciprocally regulates the phosphorylation of
Pap. These results suggest a potential role of Py and PaP phosphorylation in regulating
PDE6 by regulating cGMP levels in the photoreceptor cells. Other possible physiological
roles of Py and Pap phosphorylation in regulating PDE during phototransduction are
discussed.
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Introduction
Photoactivation of the visual pathway starts when a photon of light stimulates a
molecule of rhodopsin, initiating a transduction cascade involving the sequential
activation of rhodopsin (R), transducin (Gt) and cGMP phosphodiesterase (PDE). PDE is
the key effector enzyme in visual transduction and functions to hydrolyze the second
messenger cGMP upon activation [for reviews, see (Pugh, Jr. et al., 1999)]. The decrease
in cGMP concentration causes dissociation of cGMP from the cGMP-gated ion channels.
This causes the channels to close, resulting in a hyperpolarization of the membrane.
Protein phosphorylation plays a central role in regulating the function of several
phototransduction proteins. Many protein kinases have been found to exist in vertebrate
rod outer segments: rhodopsin kinase (RK) (Lee et al., 1981); cyclin-dependent protein
kinase 5 (cdk5) (Hayashi et al., 2000); protein kinase C (PKC) (Kelleher and Johnson,
1985; Udovichenko et al., 1997; Udovichenko et al., 1997); cAMP-dependent kinase
(PKA) (Walter, 1984), casein kinase II (CKH) (Hollander et al., 1999); Ca2+/calmodulindependent protein kinase II (CaMKH) (Liu et al., 2000); cGMP-dependent kinase (PKG)
(Taylor and Uhler, 2000), mitogen-stimulated protein kinase (MAPK) (Ko et al., 2001)
and protein-tyrosine kinase (Bell et al., 2000). Rhodopsin phosphorylation by RK has
been studied as a mechanism to terminate the initial step of the light-activated
biochemical process (Wilden, 1995; McDowell et al., 2001; Hurley et al., 1998; Krupnick
and Benovic, 1998; Wilden, 1995; Hurley et al., 1998; Krupnick and Benovic, 1998;
Kennedy et al., 2001; McDowell et al., 2001). Phosphorylation of phosducin by CaMKH
regulates transducin through regulation of Gt|3y function (Bauer et al., 1992; Lee et al.,
1992; Gaudet et al., 1999; Thulin et al., 2001; Gaudet et al., 1999; Bauer et al., 1992; Lee
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et al., 1992). Phosphorylation of the cGMP-gated channel by a tyrosine kinase is another
mechanism to regulate cGMP sensitivity in addition to calmodulin regulation (Muller et
al., 2001). RGS9-1 (regulator of G protein signaling 9) is also found to be phosphorylated
by an endogenous protein kinase in rod outer segments (Hu et al., 2001).
Most work on PDE6 phosphorylation has focused on Py phosphorylation.
Currently, Py phosphorylation has been studied in vivo (Hayashi, 1994; Hayashi et al.,
2000; Hayashi et al., 2000) and in vitro using several protein kinases including
phosphatidylinositiol (Pl)-stimulated kinase (Hayashi et al., 1991), PKC (Udovichenko et
al., 1994; Udovichenko et al., 1996; Udovichenko et al., 1994), PKA (Xu et al., 1998),
cdk5 (Tsuboi et al., 1994b; Tsuboi et al., 1994a; Sharma et al., 1999; Hayashi et al., 2000;
Matsuura et al., 2000; Hayashi et al., 2000; Sharma et al., 1999; Tsuboi et al., 1994b;
Tsuboi et al., 1994a). The physiological function of Py phosphorylation in the current
scheme of phototransduction is not well understood. The central region of Py contains
most of the predicted phosphorylation sites and the central domain of Py is also a major
site at which Py interacts with PaP (Artemyev and Hamm, 1992; Mou and Cote, 2001;
Mou and Cote, 2001; Mou and Cote, 2001). Yamazaki and colleagues have proposed that
Py phosphorylation at either Thr35 (by PKA) or at Thr22 by (cdk5) enhances almost 10fold the interaction of Py with Pap (Tsuboi et al., 1994b; Xu et al., 1998; Hayashi et al.,
2000; Tsuboi et al., 1994b; Tsuboi et al., 1994a; Matsuura et al., 2000; Hayashi et al.,
2000). However, their conclusions are open to alternative interpretations. For example,
they have not carefully evaluated the Kd of Py binding to Pap with or without
phosphorylation. Actually, the experimental conditions chosen (nanomolar concentration
of PDE) in their studies would prevent the Py binding affinity for bovine or frog Pap
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from being discerned because Py interacts with Pa(3 with such high affinity ( K d < 10
pM) (Wensel and Stryer, 1986; Mou and Cote, 2001; Mou and Cote, 2001) that both nonphosphorylated Py and phosphorylated Py should inhibit the catalysis of Pap in a titration
manner. In addition, they have not studied if Py phosphorylation would affect cGMP
binding to GAF domains on PDE6. The effect of Py phosphorylation on the ability of Py
to serve as a GTPase-activating protein (GAP) for transducin has also been reported. Xu
et al. have shown that, once phosphorylated, Py had less ability to deactivate transducin
and displace bound GTPyS from its binding site on Gta (Xu et al., 1998). However, direct
measurements of Py-transducin interactions were not performed in their study.
Several members of the PDE family are regulated and activated by
serine/threonine phosphorylation of the catalytic subunits, including PDEl(Florio et al.,
1994; Florio et al., 1994), PDE3 (Macphee et al., 1988), PDE4 (Lim et al., 1999) and
PDE5 (Thomas et al., 1990; Beltman et al., 1993; Corbin et al., 2000; Beltman et al.,
1993; Corbin et al., 2000). Phosphorylation of PDE5 may be most relevant to PDE6,
since the structure of PDE5 is the most closely related to PDE6 (McAllister-Lucas et al.,
1993; Tcheudji et al., 2001; Tcheudji et al., 2001). Phosphorylation of PDE5 is
allosterically enhanced by cGMP occupancy of cGMP binding sites (Turko et al., 1998).
No major effect of phosphorylation on the maximum rate of catalysis and the potency of
PDE5 inhibitors has been described. However, a modest decrease in the Kmfor cGMP
hydrolysis and Kd for cGMP binding has been observed (Corbin et al., 2000). To date,
only one report has suggested that PDE6 serves a substrate for PKA and ROS PKC in
vitro (Udovichenko et al., 1993). They showed that PKA phosphorylated PDE at both
subunits, but removal of Py by trypsinization abolished the phosphorylation by PKA.
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PKC only phosphorylated the P a subunit and this phosphorylation was independent of
trypsinization. A synthetic peptide AKVISNLLGPREAAV (Pa30-44) inhibited
phosphorylation of PDE catalytic subunits by PKC from ROS, suggesting that Ser34 of
P a subunit is a potential phosphorylation site for PKC. The effect of phosphorylation on
PDE6 catalysis and cGMP binding properties has not been described. In addition, no in
vivo phosphorylation of PDE6 has been reported.
In this study, we have repeated the stoichiometric phosphorylation of Py at Thr35
by PKA and at Thr22 by MAP kinase in vitro. We have measured the Kd of
nonphosphorylated and phosphorylated Py binding to Pap and found no apparent effect
of phosphorylation on the ability ofPy to inhibit both trypsinized and transducinactivated PDE. However, phosphorylation ofPy at Thr22 mildly decreases the ability of
the central region ofPy to stabilize cGMP binding to the GAF domains and to displace
the endogenous full-length Py from its binding sites in the catalytic domain ofPDE. We
have also observed an increase in Py phosphorylation upon light activation of bovine
ROS, but the stoichiometry is low. Based on these observations, we conclude that the
phosphorylation ofPy is unlikely to regulate PDE catalysis directly, but may be involved
in regulating its noncatalytic cGMP binding. It remains possible that other signaling
pathways intersect with visual excitation by recognizing Py in its phosphorylated state.
Our results show that PDE catalytic subunits are also substrates for
phosphorylation by PKA, MAP kinase, and by an unknown ROS membrane-associated
“PDE6 kinase”. When the GAF domains lack bound cGMP, PaP phosphorylation is
enhanced, opposite to the case for PDE5. We have not found the apparent effect of PDE6
phosphorylation on its catalysis. However, phosphorylation of PaP restores high affinity
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cGMP binding to low-affinity noncatalytic sites. The possible physiological role of PaP
phosphorylation in regulating PDE during phototransduction will be discussed.
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Material and Experimental Procedures
Materials—Bovine retinas were purchased from W.L. Lawson, Inc. [3H]cGMP was from
NEN Life Sciences Products and [y-32P]ATP was from ICN Biochemicals. Filtration and
ultrafiltration products were from Millipore. Scintillation fluid (Ultima Gold) was from
Packard Instrument Corporation. Zaprinast was a gift of Rhone-Poulenc Rorer
(Dagenham, UK). BCA protein assay reagent was from Pierce. Superdex 200 and Mono
Q columns were from Pharmacia, and the C l8 reverse-phase HPLC column (300A, 22 x
250 mm) was from Vydac. cAMP-dependent protein kinase (PKA) catalytic subunit and
MAP kinase 2 (Co-expressed with Erk2) were from Upstate Biotechnology. Bacterial
strains containing Py22C and Py35C are kind gifts of Dr. N O. The mutants Py22C and
Py35C both had a substitution of Ser at Cys68 of the bovine rod Py sequence, in addition
to a Cys substitution for the naturally occurring Thr at positions 22 or 35, respectively
(Granovsky et al., 1998). Artemyev and bacterial strains containing Pyl-45C (Py amino
acid residues 1-45 plus a cysteine tagged at the C-terminal end) was provided by Dr.
N.P.Skiba (Skiba et al., 1996). All other chemicals were obtained from Sigma.
Preparation o f bovine rod outer segments (ROS) —Purified bovine ROS was prepared
from frozen retinas in the dark under IR illumination following the method of McDowell
(McDowell, 1993). 50 retinas were suspended with 45 ml of solution A (0.1 M potassium
phosphate monobasic, pH 7.0, 1.0 mM MgCL, 0.1 mM Na2-EDTA, 1 mMDTT, 0.2 mM
PMSF) in a flask. The ROS were detached from the retina by stirring on a magnetic plate
for 10 min while keeping the flask on ice. After spinning at 5000 rpm for 30 minutes, the
crude ROS was collected through 4 layers of gauze. The sucrose was diluted 1.5 fold
with solution A, followed by spinning for 1 hour at 7500 rpm. The ROS-containing pellet
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was resuspended in solution A supplemented with 25.5% of sucrose (d = 1.105 g/ml),
then loaded on a discontinuous sucrose gradient containing 5 ml of 27.1% sucrose (d =
1.135 g/ml) and 5 ml 32.3% of sucrose (d = 1.115 g/ml). The sucrose gradient was
centrifuged at 27,000 rpm in SW27.1 rotor at 4°C for 1 hour. The ROS layer found in the
lower interface (1.115 g/ml and 1.135 g/ml) was removed with 15 g needle. The ROS
was then diluted with solution A and centrifuged (17K in SS-34 rotor for 60 minutes).
The purified ROS pellet was stored at -80°C until use.
Preparation o f non-activated membrane-associated PDE (PDE-M) and Pa/S dimer —
Bovine rod membrane-associated PDE was prepared from frozen bovine retinas and
purified by using ion-exchange, immunoaffinity and gel-filtration chromatography using
procedures described previously (Mou et al., 1999). The purified PDE was concentrated
with Biomax-50K and stored in PDE storage buffer (100 mM NaCl, 2 mMMgCfe, 10
mM Tris, 7.5, 2 mM dithiothreitol, 0.4 mM Pefabloc) containing 50% glycerol at -20°C.
PDE catalytic subunits (PaP) were prepared by limited proteolysis of purified PDE by L1-tosylamido-2-phenylethyl chloromethyl ketone-treated trypsin and Py fragments were
removed by Mono-Q chromatography, as described in detail previously (Mou et al.,
1999). The purity of the PaP was found to be >95%. The concentration of PDE was
determined as described previously (Mou et al., 1999; Cote, 2000; Cote, 2000).
Purification and quantitation o f P yand P y mutants (P/22C, P /35C and truncated
mutant Pyl-45C) —The recombinant bovine rod full-length Py and Py mutants were
expressed using the pETlla-Py, pETl la-Py22C, pETl la-Py35C and pETl la-Pyl-45C
vectors. The expression and purification procedures were the same as described in Mou et
al. (Mou et al., 1999). The concentration of purified Py, Py22C and Py35C were measured
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spectrophotometrically at 277 nm with an extinction coefficient of 7550 cm-M'1 (Cote,
2000). The concentration of purified Pyl-45C was determined by the bicinchoninic acid
(BCA) protein assay with bovine serum albumin (BSA) as the protein standard.
P y peptide synthesis and purification—V y\8-41 and two singly phosphorylated peptides
[Pyl8-41(22P) and Pyl8-41(35P)] were synthesized at the Protein Facility in the
Department of Biochemistry and Molecular Biology at the University ofNew Hampshire.
Cleavage of peptides from the resin and protecting groups were accomplished with
anhydrous hydrofluoric acid (HF). The peptides were first purified with cation exchange
chromatography on CM Sephadex C25 equilibrated with 1 mM NH4HCO3, pH 8.0 and
eluted with a linear 0-1.0 M NH4HCO3 gradient. After ion-exchange chromatography,
the peptides were further purified with a preparative C l8 reverse-phase column (300A,
22 x 250 mm) using a linear gradient of 30-70% acetonitrile in 0.1% trifluoroacetic acid.
The dried peptides were resuspended in 10 mM Tris, pH 7.5. The concentration ofPy
peptides was routinely measured by BCA protein assay.
Phosphorylation ofpurified recombinant Py, P y mutants, PDE-M by PKA or/and MAP
kinase — The phosphorylation assay was performed in final volume of 30-100 pi assay
dilution buffer [20 mM MOPS, pH 7.2, 25 mM [3-glycerol phosphate, 5 mM EGTA,
ImM sodium orthovanadate, ImM dithiothreitol, 15 mM MgCb], plus 100 pM ATP
(with or without 0.02-0.05 pCi/pl [y-32P]ATP), 1:50 phosphatase inhibitor cocktail-1
(Sigma, cat. # P2850; a mixture of inhibitors that will inhibit the L-isozymes of alkaline
phosphatase as well as serine/threonine protein phosphatases such as PP1 and PP2A) and
the desired concentration of Py, Py mutants or PDE-M. The phosphorylation reaction was
initiated by adding PKA (- 20 ng/pg protein) or MAP kinase (10-20 ng/pg protein). Two
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methods were used to detect the incorporation of [32P]. The first one was to apply the
phosphorylation mixture to P81 phosphocellulose paper squares (Roskoski, Jr., 1983),
then rinsed three times in 0.75% phosphoric acid to remove the free [32P]ATP. The
radioactivity was measured in a scintillation counter. The second method was to first
separate the proteins by SDS-PAGE and then detect incorporation of [32P] by
autoradiography.
In situ phosphorylation o f Pyand PDE catalytic subunits in bovine ROS —Bovine ROS
homogenates ([rhodopsin] = 50-100 pM) were incubated with 200-500 pM [y-32P]ATP
under nonactivated (in the darkness and without GTPyS) or activated (exposed to light
and in the presence of 100 pM GTPyS) conditions. The free [32P]ATP and soluble
proteins were removed by centrifugation at 13000 rpm for 10 minutes (loss of Py even in
the present of GTPyS was less than 5%). For the detection of Py phosphorylation, Py was
extracted by adding a final concentration of 20-40% of acetonitrile and heating at 80°C
for 10-20 min. For the detection of PDE catalytic subunit phosphorylation, PDE-M was
first extracted from ROS by washing ROS membranes at least three times with hypotonic
buffer (5 mM Tris, pH 7.5, 1 mM MgCl2, 1 mM DTT, 0.2 mM Pefabloc) or lOmM
CHAPS in ROS buffer. After extraction, Py was partially purified on a Sep-Pak Cl 8
cartridge using 50% of acetonitrile/0.1 % trifluoroacetic acid to elute Py; PDE-M was
concentrated with 10K Centricon ultrafiltration device. The stoichiometry of
phosphorylation was determined by comparison with [32P] incorporation into
recombinant Py or purified PDE-M by PKA in vitro.
Assay fo r PDE hydrolytic activity and measurements o f cGMP binding to noncatalytic
sites on Pa/3 —Two different methods (a radiotracer assay and a colorimetric assay) were
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used to quantify the PDE hydrolytic activity (Cote, 2000). The equilibrium binding and
kinetics of [3H]cGMP binding to the noncatalytic sites were measured with a filter
binding assay as described (Cote, 2000). For experiments in which the Py or Py peptides
were used, Py or Py peptides were added to the mixtures 10 min before cGMP or cAMP.
Data analysis - All experiments were performed at least three times and the results
presented are the mean ± S.E.M. unless noted otherwise. Fitting of the data was
performed using Sigmaplot (SPSS, Inc.), as described in the legends. Quantitation of
protein phosphorylation after autoradiography was performed using Quantiscan (Biosoft).
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Results
P art I: Regulation of PDE6 bv Py phosphorylation
Pyis phosphorylated by PKA at Thr35 and by MAP kinase at Thr22— Previous
phosphorylation studies have shown that Thr35 and Thr22on rod Py can be phosphorylated
by PKA and cdk5 in vitro (Xu et al., 1998; Matsuura et al., 2000; Matsuura et al., 2000).
Here, we confirmed that recombinant Py could achieve stoichiometric levels of phosphate
incorporation when incubated with PKA or MAP kinase. As shown in Fig. 3.1. A, the
phosphorylation level of wild-type Py by PKA was close to 1 mole of phosphate
incorporated per mole of Py. The site of phosphorylation on Py by PKA was confirmed
by 32P labeling of T35C and T22C Py mutants. Incubation of the T22C mutant with PKA
resulted in stoichiometric phosphate incorporation, whereas the T35C mutant lacked a
significant level of phosphorylation. Phosphorylation ofPy by MAP kinase has not been
previously described, but based on the substrate specificity of MAP kinase [Pro-X(Thr/Ser)-Pro; (Stokoe et al., 1992)], we predicted that the proline-rich region ofPy
would support phosphorylation at Thr22. As shown in Fig. 3.1.B, about 1 mol phosphate
was incorporated into Py. The Py mutant in which Thr22 was replaced with cysteine failed
to incorporate significant amounts of [32P] compared to wild-type Py or Py substituted at
Thr35 with a cysteine residue, suggesting that Thr22 was the site of phosphorylation.
Additional support for the PKA and MAP kinase substrate specificity was observed when
the Py peptides (Mou and Cote, 2001) were used for phosphorylation. The peptides
containing Thr35 (but lacking Thr22) could be phosphorylated only by PKA, while the
peptides containing Thr22 (but lacking Thr35) could be phosphorylated by only MAP
kinase (data not shown).
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Figure 3.1. Phosphorylation of Py and Py mutants (Py35C and Py22C) by PKA or
MAP kinase. The ability of PKA and MAP kinase to phosphorylate bovine rod Py at
Thr35 and Thr22 was determined by 32P labeling of wild type Py and two Py mutants:
PyT35C and PyT22C. The phosphorylation assay was performed in a final volume of 50
pi assay dilution buffer containing 1.0 pM final concentration ofPy orPy mutants, 100
pM [y-32P]ATP and either 50 ng PKA per tube (A) or 50 ng MAP kinase per tube (B).
After incubating at 30°C for various times, aliquots were applied to a P81 phosphocelluse
paper squares (see Experimental Procedures)
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P y phosphorylation at either ThP2 or Thr35 only slightly modifies its inhibitory activity to
P ap—The inhibition of the catalysis of PDE by Py is the primary mechanism to regulate
PDE function in visual transduction. Thus, it is important to investigate if Py
phosphorylation will affect its inhibitory function. Previous studies have proposed that Py
phosphorylation either at Thr35 or Thr22 greatly enhanced the inhibitory potency of Py
(Tsuboi et al., 1994b; Udovichenko et al., 1994; Xu et al., 1998; Matsuura et al., 2000;
Tsuboi et al., 1994a; Tsuboi et al., 1994b; Udovichenko et al., 1994; Matsuura et al.,
2000). However, in most cases, nanomolar concentrations of PDE were used and a
predicted stoichiometric inhibition of catalysis of Py or phosphorylated Py should be
observed (Wensel and Stryer, 1986; Mou and Cote, 2001; Mou and Cote, 2001). It is not
clear how an enhancement ofPy inhibition could be detected under these conditions.
Therefore, we decided to re-examine whether phosphorylation ofPy can directly alter its
potency to inhibit PDE catalysis. We used a very low concentration of PDE (1 pM) to
ensure that the equilibrium binding ofPy and PaP could be observed (Fig. 3.2). A 1-site
model did not fit well to the binding data, so a two-site model (Mou and Cote, 2001) was
chosen. The results shown in Fig. 3.2 indicated that Py binding heterogeneity was not
abolished upon phosphorylation at either or both threonine positions. In all four cases,
the very high affinity binding site had a predicted Kb value of < 0.5 pM and displayed
titration behavior. Such an extremely high affinity makes this Py binding site highly
unlikely to be regulated by phosphorylation. Indeed, this Py might never dissociate from
the PDE catalytic dimer during phototransduction, and perhaps functions as a scaffolding
protein to stabilize PDE in its native conformation. For the second, lower affinity Py
binding site, phosphorylation at Thr22 or Thr35 decreased the interaction ofPy with PaP 2
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to 2.5-fold, which was in sharp contrast to the 10-fold enhancing effects of Py
phosphorylation reported previously (Tsuboi et al., 1994b; Udovichenko et al., 1994; Xu
et al., 1998; Matsuura et al., 2000). Based on the above results, we concluded that
phosphorylation had only a mild effect to decrease the binding affinity of Py to PaJ3.
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Figure 3.2. Affinity of Py for PaP was not greatly affected by phosphorylation at
Thr22, Thr35-or both sites. Bovine PaP was prepared by limited trypsin proteolysis and
purified before use (see Experimental Procedures). Py phosphorylated at position Thr22,
Thr35 or doubly phosphorylated at both sites (Thr22,35) was prepared by incubating Py
with MAP kinase, PKA, or both kinases. Non-phosphorylated Py was treated identically,
except that the protein kinase was omitted. To measure the binding affinity ofPy or
phosphorylated Py for PaP, PaP was diluted to 1 pM and then incubated for 10 min with
the indicated concentration ofPy or phosphorylated Py. Inhibition of cGMP (100 pM)
hydrolysis was determined with the radiotracer assay. The data (averaged from three
experiments) were fit to a double hyperbolic function, assuming two equal classes of
binding sites. The higher affinity class of sites had predicted Kd values of < 0.5 pM in all
four cases and displayed titration behavior (dotted line). The lower affinity class of sites
had Kd values of 2.7 (Py, circles), 4.9 pM (Py35P, squares). 6.3 pM (Py22P, triangles)
and 6.9 pM (Py22P35P, diamonds)
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P y phosphorylation does not modify its interaction with transducin-activated PDE —
Several studies have suggested that Py phosphorylation reduces or abolishes the affinity
of Py for activated transducin a-subunit (Gta*) so that Py will dissociate from Gta* upon
phosphorylation and re-inhibit the catalysis of PDE (Xu et al., 1998; Hayashi et al., 2000;
Hayashi et al., 2000). If this is true, the phosphorylation of Py would serve to deactivate
PDE without the turnoff the Gta*. In this study, we re-examined ifPy phosphorylation
would modify its ability to inhibit transducin-activated PDE. It had previously been
shown that inhibition of transducin-activated PDE (taPDE) in frog ROS homogenates
requires excess Py since Py binds to Gta - GTPyS as well as to the active site of PDE
(Norton et al., 2000). As shown in Fig.3.3, the IC 50 values for Py to inhibit bovine taPDE
was 3.9 Py/PDE, which was somewhat lower than in frog ROS homogenates (Norton et
al., 2000). Py phosphorylated at Thr22 (IC50 = 3.5 Py/PDE) or at Thr35 (IC50 - 4.3 Py/PDE)
did not differ significantly from the non-phosphorylated control. Doubly phosphorylated
Py (Py22P35P) was also tested, and the inhibitory curve was also similar to that of the Py
itself (data not shown). Therefore, the reported dramatic effect ofPy phosphorylation on
inhibition of taPDE was not observed in our study. This indicated that Py has the similar
affinity for transducin-activated PDE regardless of its state of phosphorylation.
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Figure 3.3. Affinity of Py for activated transducin was not greatly affected by
phosphorylation at Thr*2 or Thr35. Purified bovine ROS (20-30 nM PDE) was
incubated with increasing amounts of Py or phosphorylated Py for 10 minutes. 100 pM
GTPyS was added 1 minute prior to 10 mM cGMP addition and PDE activity was
measured. Maximal transducin-activated PDE activity (1100-1200 s'1) was defined as the
activity in the absence of added Py. The IC50 value for each Py was determined by fitting
the data to a 4 parameter logistic function: non-phosphorylated Py (circles) IC50 = 3.9 Py/
PDE; Py35P {squares), IC50 = 4.3 Py/PDE; Py22P {triangles), IC50 = 3.5 Py/PDE. This
experiment is representative of three others.
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P y phosphorylation has a moderate effect on the affinity o f the P y central peptidesfo r
PaJ3 —It is possible that the effect of phosphorylation is confined to the central region of
Py where the phosphorylation sites are located. The effect of phosphorylation on the
overall binding affinity of Py to PaP might be offset in large part by other regions ofPy
in which its interaction with PaP is not modulated by phosphorylation. Therefore, we
tested whether phosphorylation has any effect on the interaction of the Py central region
for Pap. The central region of bovine rod Py is able to restore high-affmity cGMP
binding to a low-affinity noncatalytic binding site on bovine PDE and to stabilize cGMP
binding to both binding sites (Mou and Cote, 2001). In this study, we have synthetically
prepared peptides corresponding to amino acids 18-41 with and without
phosphothreonine residues at Thr22 or Thr35. As shown in Fig.3.4, phosphorylation at
either Thr22 or Thr35 did not affect the ability of Py 18-41 to restore cGMP binding to a
second low-affinity class of binding sites. In all cases, the highest cGMP binding levels
approached the expected ~2 moles of cGMP bound per mole of PDE. After initiating
cGMP dissociation from the noncatalytic sites, however, a reduced affinity ofPyl841(22P) can be inferred based on the 2-fold faster rate of cGMP dissociation. In contrast,
the phosphorylation at position 35 enhanced 1.7-fold the ability of the peptide to stabilize
cGMP binding to Pap. We conclude that phosphorylation at Thr22 weakens the intrinsic
s

affinity of the central region ofPy to interact with PDE6 while phosphorylation at Thr35
may have a slight stabilizing effect on binding.
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Figure 3.4. Phosphorylation of the Pyl8-41 peptide at Thr22 reduced its affinity for
PaP as indicated by its potency to stabilize cGMP binding to PaP: 5 nM bovine Pap
was incubated with 0.6 pM [3H]cGMP with or without 20 pM of the indicated Py 18-41
synthetic peptides. Dissociation of bound [3H]cGMP was initiated at time zero with 2
mM cold cGMP, and portions filtered at the indicated times. The curves represent a
single exponential decay function: Py 18-41 (filled circles), ty2 = 29.5 min; Pyl8-41(22P)
(squares): ti/2 = 13.8 min; Pyl8-41(35P) (triangles), t\a = 50.2 min; no peptide (open
circles), ti /2 = 2.15 min. This experiment is representative of three others.
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Next, we examined whether phosphorylation of Py peptides altered their ability to
displace endogenous Py from its binding sites on the PDE holoenzyme (Papyy). This
competition experiment took advantage of the fact that the central region ofPy binds with
high affinity to PaP but is unable to inhibit catalysis (Mou and Cote, 2001). Both the
central peptide (Pyl8-41) and the N-terminal half ofPy (consisting of amino acid residues
1-45) were tested. Pyl-45 with a phosphorylated residue at position 22 or 35 was
prepared by incubation with MAP kinase or PKA, respectively. The data in Fig.3.5
illustrated that Pyl-45 could compete with full-length Py to induce 70-100% of the
maximal catalytic activity, while Py 18-41 could stimulate up to 60% of the maximal
activity. Phosphorylation at position 22 reduced 4-fold the ability of the peptide to
stimulate catalytic activity. This result is consistent with our direct binding measurements
ofPy with PaP in Fig. 4 that Py phosphorylation at Thr22 decreases its interaction with
PDE6. We also noticed that although Pyl-45 also showed a significant drop in the
stimulated catalysis when Thr22 was phosphorylated, this effect was more apparent in
shorter peptide (Py 18-41), where the maximal activation dropped from 58% to 16% when
Thr22 was phosphorylated. This result supported the idea that the effect of
phosphorylation is confined to a small region ofPy where the phosphorylation sites are
located.
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Figure 3.5. Phosphorylation at Thr22 reduced the ability of Py peptides to displace
bound Py. Bovine PDE holoenzyme (5 nM) was incubated with increasing
concentrations Py peptides to exchange with the endogenous Py bound to Pap. In the
absence of peptide, the basal activity was 200 cGMP/PDE/sec, about 4 % of the folly
activated rate. The extent of activation and the K 1/2 values for each peptides were
determined by fitting the concentration dependence to a hyperbolic function: Pyl -45,
vm
ax= 89.3 %, K 1/2 = 3.6 pM; Pyl-45 (35P), Vmax = 97.0 %, K m = 3.5 pM. Pyl-45
(22P), Vmax = 65.7 %, K m = 2.8 pM; Pyl8-41, Vmax = 57.8 %, K1/2 = 17.2 pM; Pyl 8-41
(35P), Vmax = 56.2 %, Km = 25.2 pM; Pyl8-41 (22P), Vmax = 15.6 %, K m = 13.0 pM;
This experiment is representative of four others.
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Pycomplexed with PDE is a poor substrate fo r phosphorylation — To test the
conditions under which Py is readily phosphorylated, we first checked if Py complexed
with PDE catalytic subunits was a good substrate for phosphorylation. Equal amounts of
Py (either bound to bovine rod PaP or free in solution) were incubated with protein
kinases and the extent of phosphorylation was measured at various times (Fig.3.6). We
found that when Py was bound to PaP, very low levels of phosphorylation were detected.
In contrast, free Py was readily phosphorylated with both PKA and MAP kinase,
consistent with the results obtained with PKC (Udovichenko et al., 1994) and cdk5
(Matsuura et al., 2000). We confirmed this result by phosphorylating an increasing
amount of recombinant Py in the absence or in the presence of fixed amount of PaP
(Fig.3.7). When the added Py concentration was less than the concentration of binding
sites on PaP, Py formed a complex with PaP and was poorly phosphorylated. Once all
binding sites on PaP were occupied, PKA was able to incorporate phosphate into Py as
easily as into free Py lacking Pap. We conclude that free Py is a better substrate for both
kinases than Py complexed as PaPyy, suggesting that Thr35 and Thr22 are involved in the
interaction ofPy with Pap.
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Figure 3.6. Py bound to PaP was a poor substrate for phosphorylation. Purified
bovine PDE6 holoenzyme (~100 nM, lane 1-6) or free Py (~200 nM, same total Py
concentration, lane 7-12) were phosphorylated in a final volume of 30 p.1 assay dilution
buffer containing 50 pM [y-32P]ATP and either 50 ng PKA (lanes 1-3 and 7-9) or MAP
kinase (4-6 and 10-12) per tube. The reactions were stopped with 10 pi of 5x gel loading
buffer after 10 min (lane 1, 4, 7, 10), 30 min (2, 5, 8, 11) or 2 h (3, 6, 9, 12). The proteins
were separated by SDS-PAGE and the incorporation of [32P] into Py was detected by
autoradiography.
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Figure 3.7. Phosphorylation of Py by PKA in the presence of PaP* The
phosphorylation Py by PKA in the absence or in the presence of PaP was performed in a
final volume of 30 pi assay dilution buffer containing 50 pM [y-32PJATP and 3.4 finol
purified PaP (lane 1), increasing amounts of recombinant Py (from 2.5 - 30 finol) in the
presence of -3.4 finol PaP (lane 2-7), or in the absence of PaP (lane 8-13). 50 ng PKA/
tube was added to initiate the phosphorylation. After incubating at ~21°C for the 3 hours,
proteins were quenched and separated on 15% SDS-acrylamide gel and the incorporation
of 32P into Py was detected by autoradiography (A). The Py binds bands were also
scanned and the band intensity (in arbitrary units) was plotted versus the amount ofPy
added (B).
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We considered the possibility that transducin activation of PDE6 might induce a
conformational change in the central region of Py, allowing Py phosphorylation sites to be
exposed. To test this, we incubated bovine ROS homogenates with [y-32P]ATP and
phosphatase inhibitors under dark-adapted and light-activating conditions (i.e., light plus
100 pM GTPyS to activate transducin; see Experimental Procedures). We found that
under dark-adapted conditions (nonactivated), almost no Py in ROS could be
phosphorylated (Fig.3.8, lane 1, 4). For transducin-activated samples, some [32P] was
incorporated into Py (lane 2), but the total extent of Py phosphorylation was less than 3%
of the level for free Py. Incubation of bovine ROS with the recombinant PDE 5 subunit
(P8) (lane 3) before adding [y-32P]ATP only slightly changed the degree ofPy
phosphorylation, suggesting that membrane-association of PDE is not important for Py
phosphorylation. Furthermore, addition of a PKA inhibitor to ROS did not abolish Py
phosphorylation (lane 5), suggesting that PKA is not the only protein kinase responsible
for Py phosphorylation in bovine ROS homogenates. Based on the above results, we
conclude that Py could be phosphorylated in an activation-stimulated manner, although
the extent of phosphorylation does not approach stoichiometric levels. However, the substoichiometric phosphorylation ofPy in ROS constrains its potential role in regulating
PDE in visual transduction pathway.
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Figure 3 .8. Phosphorylation of Py in dark-adapted or light-activated bovine ROS.
Purified bovine ROS homogenates (60 pM rhodopsin) containing phosphatase inhibitors
were incubated with 100 pM [y-32P]ATP for 5 h with in the dark (-GTPyS, lane 1, 4) or in
the light (+100 pM GTPyS, lane 2, 3, 5). To investigate the effect of P5 on Py
phosphorylation, 2 pM of the recombinant P5 (lane 3) was incubated with bovine ROS at
4°C overnight before phosphorylation. For lane 5, 20 pi of the PKA inhibitor was added
to test whether the endogenous PKA activity is responsible for Py phosphorylation in
ROS. After quenching the phosphorylation reaction, Py was released from ROS
membranes with 20% acetonitrile, and partially purified on a Sep-Pak C-18 column. The
same amount of recombinant Py was phosphorylated by PKA in vitro (lane 6) to estimate
the stoichiometry ofPy phosphorylation in bovine ROS.
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Part II: Regulation of PDE6 bv PaB phosphorylation
Phosphorylation o f PDE catalytic subunits by PKA cmd MAP kinase —In part I, we have
shown that both PKA and MAP kinases could phosphorylate Py stoichiometrically. In
this part, we investigated whether these two kinases could phosphorylate the PDE a and
P catalytic subunits in vitro. As shown in Fig.3. 9 ,32P was incorporated into PDE catalytic
subunits with either PKA or MAP kinase. Quantitation o f the amount of 32P incorporated
into phosphorylated PDE (Fig.3.10) indicated that phosphorylated PDE contained a
maximum o f -1.0 mol of phosphate per PDE when PKA was used as the kinase. Longer
incubations could not enhance further phosphate incorporation into PDE, suggesting that
PKA only phosphorylates one site on either P a orPp. This result was inconsistent with a
previous report that both PDE catalytic subunits can be phosphorylated by PKA
(Udovichenko et al., 1993). However, in agreement with Udovichenko et al.
(Udovichenko et al., 1993), we found that Pap, prepared by limited-trypsinization, could
not be phosphorylated by PKA (data not shown). In addition, trypsinization also
gradually removed the radioactivity from [32P]-labeled PDE by PKA (data not shown). It
is possible that the potential phosphorylation site for PKA is localized in the C-terminal
region of PaP that is sensitive to trypsin proteolysis (Catty and Deterre, 1991). When
MAP kinase was used to phosphorylate PDE, more than 1.0 mol of phosphate per PDE
was incorporated. Longer time of incubation resulted in about 1.4 mol of phosphate per
PDE (Fig.3.10, triangles). Therefore, MAP kinase phosphorylates PaP at two or more
different sites. Similar to the case of PKA, the potential sites for MAP kinase are
sensitive to proteolysis by trypsin (data not shown).
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Figure 3.9. Phosphorylation of the catalytic subunits of the PDE holoenzyme by PKA
and MAP kinase. Purified PDE holoenzyme was diluted to a final concentration of 200
nM with assay dilution buffer and 100 pM [y32P] ATP. Phosphorylation was initiated at
room temperature by adding PKA (5 ng kinase/pg protein) or MAP kinase (5 ng
kinase/pg protein) to the reaction mixture. After incubating at room temperature for
various times, 20 pi aliquots were quenched and phosphorylation of PDE was detected by
15% SDS-PAGE followed by autoradiography.
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Figure 3.10. Time course of phosphorylation of bovine PDE by PKA and MAPK.
Purified bovine PDE holoenzyme (15 pmol) was phosphorylated with 100 pM [y32P]ATP (0.5 Ci/ pmol PDE) and 200 ng of PKA (circles) or MAP kinase (triangles) at
22°C in assay dilution buffer. At various times, aliquots were withdrawn, spotted onto
phosphocellulose P81 paper and immersed in 75 mM phosphoric acid to terminate the
reaction. The radioactivity was measured by liquid scintillation counting.
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Phosphorylation o f PDE by an unknown endogenous PDE6 kinase —After establishing
that PDE holoenzyme could be phosphorylated by PKA and MAP kinase in vitro, we
next wanted to determine if PDE served as a substrate for phosphorylation in situ. After
incubating bovine ROS homogenates with exogenous [y-32P] ATP, we found that 32P
could be incorporated into PDE catalytic subunits in a light-stimulated manner. However,
the total level of phosphorylation was low (about 0.1-0.3 mol phosphate per mol PDE),
compared to the control containing the same amount of purified PDE with exogenous
PKA added (data not shown). In bovine ROS homogenates, PDE interacts with many
proteins to form a supramolecular complex (Korschen et al., 1999). It is possible that
these interactions might block the PDE phosphorylation sites so to result in a low
stoichiometry of phosphorylation.
When we separated ROS membranes from soluble proteins followed by washing
ROS membrane extensively with isotonic buffer, we found that ROS membranes retained
their ability to incorporate phosphate into PDE catalytic subunits upon addition of the
exogenous [y-32P]ATP (data not shown). This suggested that a membrane-associated
kinase was responsible for the phosphorylation of PDE6. This membrane-associated
protein kinase could be extracted by hypotonic buffer together with PDE-M (Fig.3.11,
lane 1). It bound PDE-M tightly and was resistant to several purification steps (lane 2-4).
PDE-M had two activity peaks on Mono-Q chromatography. PDE-M in peak I which
contained no kinase activity was loaded on the gel-filtration to get purified PDE-M
sample free of the endogenous kinase (lane 5). PDE-M in peak II was also further
purified on gel-filtration without loss of kinase activity (data not shown), suggesting that
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this endogenous kinase complexed with PDE with a high affinity. Soluble PDE fractions
were also checked. After separating cone PDE (PDE-C) and soluble rod PDE (PDE-S) on
a Q-Sepharose column, PDE-C could be phosphorylated by an unknown protein (lane 6),
while no kinase activity was observed in the PDE-S peak (lane 7).
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Figure 3.11. Phosphoiylation of PDE at different purification steps. Bovine rod PDE
was extracted from ROS membrane with hypotonic buffer (lane 1) and purified
sequentially on a Q-Sepharose ion-exchange column (lane 2), ROS-1 immunoaffinity
column (lane 3) and Mono-Q ion exchange column (lane 4). Two PDE activity peaks
were detected after Mono-Q chromatography. The PDE peak II containing kinase activity
was loaded in lane 4. The PDE peak I free of kinase activity was further purified on a
Superdex 200 gel-filtration column (lane 5). Soluble proteins from bovine retinal extract
were loaded on a Q-Sepharose ion-exchange column to separate cone PDE (lane 6) and
PDE-S (lane 7). The same amount of PDE from each purification step (based on an
activity assay) was incubated with 100 pM [y-32P] in the assay dilution buffer. No
exogenous protein kinase was added. After incubating the phosphorylation mixtures at
room temperature for 0.5 (a) or 2 h (b), all samples were quenched and separated on 15 %
SDS-PAGE followed by autoradiography.
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In order to identify the catalytic subunit of PDE being phosphoiylated by protein
kinases, we used a low percentage bisacrylamide gel (15% acrylamide and 0.04%
bisacrylamide) to separate P a and P$ (Catty and Deterre, 1991). We found that the
endogenous kinase phosphorylated only the P a subunit, and PKA preferably
phosphorylated the PP subunit. MAP kinase could phosphorylate PDE Pa and PJ3 equally
well (Fig.3.12). Thus, it appeared that the endogenous kinase is neither PKA nor MAP
kinase. To date, we have not identified the protein kinase responsible for phosphorylating
PDE in vivo. However, PKC is one candidate for the PDE kinase, since it is present in rod
outer segment (Wolbring and Cook, 1991), and has been reported to phosphorylate only
the Pa subunit in vitro (Udovichenko et al., 1993).
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Figure 3.12. Subunit specificity for phosphorylation by an endogenous kinase, PKA
or MAP kinase. For lane 1, PDE purified by ROS-1 affinity chromotography was diluted
to -50 nM with assay dilution buffer and a final concentration of 100 pM [y-32P]ATP. No
exogenous kinase was added. For lane 2 and 3, PDE was purified by ROS-1 affinity
chromatography, Mono-Q chromatography and gel-filtration chromatography (see Fig.
11); only trace amount of endogenous kinase have been detected to exist in this purified
PDE sample. PDE was phosphorylated in the similar way except that PKA (5 ng
kinase/pg protein) or MAP kinase (5 ng kinase/pg protein) was used. All reactions were
incubated at 22°C for 5 hours. P a and PP were separated on a 15% acrylamide, 0.04%
bisacrylamide gel (18 h at 100 V), followed by autoradiography.
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Depletion o f noncatalytic cGMP binding enhances PDE catalytic subunit
phosphorylation —Work done with PDE5 has suggested that binding of cGMP to
allosteric sites of PDE5 is required to expose the site of phosphorylation (Ser92) by the
cGMP-dependent protein kinase (Thomas et al., 1990; Turko et al, 1998; Francis et al.,
1990; Turko et al., 1998). Since PDE6 is the closest to PDE5 both structurally and
functionally, it is plausible that the GAF domains also allosterically regulate the
phosphorylation of PDE6. In order to investigate this hypothesis, PDE holoenzyme with
different states of cGMP occupancy were tested. PDE was depleted of its endogenous
cGMP by incubating at 37°C overnight. P5 was added to one PDE preparation to
facilitate the dissociation of cGMP from the non-exchangeable binding sites (Mou et al.,
1999). The results in Fig.3.13 show that depletion of cGMP from its binding sites
enhanced the phosphorylation by increasing the rate of [32P] incorporation. This
enhancement was not due to the interaction of P5 with PDE, since P8 itself could not
change the rate and degree of PDE phosphorylation when both noncatalytic cGMP
binding sites were occupied (Fig.3.14).
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Figure 3.13. Depletion of cGMP from the noncatalytic cGMP binding sites enhanced
the phosphorylation of PDE holoenzyme. ROS 1-affinity chromotography purified
bovine rod PDE-M was incubated at 37°C overnight to deplete the endogenous cGMP
from its GAF domains, for one samples (lanes 7-9), PS was added to allow cGMP
exchange at an otberwsie nonexchangeable site (Mou et al., 1999). After overnight
incubation, PDE lost less than 20% its total PDE activity. For lane 1-3, PDE-M was
replenished with 20 pM cGMP and 200 pM zaprinast immediately before
phosphorylation. PDE was diluted to ~50 nM with assay dilution buffer and incubated
with a final concentration of 100 pM [y-32P]ATP. No exogenous kinase was added. The
reactions were stopped at 0.5,3 and 6 hours by addition of 10 pi of gel sample buffer.
PDE was separated on a 15% acrylamide, 0.04% bisacrylamide SDS-PAGE (18 h at 100
V), followed by autoradiography.
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Figure 3.14. Interaction of PS with PDE has no effect on the rate or extent of PDE
phosphorylation when the noncatalytic cGMP binding sites are occupied. 50 nM
PDE holoenzyme (gel-filtration purified) was phosphorylated by 50 ng PKA in assay
dilution buffer containing 200 pM zaprinast, 20 pM cGMP, 100 pM [y-32P] ATP and
increasing concentrations of PS (lane 1 and lane 2: 0 nM; lane 3: 30 nM; lane 4: 60 nM;
lane 5: 120 nM; lane 6: 300 nM; lane 7: 600 nM). PKA was omitted in lane 1. After
incubating at 22°C for 40 minutes or 6 hours, the reactions were stopped by addition of
10 pi of electrophoresis sample buffer. PDE was separated by 10% SDS-PAGE, followed
by autoradiography.
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Effect o f phosphorylation on the regulation o f PDE function— The possible function of
PDE6 catalytic subunit phosphorylation has been studied. After phosphorylation, both
PDE3 and PDE5 gain a higher koat and lower Kmfor substrate at the active sites
(Macphee et al., 1988; Beltman et al., 1993; Turko et al., 1998; Corbin et al., 2000;
Macphee et al., 1988; Corbin et al., 2000; Turko et al., 1998). For PDE6, no alteration in
kcat or Kmhas been observed upon phosphorylation of the catalytic subunits (data not
shown). However, we discovered that the cGMP binding stoichiometry of bovine rod
PDE at the noncatalytic sites was increased from 2 to 3-4 cGMP bound per Pocj3 if ROS
homogenates were incubated beforehand with ATP. The total amount of increase varied
in different ROS preparations from no change to 2 cGMP per PDE (Fig.3.15). The reason
for this variation is not known. In addition, this effect of phosphorylation on cGMP
binding is much less apparent with purified PDE6. It is also not clear whether there is a
direct relationship between the stoichiometry of phosphorylation and the extent of cGMP
binding to Pa(3. The increase in cGMP binding stoichiometry upon ATP addition was
also seen in frog ROS homogenates when exogenous ATP was added (Grazio, 1997). It is
possible that phosphorylation of PDE6 induces a conformational change in the GAF
domains on Pap so to convert low affinity cGMP binding sites to a state of higher
binding affinity for cGMP.
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Figure 3.15. Effect of PDE phosphorylation on cGMP binding to the GAF domains.
Purified bovine ROS was first diluted to 6.6 pM rhodopsin (-20 nM PDE) in 77 mM
KC1, 35 mM NaCl, 2.0 mM MgCl2, 1.0 mM CaCl2, 1.18 mM EGTA ([C a 2+free] = 240
nM), 10 mM HEPES, pH 7.5, 5.0 mM dithiothreitol, 2.5 pg/ml leupeptin, 1 mM
Pefabloc, 3.5 pg/ml pepstatin, and 200 pM zaprinast. 1 pM of [3H]cGMP was added to
the binding mixture followed by incubating at 30°C for 24 hours to exchange the
endogenous nucleotides for radioactive-labeled cGMP (column 1). The function assay
determined after incubation indicated that loss of PDE activity was less than 20% over
the 24 h period. To investigate the effect of P5 and phosphorylation ofPaP on the
noncatalytic cGMP binding, 2 pM purified PS (column 2) or 200 pM of ATP (column 3)
or 2 pM PS plus 200 pM ATP (column 4) was also added to the binding mixture. The
amount of [3H]cGMP bound to PDE was determined by filter binding assay: cGMP
binding to bovine ROS itself: Vmax = 1.60 mol cGMP/mol PDE; bovine ROS + PS: Vmax
= 1.97 mol cGMP/mol PDE; bovine ROS + ATP: Vmax = 3.52 mol cGMP/ mol PDE;
bovine ROS + P5 + ATP: Vmax = 3.38 mol cGMP/mol PDE. This figure represents one of
three similar experiments.
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Discussion
Functional effects and potential physiological role ofphosphorylation o f P yat Thr22 and
Thr35. Several G-protein independent pathways for modulating PDE6 activity and
lifetime have been suggested, such as GARP2-dependent inactivation of PDE6 (Korschen
et al., 1999) and solubilization of PDE6 by P8 (Cook et al., 2001). In this work, the role
of Py phosphorylation in modulating the interaction between Py and Pap was studied.
Our results failed to support the previous idea that Py phosphorylation is involved in a Gprotein-independent pathway by directly enhancing the inhibitory ability of Py (Tsuboi et
al., 1994a; Tsuboi et al., 1994b; Xu et al., 1998; Matsuura et al., 2000). We did not detect
an increase in Py binding affinity or its inhibitory potency for PDE6 upon
phosphorylation of Py at either Thr35 or Thr22. On the contrary, we observed that Py
phosphorylation decreases the ability of the central region of Py to bind to PDE, as well
as modestly reducing its inhibitory potency. The reason for the discrepancy between our
results and previously published work is probably due to the different experimental
conditions used, as well as different interpretation of the observed results. In most of the
published papers, nanomolar concentrations of PDE were used and it was difficult to
extract meaningful binding affinity values. In this study, we used conditions where the
Kd for Py could be accurately assessed as a result of phosphorylation.
Although no direct modulation of Py phosphorylation in the interaction of Py with
PDE has been found, we did observe that transducin activation stimulates Py
phosphorylation in bovine ROS, in agreement with previous reports (Tsuboi et al., 1994b;
Hayashi et al., 2000). Together with the finding that Py complexed with PDE is a poor
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substrate for phosphorylation, we suggested that the condition under which Py is likely to
be phosphorylated is when Py is displaced from Pap binding sites by activated transducin.
However, less than 5% of total pool ofPy could be phosphorylated in bovine ROS, which
makes the importance of this post-translation modification ofPy in visual transduction
questionable. It is unlikely that such a small effect could act directly onto PDE. We
speculate that the light-induced increase in Py phosphorylation may have some alternative
function in connecting the visual transduction pathway with other signaling pathways in
the rod outer segment. The central region ofPy contains a potential Type II SH3 domain
ligand binding site, which is known to be involved in protein-protein interactions. The
fact that Py is expressed in non-retinal cells (Tate et al., 1998) and can serve as a novel
intermediate regulating p42/p44 MAP kinase signaling (Wan et al., 2001) suggests that
Py may indeed act on other signaling pathways. Whether Py phosphorylation regulates its
function in these novel pathways in photoreceptors is a subject for further study.
At this time, we are not clear which residues on Py are phosphorylated in vivo. To
clarify this question, we will need to extract Py from the intact retinas or intact ROS
under different dark and light conditions and to perform the mass spectrometric analysis
ofPy to determine the occurrence and site(s) ofPy phosphorylation.
Functional effects and potential physiological role o f phosphorylation o f the catalytic
subunits o f PDE6: The occurrence and significance of phosphorylation of the PDE6
catalytic dimer for PDE6 regulation was studied in this work since many of known PDE
families (PDE1, PDE3, PDE4, PDE5) have been reported to be regulated in a
phosphorylation-dependent manner. In addition, phosphorylation of PDE6 catalytic dimer
might represent an additional G-protein-independent pathway during light adaptation.
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Our results showed that the PDE catalytic dimer is a substrate for several protein kinases,
including PKA and MAP kinase in vitro, as well as an unknown endogenous, membraneassociated “PDE6 kinase” from bovine ROS. Protein kinase activity co-purifies with
bovine PDE through several stages of purification, and represents one candidate for a
PDE-binding protein.
No direct regulation of catalysis by the phosphorylation of PDE6 catalytic dimer
has been found in our work. However, our results showed for the first time that the
phosphorylation of PDE6 is allosterically regulated by its GAF domains. Depletion of
cGMP from the GAF domains enhances phosphorylation of the PDE6 catalytic dimer,
suggesting that occupancy of the GAF domains of PDE6 elicits a conformation change
that masks the phosphorylation sites on P a and/or Pp. After PaP phosphorylation, low
affinity cGMP binding sites are converted to their high affinity state, similar to the case
for PDE5 (Corbin et al., 2000). Therefore, it is possible that PaP phosphorylation
represents a negative feedback mechanism to regulate cGMP levels and to regulate the
lifetime of active PDE during light adaptation. In this scenario, when photoreceptors are
exposed to bright light or continuous light, the cytoplasmic cGMP will be decreased to a
certain level to induce cGMP dissociation from the GAF domains. The unoccupied GAF
domains in turn induce a conformational changes in Pap to decrease Py affinity for better
GAP activity, consequently shortening the lifetime of active PDE. However, the empty
GAF domains also will enhance the phosphorylation ofPap. Upon Pap phosphorylation,
high affinity cGMP binding is restored to the low affinity binding sites leading to re
binding of cGMP which also promote Py association with PaP.
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SUMMARY
The major objective of this study is to explore what is the functional significance
of cGMP binding, as well as Py and Pap phosphorylation, for the mechanism of PDE
regulation.
First, we characterized the cGMP binding properties to bovine rod PDE. We
showed that two mammalian rod photoreceptor PDE isoforms (soluble and membraneassociated PDE) have two non-identical, high-affinity noncatalytic sites. Interaction of P8
with PDE-S permits cGMP release from a second noncatalytic binding site on nPDE-S
that remains functionally nonexchangeable in PDE-M. The Py subunit not only acts as an
inhibitor of cyclic nucleotide catalysis at the active sites on Pap, but also serves to
regulate the binding affinity of cGMP on the Pap dimer. Upon activation of PDE by
removal of the Py subunits, one of the two classes of noncatalytic sites on the Pap dimer
eliminates its detectable binding ( K d > 1 pM) of cGMP. The remaining cGMP binding
sites exhibit a 3-fold reduction in overall binding affinity. In addition, we also
demonstrated that Py subunit is primarily responsible for altering cGMP exchange upon
activation.
Interactions between Py and the PaP are essential for the regulation of PDE
function in vertebrate rod photoreceptors during visual transduction. In this study, we for
the first time measured Kd of Py binding to mammalian rod PDE and found that the value
is in the range of picomolar to sub-picomolar. Py binds to two distinct high-affinity
binding sites on Pap when cGMP occupies the noncatalytic sites. Our work also
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describes the reciprocal allosteric regulation of PDE6 resulting from Py binding to PaP
and cGMP binding to high-affinity sites in the GAF domains of Pap. By using synthetic
peptides, we revealed that Py has multiple sites of interaction with rod PaP: the Cterminus functions to inhibit the catalysis, while the central region functions to restore
and stabilize cGMP binding to the GAF domain. We also mapped regions within the Nterminal half of the molecule that interact with Pap, some of which induce
conformational changes at the GAF domain.
The role of Py phosphorylation in modulating the interaction between Py and PaP
was also studied. Our results showed that Py binding affinity or its inhibitory potency for
PDE6 was not increased upon phosphorylation of Py at either Thr35 or Thr22. In contrast,
Py phosphorylation decreases the ability of the central region of Py to bind to PDE, as
well as modestly reduces its inhibitory potency. We speculate that the light-induced
increase in Py phosphorylation may have some alternative function in connecting the
visual transduction pathway with other signaling pathways in the rod outer segment,
rather to be involved in a G-protein-independent pathway by directly enhancing the
inhibitory ability of Py .
Finally phosphorylation of the PDE6 catalytic dimer was studied to evaluate if it
represents a G-protein-independent pathway to regulate PDE during light adaptation. Our
results showed that the PDE catalytic dimer is a substrate for several protein kinases,
including PKA and MAP kinase in vitro, as well as an unknown endogenous, membraneassociated “PDE6 kinase” from bovine ROS. We also for the first time showed that the
phosphorylation of PDE6 is allosterically regulated by its GAF domains. Depletion of
cGMP from the GAF domains enhances phosphorylation of the PDE6 catalytic dimer.
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After PaP is phosphorylated, low affinity cGMP binding sites are converted to their high
affinity state, similar to the case for PDE5. Therefore, it is possible that Pap
phosphorylation represents a negative feedback mechanism to regulate cGMP levels and
to regulate the lifetime of active PDE during light adaptation.
The above work helps us understand how PDE is regulated during the visual
transduction and light adaptation. In dark-adapted rod outer segments, the cytoplasmic
cGMP concentration is about 4 pM. In this condition, both noncatalytic sites on nPDE-S
and nPDE-M will be fully occupied. Py binds to Pap tightly and inhibits its catalysis.
When photoreceptor cells are exposed to light, Gta* -GTP binds to Py and displaces it
from its inhibitory site on Pap, causing activation of PDE. During the recovery phase of
the flash photoresponse, activation of PDE results in the immediate loss of cGMP binding
to one of the GAF domains on both PDE-M and PDE-S. As a result, its bound cGMP is
released rapidly to the cytoplasmic space on the same time scale as recovery phase of the
photoresponse to buffer free cGMP levels. However, upon cGMP release from the bound
state, it is likely that the free cGMP would be destroyed by the still-active catalytic sites,
and therefore not contributes to elevating the cytoplasmic cGMP levels during
photoresponse recovery. Activation of PDE also reduces cGMP binding affinity 3-4 fold
at the second cGMP binding site on PDE.
The noncatalytic sites might be indirectly involved in regulating the lifetime of
transducin-activated PDE via modulation of Py binding affinity to Pap. In chapter II, we
showed that there exists a reciprocal relationship between cGMP binding to the GAF
domains and the binding affinity of Py to Pap. In bovine ROS, Py serves as a GTPase
accelerating factor, acting in concert with the RGS9 protein. Therefore, dissociation of
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bound cGMP from the noncatalytic sites reduces Py binding affinity to PaP and Py is
partitioned from PaP to transducin. Consequently, Py interacts with RGS9 to stimulate
GTPase activity of transducin to inactivate PDE during the recovery phase of the
photoresponse.
Dissociation of Py from Pap together with Gta also makes Py a good substrate for
phosphorylation. Upon phosphorylation, Py may act on other proteins in a
phosphorylation-dependent manner so that the several signaling pathways are connected.
In addition to Py, PDE catalytic subunits are phosphorylated when the GAF domains
becomes empty. Phosphorylation of Pap will elicit a conformation change on Pap so that
low affinity cGMP binding sites are converted to their high affinity state, which also
promotes Py re-association with Pap. In this scenario, Pap phosphorylation serves as a
negative feedback mechanism to regulate cGMP levels and to regulate the lifetime of
active PDE during light adaptation.
Although our work has made a significant advance in our understanding of the
regulation of PDE during the visual excitation and adaptation, there are still many
questions needing to be answered. For example, which cGMP binding site on PDE-M is
the non-exchangeable site? Is the heterogeneity in Py binding correlated with the
heterogeneity in two GAF domains as well as the different subunit composition of PaP?
How does Py phosphorylation communicate with other signal pathways? Which
endogenous protein kinase is responsible for phosphorylating Pap? Under what
condition is Pap phosphorylated during visual transduction, and how does its
phosphorylation contribute to a novel negative feedback mechanism to regulate cGMP
levels and PDE function. All of these questions will be subjects for further study.
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